 
 
 
 
A Double -Blind, Placebo -Controlled, Phase 2 Study to Assess the Safety, 
Tolerability, and Efficacy of ISIS 766720 (IONIS -GHR -LRx, an Antisense 
Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 
Days  for 16 Weeks  in Patients  With  Acromegal y Being  Treated  With  Long - 
acting Somatostatin Receptor Ligands (SRL)  
[STUDY_ID_REMOVED] 
18-May -2020  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
A Double -Blind, Placebo -Controlled, Phase 2 Study to Assess the Safety, 
Tolerability, and Efficacy of ISIS 766720 (IONIS -GHR -LRx, an Antisense 
Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 
Days for 16 Weeks in Patients With Acromegal y Being Treated With Long - 
acting Somatostatin Receptor Ligands (SRL)  
 
 
[STUDY_ID_REMOVED]  
 
 
Clinical  Study  Protocol  Version  4.0: 18-May -2020 Official  Title:  
 
 
NCT Number:  
 
Document  Dates:  
 
1 of 84  Clinical Study Report  CONFIDENTIAL  Ionis  Pharmaceuticals,  Inc. 
Study  Number:  ISIS [ADDRESS_683699]  version  of the protocol  (Protocol  Amendment  4) 
is provided along with the change summary for the revision.  
 
Protocol  Version  Date  Document  Provided  
Original  [ADDRESS_683700]  2018  None  
Protocol  Amendment  3 14 May 2019  None  
Protocol  Amendment  4 18 May 2020  Protocol  and change  summary  
2 of 84   
 
 
 
IONIS  PHARMACEUTICALS,  INC.  
 
ISIS  766720 -CS2 
A Double Blind, Placebo -Controlled, Phase 2 Study to Assess the 
Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR -LRX, 
an Antisense Inhibitor of the Growth Hormone Receptor) 
Administered Once Every 28 Days for 16 Weeks in Patients with 
Acromegaly  Being  Treated  with  Long -acting  Somatostatin  Receptor 
Ligands (SRL)  
 
Protocol  Amendment  4 – [ADDRESS_683701]  No: 2017 -004259 -22 
 
Trial  Sponsor:  Ionis  Pharmaceuticals,  Inc. 
[ADDRESS_683702]  
Carlsbad,  CA [ZIP_CODE] 
Phone:  
Fax: 
 
Key Sponsor  Contact:  
 [ADDRESS_683703]  No: 2017 -004259 -22 
Clinical  Phase:  2 
A Double Blind, Placebo -Controlled, Phase 2 Study to Assess the 
Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR -LRX, 
an Antisense Inhibitor of the Growth Hormone Receptor) 
Administered Once Every 28 Days for 16 Weeks in Patients with 
Acromegal y Being  Treated  with  Long -acting  Somatostatin  Receptor 
Ligands (SRL)  
 
Protocol  History:  
Original  Protocol:  25 January  2018  
Amendment  1: 11 May 2018  
Amendment  2: 21 June 2018  
Amendment  3 1 May 2019  
 
Sponsor:  
Ionis  Pharmaceuticals,  Inc. 
Carlsbad, CA  [ADDRESS_683704] of the clinical  investigation without the prior written consent of Ionis Pharmaceuticals, Inc  
. 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
3 
3 of 84  
  
Protocol  Signature  [CONTACT_527020]:  ISIS 766720 -CS2 
Protocol Title:  A Double Blind, Placebo -Controlled, Phase 2 Study to Assess the Safety, 
Tolerability,  and Efficacy  of ISIS 766720  (IONIS  GHR -LRX, an Antisense 
Inhibitor of the Growth Hormone Receptor) Administered Once Every  
28 Days  for 16 Weeks  in Patients  with Acromegaly  Being  Treated  with 
Long -acting Somatostatin Receptor Ligands (SRL)  
Amendment:  Amendment  4 
Date:  18 May 2020  
 
 
I hereby [CONTACT_311141] I ha ve read and understand the attached clinical protocol, entitled “A 
Double  Blind,  Placebo -Controlled,  Phase  2 Study  to Assess  the Safety,  Tolerability,  and Efficacy 
of ISIS 766720 (IONIS GHR -LRX, an Antisense Inhibitor of the Growth Hormone Receptor) 
Administered Once Every 28 Days for 16 Weeks in Patients with Acromegaly Being Treated 
with Long -acting Somatostatin Receptor Ligands (SRL),” dated [ADDRESS_683705] the study as desc ribed herein.  
I agree  to comply  with the International  Conference  on Harmonization  Tripartite  Guideline  on 
Good Clinical Practice (E6).  
I agree  to ensure  that the confidential  information  contained  in this document  will not be used for 
any purpose other th an the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.  
 
 
 
Investigator’s  Signature  
 
[CONTACT_10670]’s  Name  (please  print)  Date  (DD Month  YYYY)  
ISIS [ADDRESS_683706] (OGTT)  ................................ ................................ ........  37 
6.2.3.  Assessments  for Acromegaly  ................................ ................................ ......................  38 
[IP_ADDRESS].  Acromegaly  Quality  of Life Questionnaire (AcroQoL)  ................................ ..............  38 
[IP_ADDRESS].  Acromegaly  Symptoms  and Treatment  Score  Questionnaire  (ASTS)  ........................  38 
[IP_ADDRESS].  Ring  Size Assessment  ................................ ................................ ................................ .. 38 
6.3. Restriction  on the Lifestyle  of Patients  ................................ ................................ ....... 39 
6.3.1.  Contraception  Requirements  ................................ ................................ .......................  39 
6.3.2.  Other  Requirements  ................................ ................................ ................................ .... 40 
7. STUDY  DRUG  ................................ ................................ ................................ ...........  40 
7.1. ISIS 766720  or Placebo ................................ ................................ ...............................  40 
7.2. Packaging  and Labeling  ................................ ................................ ..............................  40 
7.3. Study  Drug  Accountability  ................................ ................................ ..........................  40 
8. TREATMENT  OF PATIENTS  ................................ ................................ ..................  40 
8.1. Study  Drug  Administration  ................................ ................................ .........................  40 
8.2. Other  Protocol -Required  Drugs  ................................ ................................ ..................  41 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
6 
6 of 84  
 8.3. Other  Protocol -Required  Treatment  Procedures  ................................ .........................  41 
8.4. Treatment  Precautions  ................................ ................................ ................................ . 41 
8.5. Safety  Monitoring  Rules  ................................ ................................ .............................  41 
8.5.1.  Safety  Monitoring  Rules for  Liver  Chemistry  Tests  ................................ ...................  42 
[IP_ADDRESS].  Dose  Adjustments  Guidelines  for Liver  Monitoring  ................................ ...................  [ADDRESS_683707] Results  ................................ ...... 45 
8.6.3.  Stoppi[INVESTIGATOR_526907]  ................................ ................................ ... 46 
8.7. Adjustment  of Dose  and/or  Treatment  Schedule  ................................ ........................  47 
8.8. Discontinuation  of Study  Drug  ................................ ................................ ....................  48 
8.9. Withdrawal  of Patients from  the Study  Procedures  ................................ ....................  48 
8.10. Concomitant Therapy  and Procedures  ................................ ................................ ........  49 
8.10.1.  Concomitant  Therapy  ................................ ................................ ................................ .. 49 
8.10.2.  Concomitant  Procedures  ................................ ................................ .............................  50 
8.11. Treatment  Compliance  ................................ ................................ ................................  50 
9. SERIOUS  AND  NON -SERIOUS  ADVERSE  EVENT  REPORTING  ......................  50 
9.1. Sponsor  Review  of Safety  Information  ................................ ................................ ....... 50 
9.2. Regulatory  Requirements  ................................ ................................ .............................  50 
9.3. Definitions  ................................ ................................ ................................ ...................  51 
9.3.1.  Adverse  Event  ................................ ................................ ................................ .............  51 
9.3.2.  Adverse  Drug  Reaction  and Unexpected  Suspected  Adverse  Drug Reaction  ............  51 
9.3.3.  Serious  Adverse  Event  (SAE)  ................................ ................................ .....................  52 
[IP_ADDRESS].  Adverse  Events  of Special  Interest  (AESI)  ................................ ................................ . 52 
9.4. Monitoring  and Recording  Adverse  Events  ................................ ................................  53 
9.4.1.  Serious  Adverse  Events  ................................ ................................ ..............................  53 
9.4.2.  Non-Serious  Adverse  Events  ................................ ................................ ......................  53 
9.4.3.  Evaluation  of Adverse  Events  (Serious  and Non-Serious)  ................................ .........  53 
[IP_ADDRESS].  Relationship to the Study  Drug  ................................ ................................ ...................  53 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
7 
7 of 84  
 [IP_ADDRESS].  Severity  ................................ ................................ ................................ .......................  54 
[IP_ADDRESS].  Action  Taken  with Study  Drug  ................................ ................................ ...................  54 
[IP_ADDRESS].  Treatment  Given  for Adverse  Event  ................................ ................................ ...........  54 
[IP_ADDRESS].  Outcome  of the Adverse  Event  ................................ ................................ ...................  55 
[IP_ADDRESS].  Follow -up of Adverse  Event  ................................ ................................ .......................  55 
9.5. Procedures for  Handling  Special  Situations  ................................ ................................  56 
9.5.1.  Abnormalities  of Laboratory  Tests  ................................ ................................ .............  56 
9.5.2.  Prescheduled  or Elective Procedures  or Routinely  Scheduled  Treatments  .................  56 
9.5.3.  Dosing  Errors  ................................ ................................ ................................ ..............  56 
9.5.4.  Contraception  and Pregnancy  ................................ ................................ .....................  57 
10. STATISTICAL  CONSIDERATIONS  ................................ ................................ ........  58 
10.1. Study  Endpoints,  Subsets, and Covariates  ................................ ................................ .. 58 
10.1.1.  Primary  Efficacy  Endpoint  ................................ ................................ ..........................  58 
10.1.2.  Secondary  Efficacy  Endpoints  ................................ ................................ ....................  58 
10.1.3.  Tertiary  and Pharmacodynamic  Endpoints  ................................ ................................ . 58 
10.1.4.  Exploratory  Endpoints  ................................ ................................ ................................  58 
10.1.5.  Safety  Endpoints  ................................ ................................ ................................ .........  59 
10.2. Sample  Size Considerations  ................................ ................................ ........................  59 
10.3. Populations  ................................ ................................ ................................ ..................  59 
10.4. Definition  of Baseline  ................................ ................................ ................................ . 59 
10.5. Interim  Analysis  ................................ ................................ ................................ ..........  59 
10.6. Planned  Methods  of Analysis  ................................ ................................ .....................  60 
10.6.1.  Demographic  and Baseline  Characteristics  ................................ ................................ . 60 
10.6.2.  Safety  Analysis  ................................ ................................ ................................ ...........  60 
10.6.3.  Efficacy  Analysis  ................................ ................................ ................................ ........  60 
10.6.4.  Pharmacokinetic  Analysis  ................................ ................................ ............................  61 
10.6.5.  Additional  Analyses  ................................ ................................ ................................ .... 62 
11. INVESTIGATOR’S  REGULATORY  OBLIGATIONS ................................ ..............  [ADDRESS_683708]  of the Study  ................................ ................................ .......................  62 
11.3. Independent  Ethics  Committee  (IEC)/Institutional  Review  Board  (IRB)  ..................  [ADDRESS_683709]  OF LABORATORY  ANALYTES  ................................ ...........................  75 
APPENDIX  C. PK SAMPLING  SCHEDULE  ................................ ................................ ...........  77 
APPENDIX D.  GRADING SCALE FOR ADVERSE EVENTS RELATING TO  
LABORATORY ABNORMALITIES  ................................ ................................ ....... 79 
 
 
 
TABLE  OF TABLES  
Table  1 Sampling  Schedule:  Day of Oral Glucose  Tolerance  Test (OGTT)  ..........................  37 
Table  2 Study  Drug  Characteristics  ................................ ................................ ..........................  40 
Table  3 Study  Drug  Dosing  Information  ................................ ................................ ..................  41 
Table  4 Additional Labs  to be Performed  in the Event  of a Platelet  Count  
< 75,000/mm3 ................................ ................................ ................................ ................................ ................................ ...... 44 
Table  5 Actions  in Patients  with Low Platelet  Count  ................................ ..............................  47 
TABLE  OF FIGURES  
Figure  1 Design  of GalNAc  Conjugated  Chimeric  2ʹ-MOE Phosphorothioate  
Oligonucleotides  (MOE -Gapmer) ................................ ................................ ...............  25 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
9 
9 of 84  
 PROTOCOL  AMENDMENT  
 
Protocol  Number:  ISIS 766720 -CS2 
Protocol  Title:  A Double  Blind,  Placebo -Controlled,  Phase  2 Study  to 
Assess the Safety, Tolerability, and Efficacy of ISIS 766720 
(IONIS  GHR -LRX, an Antisense  Inhibitor  of the Growth  Hormone 
Receptor) Administered Once Every 28 Days for 16 Weeks in 
Patients with Acromegaly Being Treated with Long -acting 
Somatostatin Receptor Ligands (SRL)  
Amendment  Number:  4 
Amendment  Date:  18 May 2020  
 
 
The main purposes of this amendment are to:  (1) update several requirements for patient 
eligibility  for the study  based  on available  safety  data to date,  (2) formalize  the procedures added 
to the protocol based on the guidance given in the May 1, 2020 Memo to Investigators entitled 
“ISIS 766720 -CS2:  Coronavirus COVID -19 Guidance – Follow -Up”, and (3) update the 
protocol to reflect the decision to conduct Cohort D.  
1. Patient  Eligibility  Updates:  
a. Three (3) entry criteria have been revised that were originally exclusionary until 
experience with ISIS 766720 in the acromegaly  population was obtained which is now 
available  and includes  the acceptable  safety  profile  observed  from  two ongoing  clinical 
trials including 39 patients from Cohorts A, B, C and D as well as 31 patients in the 
Open -Label Trial ISIS 766720 -CS3 (up to 9 months) to date.  
• The safety data demonstrate a lack of hypoglycemia, therefore, insulin is now 
permitted at screening and during t he study.  Exclusion Criteria #19 and #[ADDRESS_683710] this change.  
• The safety data demonstrate no adverse effect on the hypothalamic -pi[INVESTIGATOR_2117] -adrenal 
axis (HPA)  as ACTH  and cortisol  levels  remained  within  normal  limits  pre- and post- 
dosing, therefore, two exclusion criteria have been revised:  
i. A morning blood cortisol le vel of < 10 mcg/dL was initially considered 
exclusionary  in order  to ensure  that patients  did not have  suppression  of HPA  axis 
until sufficient data to assess the effects of ISIS 766720 on the HPA axis in 
acromegaly patients was available.  Further, morning  cortisol levels are variable 
and cannot establish the presence or absence of adrenal insufficiency with 
certainty  – for example,  many  clinicians  consider  a value  of cortisol  < 7-8 mcg/dL 
as indicative of adrenal insufficiency.  Most clinicians assess adrenal  
insufficiency based on cortisol levels coupled with clinical judgement that 
evaluates signs and symptoms and may use a cosyntropin suppression test (if 
available).  Taken together , Exclusion Criteria #10h has been changed to remove  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
10 
10 of 84  
  
the specific  numeric  cut-off value  for a morning  blood  cortisol  level of 
<10 mcg/dL  and replaced  with the exclusion  of a patient  if an abnormal  morning 
cortisol test is consistent with symptomatic adrenal insufficiency based on 
Investigator judgement.  
ii. Patients on glucocorticoid replacement therapy are now permitted. Exclusion 
Criteria  #[ADDRESS_683711] this change and specifies that changes in a stable 
regimen of glucocorticoid replacement therapy may be considered during the 
study in consultation with the Sponsor Medical Monitor or des ignee.  
b. The protocol  contraceptive  requirements  for male  patients  has been  revised to  clarify 
the requirements for a male patient with a non -pregnant female partner.  Inclusion 
Criteria #5d and Section 6.3.1  Contraception Requirements are revised accordingly.  
2. Procedures  added  based  on Memo  to Investigators  dated  May 1, 2020  
The changes will allow for additional visits and procedures to be conducted via home health 
visits when in -clinic visits are affected due to local precautions and restrictions related to 
COVID -19 Pandemic  (or other  circumstances)  that may limit  the patient ’s ability  to go to the 
clinic. Specifically, the following has been added to Section 6 Study Procedures and 
Appendix A  Schedule of Procedures:  
• The option  to conduct  a Home  Health  Care  visit in place  of a clinic  visit.  This can be 
accommodated in consultation with the Sponsor  
• A Patient Contact [CONTACT_78921] (e.g., phone, text, email or video) was added to assess 
adverse  events  and changes  in concomitant  medications  if a visit cannot  be performe d 
3. Based on the safety and efficacy observed in lower dose levels, the decision to conduct 
Cohort D was communicated to sites in September 2019. The protocol has been revised to 
remove  the reference  that Cohort  D “may  be conducted”  (not included  in the list of changes 
below).  
Minor changes (not included in the list of changes below) have been made throughout the 
protocol  to correct  errors and/or  to improve  the overall  clarity  of the original  protocol  but these 
changes do not impact the subject safety, exposure, or the overall study design.  
A list of  changes  to the protocol  are BOLDED  and underlined  below:  
ISIS [ADDRESS_683712] be surgically sterile, abstinent or, if engaged in sexual relations 
with a female of child -bearing potential, the patient or the patient’s non - 
pregnant female partner  must be using 1 highly effective contraceptive 
method  (refer  to Section  6.3.1 ) from  the time of signing  the informed  consent 
form until [ADDRESS_683713] dose of Study Drug.  
 
6.3.1  Contraception  Requirements  The update removed the 
protocol mandated 
contraception requirement 
for patient’s  fema le partner 
and added that female 
partner use of a highly 
contraceptive  method  as an 
alternative  option  to meet  a 
male patient’s 
contraception  requirement.  
 All male patients and WOCBP must refrain from sperm/egg donation and 
practice  highly  effective  contraception  from  the time of signing  the informed 
consent form until [ADDRESS_683714] also encourage their female partner to use contraception from  
the time of signing  the informed  consent  until 14 weeks  after the patient’s  last 
dose of study treatment.   
 If the male patient’s non -pregnant female partner is using a highly  
effective contraception method, from the time of signing the informed  
consent  form  until  [ADDRESS_683715] dose  of study  treatment,  the 
male patient’s contraception requirement is considered fulfilled.   
Synopsis:  Study  
Population  
Section  5.2 
Exclusion 
Criteria  Exclusion  Criteria  
10h. Morning  (prior  to 9 AM)  blood  cortisol  < 10 mcg/d:  (280 nmol/L)  
Abnormal morning cortisol test consistent with symptomatic  
adrenal insufficiency based on Investigator judgement  
19. Patients  may not have  insulin , chronic  systemic  use of glucocorticoids, 
weight loss medications or participate in weight loss programs within  
[ADDRESS_683716] be on a stable dose and regim en (increases used  
to prevent adrenal crisis is permitted) for ≥ [ADDRESS_683717] be on a stable dose and 
regimen for ≥ [ADDRESS_683718]-Treatment 
Period  Additional  text was added:  
In consultation with the Sponsor, a Home Health Care visit may be  
conducted for a study visit that was intended to be a clinic visit.  A 
confirmation of Study Drug dosing by [CONTACT_526943] 48 hour s. It is preferable  
that the entire  visit is conducted,  however,  the following  assessments  may 
be omitted from the Home Health Care visit:  ECG, body weight,  
physical exam, ring size, and OGTT.  Any assessments not performed at  
the Home Health Care visit should be attempted at the next clinic visit.  Added to allow flexibility 
for Home  Health  Care  visits 
to be  conducted to  decrease 
patient burden due to  
Covid -[ADDRESS_683719]  (e.g. phone,  text or video)  
is required by [CONTACT_526944].   
Section  6.2.1  
Clinical 
Laboratory 
Assessments  
Appendix  A 
Footnote 9  Additional  text added:  
At any time,  the Sponsor  Medical  Monitor  or designee  may request  both  
a central and local lab collection in parallel to assess patient safety.  To reduce  patient  burden 
for possible  unscheduled 
visits due to safety 
follow -up, local lab  
collections  in parallel  with 
central lab collection was 
added  
Section  8.10.1 : 
Concomitant 
Therapy  Disallowed  Concomitant  Therapy:  
The following medications or interventions cannot be started during the trial: 
other approved or investigational medications for acromegaly (e.g., 
pasireotide,  dopamine  agonist  or pegvisomant), insulin , anti-obesity  agents  or 
weight loss programs, and chro nic systemic use of  glucocorticoids.  Section updated to allow 
insulin  use as concomitant 
medication.  
Appendix A A schedule  item for Patient  Contact  [CONTACT_526945]:  
If a visit cannot be performed, patient contact [CONTACT_526946]:  
B In consultation with the Sponsor, a Home Health Care visit may be  
conducted  for a study  day visit that was intended  to be a clinic  visit;  it is 
preferable that the entire visit is conducted, however, the following  
assessments may be omitted: ECG, body weig ht, physical exam, ring  
size, and OGTT.  These assessments should be attempted at the next  
clinic visit if not performed at the Home Health Care visit.  A 
confirmation of ISIS 766720 dosing by [CONTACT_526947] 48 hours  
Footnote 20 – removed as Home Health Care is covered in Footnote B  
now 
20. Home  Health Care  Option can be  used for retesting  only Added to allow flexibility 
for Home  Health  Care  visits 
to be  conducted  to decrease 
patient burden due to  
Covid -19 related 
restrictions or other 
circumstances that arise 
during  the study  that will 
require Sponsor 
consultation  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
13 
13 of 84  
  
PROTOCOL  SYNOPSIS  
 
Protocol  Title  A Double  Blind,  Placebo -Controlled,  Phase  2 Study  to Assess  the Safety, Tolerability,  and Efficacy  of 
ISIS 766720 (IONIS GHR -LRX an Antisense Inhibitor of the Growth Hormone Receptor) 
Administered Once Every 28 Days for 16 Weeks in Patients with Acromegaly Being Treated with 
Long -acting Somatostatin Receptor Ligands (SRL)  
Study  Phase  2 
Indication  Acromegaly  
Primary  Objectives  To evaluate the efficacy of ISIS 766720 subcutaneous injection on serum insulin -like growth factor 1 
(IGF -1) vs. placebo  as an add-on therapy  to long acting  somatostatin  receptor  ligands  (SRL)  octreotide 
or lanreotide.  
To evaluate  the safety  and tolerability  of ISIS [ADDRESS_683720]  of ISIS 766720  to normalize  serum  IGF-1 levels.  
Tertiary  Objectives  To evaluate  the effects  of ISIS 766720 subcutaneous  injection  on growth hormone  (GH)  over time.  
To evaluate the effects of ISIS 766720 subcutaneous injection on the following pharmacodynamic 
endpoints:  fasting  plasma  growth  hormone  binding  protein  (GHBP),  acid labile  subunit  (ALS),  insul in 
growth factor binding protein 3 (IGFBP3).  
Exploratory  Objectives  To evaluate  the effects  of ISIS 766720  subcutaneous  injection  on the following  glycemic  parameters: 
HbA1c, fasting plasma glucose, glycated albumin as well as glucose, insulin and C -peptide during  
2-hour oral glucose  tolerance  test (OGTT).  
To evaluate the effects of ISIS 766720 subcutaneous injection on the clinical endpoints using 
acromegaly  quality  of life questionnaire  (AcroQoL),  acromegaly  symptoms  and treatment  score 
questionnaire (ASTS) and ring size measurement.  
To evaluate  PK exposure  over time and potential  PK/PD  correlation  on relevant  biomarkers.  
Study  Design  This is a randomized,  double  blind,  placebo -controlled,  multi -center  study  of ISIS 766720  or placebo 
as add -on to SRL  
Number  of Patients  Approximately  60 patients are  planned to be randomized in this study.  The needed evaluable patients 
per cohort  and their corresponding  randomization  ratio (ISIS  766720  vs. placebo)  are listed  as follows:  
Study  Population  The Sponsor  Medical  Monitor  may be consulted  if any questions  arise  regarding  the inclusion  or 
exclusion criteria.  
Inclusion  Criteria  
1. Must  have  given written  informed  consent  (signed  and dated)  and any authorizations  required  by 
[CONTACT_10523]  
2. Males  or females  with documented  diagnosis  of Acromegaly*.  Aged  18 to 75 years  old 
(inclusive) at the time of informed consent  
* Defined as a previous diagnosis of GH -secreting adenoma by [CONTACT_38165]; or the 
presence of a pi[INVESTIGATOR_526908] (MRI) or computed 
tomogra phy (CT) scan (if MRI is contraindicated) and serum IGF -1 levels above the upper 
limit  of normal for  age and sex at time  of diagnosis  (serum  IGF-1 level  and MRI  at diagnosis 
will be collected in the CRF).  Cohort  Number  of 
Patients  Randomization 
Ratio  
A 15 2:1 
B 15 2:1 
C 12 5:1 
D 12 5:[ADDRESS_683721] be on stable maximum  or maximally  tolerated dose of  SRL (lanreotide Autogel or 
octreotide LAR, per treating physician judgment) every 28 days* for a minimum of 3 months 
prior  to screening  and will be required  to continue  their stable  dose of SRL throughout  the study. 
In accordance with US approved prescribing information, the maximal dose recommended per 
the package insert for lanreotide Autogel is 120 mg every 28 days and for octreotide LAR is  
40 mg  every  28 days (the reason  for the maximally  tolerated  dose of SRL will be collected  in the 
CRF).  SRL dose should not exceed the maximum dose as approved in the local region (as 
indicated in the SRL label).  Prior use of other medications for treating acromegaly  (pasireotide, 
dopamine agonist or pegvisomant) is allowed  but not within 6 weeks of screening  
*Patients who are on a stable monthly dosing regimen, but not exactly every 28 days will be 
considered  for inclusion  to this study.  Patients  who are on a stable  regimen,  that is not monthly 
e.g., every 3 weeks or every 6 weeks are excluded.  
4. At Screening,  serum  IGF-1 (performed  at central  lab) between  1.3 to 5 × ULN,  inclusive, 
adjusted for age and sex  
5. Females  must  be non-pregnant  and non-lactating,  and either:  
a. surgically  sterile  (e.g.,  tubal  occlusion,  hysterectomy,  bilateral  salpi[INVESTIGATOR_1656],  bilateral 
oophorectomy)  
b. post-menopausal  (defined  as 12 months  of spontaneous  amenorrhea  in females  > 55 years 
of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an 
alternative medical cause and FSH levels in the postmenopausal range for the laboratory 
involved);  
c. abstinent  or 
d. Women of childbearing potential (WOCBP) should agree to t aking all precaution to avoid 
pregnancy  during  the trial period  (including  Post-Treatment),  including  agreeing  to receive 
pregnancy testing before each monthly dose, using 1 highly effective method of birth 
control (Section  6.3.1), from  the time of signing  the informed consent form  until [ADDRESS_683722] be using 1 highly effective contraceptive 
method (refer to Section 6.3.1 ) from the time of signing the informed consent form until 
[ADDRESS_683723] dose of Study Drug  
6. Willing  to refrain  from  strenuous  exercise/activity  (for example  heavy  lifting,  weight  training, 
intense aerobics classes etc.) for at least 24 hours prior to study visits  
7. Willing  to refrain from  alcohol  or tobacco  use for 8 hours  prior  to study  visits  
Exclusion  Criteria  
1. Clinically -significant abnormalities in medical history (e.g., previous acute coronary syndrome 
within  6 months  of screening,  major  non-pi[INVESTIGATOR_526909]  3 months  of screening)  or from 
screening physical examination  
2. Patients  who received  surgery  for pi[INVESTIGATOR_526910] 6 months  before  the trial, 
and/or planning to receive surgery during the trial  
3. Patients  who received  radiotherapy  for pi[INVESTIGATOR_526911] 3 years  before  the trial, 
and/or planning to receive radiotherapy during the trial  
4. Patients  with a pi[INVESTIGATOR_526912], per Investigator  judgment,  is worsening  (e.g.,  either  growing, 
or at risk of compressing or abutting the optic chiasm or other vital structures) as assessed by 
[CONTACT_21173][INVESTIGATOR_2117]/sellar MRI or CT scan protocol at screening or within 6 months of screening  
5. Evidence  of decompensated  cardiac  function per  medical  judgement  and/or  NYHA  class  3 or 4 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
PROTOCOL  SYNOPSIS  Continued  
15 
15 of 84  
  
 
 
Study  Population  
Continued  Exclusion  Criteria  Continued  
6. Clinical  evidence  of symptomatic  hyperprolactinemia  that would  necessitate  treatment  
7. Symptomatic  cholelithiasis,  and/or  choledocholithiasis  
8. Have  a diagnosis  of Gilbert’s  disease  
9. Patients  with history  of hypoglycemia  unawareness  (who  have  had > [ADDRESS_683724] 6 months) or documented reactive hypoglycemia  
10. Screening laboratory results as follows, or any other clinically -significant abnormalities in 
screening  laboratory  values  that would  render  a patient  unsuitable  for inclusion.  (abnormalities 
may be retested for eligibility purposes)  
a. Urine protein/creatinin e (P/C) ratio ≥ 500 mg/g.  In the event of P/C ratio above this 
threshold  eligibility  may be confirmed  by a quantitative  total urine  protein  measurement  of 
< 1000  mg/[ADDRESS_683725] (including trace) for blood on urinalysis.  In the event of a positive t est 
eligibility  may be confirmed  with urine  microscopy  showing  < [ADDRESS_683726]  > 1.2 × ULN,  bilirubin  > ULN;  alkaline  phosphatase  > 3 × ULN  
d. eGFR  < 45 mL/min/1.73m2 as determined  by [CONTACT_526948] -Epi[INVESTIGATOR_526913] (CKD -EPI) equation for creatinine clearance OR serum creatinine  
> 1.8 mg/dL  in males  and > 1.5 mg/dL  in females  
e. Platelet  count  < LLN 
f. Abnormal  thyroid function  tests must  be approved  by [CONTACT_526949]  
g. HbA1c  > 10% 
h.  Abnormal  morning  cortisol  test consistent  with symptomatic  adrenal  insufficiency  based 
on Investigator judgement  
11. Active  infection  requiring  systemic  antiviral  or antimicrobial  therapy  that will not be completed 
prior to Study Day [ADDRESS_683727] for human  immunodeficiency  virus  (HIV),  hepatitis C  or 
chronic hepatitis B  
14. Malignancy  within  5 years,  except  for basal  or squamous  cell carcinoma  of the skin,  carcinoma 
in situ of the cervix, follicular Stage 1 or papi[INVESTIGATOR_526914];  patients  with a history  of other  malignancies  that have  been  treated  with curative  intent 
and which have no recurrence within 5 years may also be eligible if approved by [CONTACT_526950]  
15. Treatment  with another  investigational  drug,  biological  agent,  or device  within  1 month  of 
screening, or 5 half -lives of investigational agent, whichever is longer  
16. Treatment with any non - ION- or ISIS -oligonucleotide  (including siRNA) at any time or prior 
treatment  with an ION- or ISIS-oligonucleotide  within  [ADDRESS_683728] 
previously received only a single -dose of an ION - or ISIS -oligonucleotide as part of a clinical 
study may be included as long as a duration ≥ [ADDRESS_683729]  be 
on a stable dose and regimen (increases used to prevent adrenal crisis is permitted) for  
≥ [ADDRESS_683730]  be on a stable  dose and regimen  for ≥ [ADDRESS_683731]  be on a stable  dose and regimen for  ≥ [ADDRESS_683732] dose of 
Study Drug and regular clinical monitoring is performed during the trial  
23. Blood  donation  of 50 to 499 mL within  30 days of screening  or of > [ADDRESS_683733]  any other  conditions,  which,  in the opi[INVESTIGATOR_526915], or could interfere with the patien t participating in or completing 
the Study  
Treatment  Groups  There will  be up to 4 treatment  groups:  
Cohort  A: ISIS 766720  60 mg or placebo  (2:1)  + SRL every  28 days.  In addition,  a booster  dose of 
Study Drug is administered on Day 15.  
Cohort  B: ISIS 766720  80 mg or placebo  (2:1)  + SRL every  28 days.  In addition,  a booster  dose of 
Study Drug is administered on Day 15.  
Cohort  C: ISIS 766720  120 mg or placebo  (5:1)  + SRL every  28 days.  In addition,  a booster  dose 
of Study Drug is administered on Day 15.  
Cohort  D: ISIS 766720  160 mg or placebo  (5:1)  + SRL every  28 days.  In addition,  a booster  dose 
of Study Drug is administered on Day 15.  
Study  Drug  Dosage 
and Administration  ISIS 766720  (100 mg/mL)  and placebo  will be supplied  in vials  of 0.8 mL. Study  Drug  (ISIS 766720 
or placebo) injection volumes will be 0.6 and 0.8 mL for Cohort A (60 mg) and Cohort B (80 mg) 
respectively.  For Cohort C the total injection volume will be 1.2 mL (120 mg) and for Cohort D the 
total injection volume will be 1.6  mL (160 mg).  The administration of Study  Drug for Cohort C and 
D may be delivered as a single injection or 2 non -contiguous injections (If 2 non -contiguous 
injections,  volumes  such as,  0.6 mL × 2 for 120 mg and 0.8 mL × 2 160 mg, may be used).  All Study 
Drug injections will be subcutaneously administered in the clinic.  
The patient’s stable SRL regimen will continue throughout study participation and ideally 
administered  on the same  day as the Study  Drug.  If the SRL cannot  be administered  in the Clinic,  the 
administration of SRL relative to Study Drug should be consistent  (e.g., 1 -3 days after the Study  
Drug administration during the Treatment Period) throughout the trial.  The date and time of each 
SRL dose will be documented by [CONTACT_89410] a SRL dosing diary and provided to the study center 
staff at subsequent visits.  
Rationale for Dose  
and Schedule  Selection  The dose levels of 60 mg/q28 days and 80 mg/q28 days were selected based on the safety, 
pharmacokinetic,  and pharmacodynamic  data from  ISIS 766720  Phase  1 study  in healthy  volunteers. 
The Phase 1 study evaluated ISIS 766720 doses  of 40 mg, 60 mg, and 80 mg administered as single 
doses  and 10 mg, 20 mg and 30 mg administered  as 4 doses  over a 2-week  period  that were found  to 
be generally well -tolerated and induced significant  reductions in GHBP, a biomarker of GHR 
inhibition.  The safety data obtained in the Phase 1 study (ISIS 766720 -CS1) as well as the clinical 
experience  with several  other  2ʹ-MOE  modified  ASOs  (Sewell  et al.  2002 ; Chi et al. 2005 ; Kastelein  
et al. 2006 ) and GalNAc conjugated ASOs ( Viney et al. 2016 ; Graham et a l. 2017 ) supports the 
dosing regimen planned for this Phase 2 study.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
PROTOCOL  SYNOPSIS  Continued  
17 
17 of 84  
  
 
 
Rationale for Dose  
and Schedule  Selection 
Continued  The every  28-day dosing  regimen  (Day  1, 29, 57, 85 and 112) is supported  by [CONTACT_526951] - 
life of this compound (approximately 2 -3 weeks) and significant GHBP reductions observed after 
single doses of  [ADDRESS_683734] dose (Day 15), is included to achieve steady -state 
concentrations earlier in the Treatment Period to allow assessment of efficacy with the proposed 
dosing period (af ter steady -state concentrations are achieved.  
The range of dosing proposed for the present study will provide the equivalent drug exposure of 
[ADDRESS_683735] 4 weeks and 15 mg and 20 mg administered 
weekly  for the remainin g 12 weeks  respectively  for Cohort  A (60 mg)  and Cohort  B (80 mg). The 
highest dose selected for this study, 80 mg every 28 days (e.g., 20 mg per week), is predicted to 
decrease growth hormone receptor expression aiming for at least 50% reduction in serum IGF -1 
levels in acromegaly patients.  
The dose level of 120 mg/q28 d ay, and potentially 160 mg/q28 day, have been added to assess the 
safety  and efficacy  of higher  doses  of ISIS 766720.  Based  on all available  data from  the nonclinical 
toxicology  program,  the no-observed -adverse -effect -level  (NOAEL)  for ISIS 766720  in the monkey 
was determined to be 30 mg/kg based on the weekly study for 16 weeks and the monthly dosing 
regimen  study  for 9 months.  This provides  a therapeutic  margin  of up to 35-fold for an approximate  
2.3 mg/kg/month  (160 mg/month)  clinical  dose based  on plasma  AUC  (extrapolated  from  the 
Phase 1, 80 mg data).  
Each patient will receive 6 SC injections of Study Drug in the clinic during the 16 -week Treatment 
Period  on Days  1, 15, 29, 57, 85 and 112. The 16-week  treatment  duration  of the trial is supported  by 
[CONTACT_526952] 766720 nonclinical 16 -week toxicology studies (See Investigators Brochure) and by  
[CONTACT_526953] -term weekly clinical dosing studies with several other 2′ -MOE -modified ASOs.  
The SRL dosing regimen will be every  [ADDRESS_683736] -Treatment 
Period.  If the SRL  cannot be administered in the Clinic, the administration of  SRL relative to Study  
Drug should be consistent (e.g., same number of days [1 to 3 days] post Study  Drug administration) 
throughout the trial.  The date and time of each SRL dose administered outside of the clinic will be 
documented  by [CONTACT_526954] a SRL dosing  diary  and provided to the study  center  staff at subsequent 
visits.  
Study  Visit  Schedule 
and Procedures  Detailed  information  regarding  the study  procedures  is outlined  in Section  6, Appendix  A, 
Appendix B , and Appendix C . 
The study  for an individual  patient  will generally  consist  of the following  periods:  
• A ≤ 9-week  Screening  Assessment  Period  
• A 16 -week Treatment Period during which Study  Drug will be administered as a once -every - 
28 days SC injection  (except  during  Month  1 where  a booster  dose is administered  on Day 15) 
• A 14-week  Post-Treatment  Evaluation  Period  
Once in the Post -Treatment Period, patients who meet eligibility requirements for the open -label 
extension (OLE) study may elect to enroll in the OLE study and will need to sign the IRB/IEC 
approved  informed  consent.  Patients  not participating  in the OLE  study will enter  the 14-week  Post- 
Treatment Evaluation Period.  
Laboratory and other study procedures will be performed to assess eligibility during the Screening 
Periods.  Safety  and tolerability  will be assessed  biweekly  while  efficacy,  exploratory  and plasma  PK 
assessments will be conducted periodically during the Treatment Period of the study.  During the 
Post-Treatment Period, safety, exploratory and PK will be assessed for 14 weeks. (Schedule of 
Events in Appendix A  and Appendix B ). 
A 2-hour OGTT  will be performed  (3×) during  the study  (see Appendix A  for details).  
Assessment  of acromegaly  clinical  symptoms,  patient  reported  outcome,  and ring size measurement 
will be monitored during the Treatment Period and Post -Treatment Period.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
PROTOCOL  SYNOPSIS  Continued  
18 
18 of 84  
  
 
 
Safety and 
Tolerability 
Evaluations  The safety and tolerability of ISIS 766720 will be assessed by [CONTACT_67484], severity, 
dose-relationship  of adverse  effects  and changes  in laboratory,  ECG,  and physical  exam evaluations. 
Safety results in patients dosed with ISIS 766720 will b e compared with those from patients dosed 
with placebo.  The safety and tolerability profile of the Study Drug (including liver, renal function, 
platelet,  hypoglycemia  and hyperglycemia,)  will be monitored  regularly  during  the Treatment  Period 
and at schedu led visits in the Post -Treatment Period.  
Efficacy  Evaluations  Assessment  of the effects  of ISIS [ADDRESS_683737] dose (Study Visit PTWk5)  
Pharmacokinetic 
Evaluations  The plasma  pharmacokinetics  of ISIS 766720  (as total full-length  ASO,  from  fully  conjugated  to 
unconjugated ISIS 766720) will be assessed throughout treatment and Post -Treatment Periods. 
Plasma PK sample collection time points are detailed in Appendix C . 
Assessment  of the effects  of ISIS 766720  on serum  IGF-1, GH, GHBP,  ALS,  IGFBP3,  as well as 
glycemic parameters (both fasting and during OGTT) will be measured over time during the 
Treatment Period and Post -Treatment Period.  
Statistical 
Considerations  Based on prior clinical trial experience with pegvisomant, it is estimated that the standard  deviation 
of the percent change from Baseline serum IGF -1 is approximately 20%.  In the Per Protocol Set, 
with at least [ADDRESS_683738] 90% power to detect a 45% difference in mean percent change from 
Baseline  serum  IGF-1 between  each of the ISIS 766720  dose groups  and the pooled  placebo  group  at 
an alpha level of 0.05.  
Eligible patients will be stratified based on screening serum IGF -1 levels (> 2.5 × ULN vs. ≤ 2.5 × 
ULN age and sex adjusted by [CONTACT_6626]).  Cohort A and Cohort B are enrolled in parallel and 
patients will be randomized to 1 of 2 dose cohorts in a 1:1 ratio (Cohort A or Cohort B).  Once 
Cohort A and B enrollment is completed, Cohort C will be gin enrollment.  Cohort D will be 
conducted  based  on the safety  and efficacy  observed  in the lower  dose cohorts.  Upon  randomization 
to Cohort A or Cohort B patients will be further randomized in a 2:1 ratio to receive either  
ISIS 766720  or placebo.  For Cohort  C and Cohort  D, the randomization  will be in a 5:[ADDRESS_683739] 6 patients in the higher strata (> 2.5 ×x ULN 
serum  IGF-1) or at least 6 patients  in the  lower  strata  (≤ 2.5 ×  ULN  serum  IGF-1) complete  the Week 
11 assessments (2 weeks after Day  57 [i.e., 3 month] dose).  Additional interim  analysis may also be 
conducted once each cohort completes the Post -Treatment Week 5 assessments.  
Sponsor  Ionis  Pharmaceuticals  Inc. 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
19 
19 of 84  
  
TREATMENT  PERIOD  
Dosing  at Day 1, 15, 29, 57, 85, 112 
END-OF-STUDY 
PROCEDURES 
Day 211 (PTWk15)  
or Early  termination  from 
Post-Treatment (ETPT)   
STUDY  DESIGN  AND  TREATMENT  SCHEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 POST -TREATMENT 
(PT) EVALUATIONS  
Days  113 to 210  
EARLY 
TREATMENT 
TERMINATION 
(ETTX)  SCREEN  
-63 to -1 days  before  Baseline  
(Day  1) 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
20 
20 of 84  
  
STUDY  GLOSSARY  
Abbreviation  Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AcroQoL  acromegaly  quality  of life questionnaire  
AE adverse  event  
ALP alkaline  phosphatase  
ALT  alanine  aminotransferase  (SGPT)  
aPTT  activated  partial  thromboplastin  time 
ASO  antisense  oligonucleotide  
AST aspartate  aminotransferase  (SGOT)  
ASTS  acromegaly  symptom  and treatment  score  questionnaire  
AUC t area under  the plasma  concentration -time curve  from  time zero to time t 
Bb complement factor Bb (activated complement split product)  
βhCG  beta-subunit  of human  chorionic  gonadotropin  (pregnancy  test) 
BP blood pressure  
BUN  blood  urea nitrogen  
C5a complement  factor  C5a (activated  complement  split product)  
Cmax maximum  concentration  
CBC  complete  blood  count  
CMV  cytomegalovirus  
CRF case report  form  
CRP C-reactive  protein  
CS clinically -significant  
CT computed  tomography  
CTCAE  Common  Terminology  Criteria  for Adverse  Events 
dL deciliter  
EBV  Epstein -Barr Virus  
ECG  electrocardiogram  
eCRF  electronic  Case  Report  Form  
ETPT  early  termination  visit from  post-treatment  
ETTX  early  termination  from  treatment  
FAS full analysis  set 
FSH follicle  stimulating  hormone  
GCP  good  clinical  practice  
GHBP  growth  hormone  binding  protein  
GHR  growth  hormone  receptor  
HAV  hepatitis  A virus  
HBsAg  hepatitis  B surface  antigen  
HBV  hepatitis  B virus  
HCV  hepatitis  C virus  
HIV human  immunodeficiency  virus  
HR heart  rate 
hsCRP  CRP  measured  by [CONTACT_526955] [ADDRESS_683740]  
ISIS 766720  antisense  inhibitor  of GHR  
MCH  mean  corpuscular  hemoglobin  
MCHC  mean  corpuscular  hemoglobin  concentration  
MCV  mean  corpuscular  volume  
MedDRATM Medical  Dictionary  for Regulatory  Activities 
MPV  mean platelet volume  
MRI magnetic  resonance  imaging  
mRNA  messenger  ribonucleic  acid 
NCS  not clinically -significant  
NSAID  non-steroidal  anti-inflammatory  drug 
NYHA  New  York  Heart  Association  
on study  the patient is  ‘on study’ from  signing  of the  informed  consent until  their last study 
visit 
OGTT  oral glucose  tolerance  test 
pH measure  of the acidity  or basicity  of a solution  
PK pharmacokinetic(s)  
PPS Per Protocol  Set 
PT prothrombin  time 
QoL quality  of life 
RNase H1  an ubiquitous  endonuclease  that specifically  hydrolyzes  the RNA  strand  in 
RNA/DNA hybrids  
SAE serious  adverse  event  
SAP statistical  analysis  plan 
siRNA  small  interfering  ribonucleic  acid 
SC subcutaneous(ly)  
Study Day [ADDRESS_683741]  upper  limit  of normal  
WBC  white  blood  cell 
WOCBP  women  of childbearing  potential  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
22 
22 of 84  
  
1. OBJECTIVES  
1.1. Primary  Objectives  
To evaluate the efficacy  of ISIS 766720 subcutaneous (SC) injection on serum insulin -like 
growth  factor  1 (serum IGF -1) vs. placebo  as an add-on therapy  to long acting  somatostatin 
receptor ligands (SRL) octreotide or lanreotide.  
To evaluate  the safety  and tolerability  of ISIS [ADDRESS_683742]  of ISIS 766720  to normalize  serum IGF -1 levels.  
 
1.3. Tertiary  Objectives  
To evaluate  the effects  of ISIS 766720  SC injection  on GH over time.  
To evaluate  the effects  of ISIS  766720  SC injection  on the following  pharmacodynamic 
endpoints:  fasting plasma GHBP, ALS, IGFBP3.  
 
1.4. Exploratory  Objectives  
To evaluate  the effects  of ISIS  766720  SC injection  on the following  glycemic  parameters: 
HbA1c,  fasting  plasma  glucose,  glycated  albumin  as well as glucose,  insulin  and C-peptide 
during [ADDRESS_683743].  
To evaluate the effects of ISIS 766720 SC injection on the clinical endpoints using AcroQoL, 
acromegaly  sign and symptom  treatment  score  question naire  (ASTS)  and ring size measurement.  
To evaluate  pharmacokinetic  (PK)  exposure  over time and potential  PK/PD  correlation  on 
relevant biomarkers.  
 
2. BACKGROUND  AND  RATIONALE  
2.1. Overview  of Disease  
Acromegaly  is a chronic  disorder  caused  by [CONTACT_526956],  most  commonly  secondary  to a 
GH secreting pi[INVESTIGATOR_296953] ( Katznelson et al. 2014 ). Growth hormone circulates and 
through binding and activation of growth hormone receptor (GHR), it stimulates production of  
IGF-1. Circulating IGF -1 is mostly  made in the liver ( Liu et al. 2000 ); IGF -1 in large part 
mediates the somatic and metabolic effects of GH.  Hypersecretion of GH leads to excess 
production of IGF -1 (Katznelson et al. 2014 ). High levels of circulating  GH and IGF -1, lead to 
multisystem diseases due to somatic overgrowth and metabolic dysregulation, causing multiple 
comorbidities  (e.g.,  type 2 diabetes,  cardiomyopathy,  and respi[INVESTIGATOR_526916]),  premature 
mortality, physical disfigurement (e.g., enlarged facial features, hands, and feet, and painful 
arthritis), and decreased quality of life ( Melmed 2006 ). Growth hormone hypersecretion 
worsens insulin resistanc e, producing impaired glucose tolerance and diabetes mellitus in  
15-38% of patients  (Katznelson et al.  2014 ). The incidence  of acromegaly  is approximately  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
23 
23 of 84  
  
3 cases per 1 million persons per year, and the prevalence is about 60 per million ( Melmed  
2006 ). The therapeutic  goal for acromegaly  includes  normalization  of biochemical  variables 
(GH and IG F-1), reversal  of mass  effects  of the tumor,  improvement  in signs,  symptoms  and 
comorbidities of the disease and minimization of long -term mortality risk.  Treatment goals 
include  assessment  and management  of the comorbidities,  such as aggressive  control  of lipid 
abnormalities and type 2 diabetes ( Katznelson et al. 2011 ). 
Surgical removal of the pi[INVESTIGATOR_526917].  However, if the biochemical and clinical eva luation after surgery reveals persistent 
disease,  or if surgery  is not an option  for the patient,  then medical  therapy  is necessary.  Current 
medical treatments include dopamine agonists, SRLs, and GHR antagonist (pegvisomant, or 
Somavert).  According  to societal guideline  for acromegaly, ( Katznelson  et al.  2014 ), Somavert 
is recommended as a potential first line medication prior to combination therapy to treat 
persistent disease with or without surgery.  In Phase [ADDRESS_683744] -market observational studies, 
Somavert can normalize ~63% of the patients not previously controll ed, however with the side 
effects of increased transaminases, and low incidence of adenoma growth ( van der Lely et al.  
2012 ). As currently available medications are limited by [CONTACT_526957],  gastrointestinal  upset,  gallbladder  disease,  injection  site reaction, 
or liver enzyme elevations, more safe and effective medical therapi[INVESTIGATOR_526918].  
 
2.2. Therapeutic  Rationale  
Since acromegaly  is du e to excessive GH and IGF -[ADDRESS_683745], normalization of circulating IGF -1 is a surrogate endpoint for the treatment  
of acromegaly.  Inhibition  of GH signaling  results in  suppression  of IGF -1 secretion (Rowland et  
al. 2005 ). This can be achieved by [CONTACT_526958].  Clinical evidence that this 
mechanism  lowers  IGF-1 levels  comes  from  studies  conducted  with Somavert  (pegvisomant)  and 
ATL1103.  Somavert is a human GHR antagonist that competes with endogenous GH for 
binding to its receptor and blocks production of IGF -1, and can normalize IGF -1 in ~63% of 
patients.  However, Somavert dosing regimen is inconvenient for pat ients as it requires daily 
administration by [CONTACT_526959] ( Melmed 2006 ). Additionally, clinical evidence of a reduction in IGF -1 
levels by [CONTACT_526960]1103 (an 
antisense inhibitor of GHR) in which ATL1103, by [CONTACT_526961], reduced serum IGF -1 levels 
by 26% after 13 weeks of dosing ( Trainer et al. 20 15). 
As a GalNAc conjugated 2ʹ -MOE -gapmer, ISIS 766720 has the potential to be efficacious in 
treating acromegaly by [CONTACT_526962] -1 levels.  In addition, since mature GHR is cleaved to pro duce the 
circulating  growth  hormone  binding  protein  (GHBP)  which  binds  to circulating  GH and prolongs 
its half -life ( Fisker 2006 ), ISIS 766720 has the potential to decrease circulating GHBP therefore 
increase  GH clearance.  Indeed,  while  preclinical mouse  and primate  studies  with GHR  antisense 
inhibitor demonstrated reduction in hepatic GHR ribonucleic acid (RNA), hepatic GHR protein 
as well as plasma IGF -[ADDRESS_683746]  a superior 
duration of action, decreased treatment burden, thereby [CONTACT_526963] 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
24 
24 of 84  
  
ISIS 766720  having  an enhanced  pharmacological  benefit  and tolerability  relative  to available 
acromegaly treatments.  
The known  potential  risks  to study  participants  associated  with ISIS 766720  are described  in the 
Guidance to the Investigator section of the ISIS 766720 Investigator’s Brochure.  
 
2.3. ISIS  766720  
2.3.1.  Mechanism  of Action  
ISIS 766720  is an antisense  oligonucleotide  (ASO)  drug targeting  GHR  RNA.  It is covalently 
bonded to triantennary N-acetyl galactosamine (GalNAc), a high -affinity ligand for the 
hepatocyte -specific  asialoglycoprotein  receptor  (ASGPR)  to form  an ASO -GalNAc  conjugate. 
This GalNAc -conjugate approach results in en hanced ASO delivery to hepatocytes vs.  
non-parenchymal cells in the liver and increases ASO potency by ≥ 10 -fold in mice ( Prakash et  
al. 2014 ) compared to unconjugated ASOs.  The ASO portion is  complementary to base -pair 
positions  154678 -154697  within Intron  2 of the GHR  RNA  and binds  to the RNA  by [CONTACT_526964].  The hybridization (binding) of ISIS 766720 to the cognate RNA results in 
the ribonuclease H1 (a non -specific endonuclease that catalyzes the cleavage of RNA via a 
hydrolytic mechanism) (RNase H1) -mediated degradation of the GHR RNA, thus preventing 
product ion of GHR protein and its cleavage product GHBP.  Since GHBP is in circulation, its 
level can be used as a biomarker for GHR protein reduction by [CONTACT_526965].  
 
2.3.2.  Chemistry  
Chemically,  ISIS 766720  is a synthetic  oligonucleotide  covalently  linked  to a ligand  antis ense 
conjugate (LICA).  The oligonucleotide portion of the drug consists of 20 nucleotides (i.e., a 
20-mer).  Of the nineteen (19) internucleotide linkages, fifteen (15) are 3ʹ -O to 5ʹ-O 
phosphorothioate bonds, and 4 are 3ʹ -O to 5ʹ-O phosphodiesters.  The nuc leotide sequence of 
ISIS 766720 is complementary to a 20 -nucleotide stretch within Intron 2 of the GHR RNA 
genomic sequence (NC_000005.10) and binds to the RNA by [CONTACT_213303] -Crick base pairing.  
Structurally,  the oligonucleotide  has 4 regions.  Two (2) of them,  the 5 nucleotides  at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2ʹ -O-(2-methoxyethyl) (MOE) -modified 
ribonucleotides, as per Figure 1  below.  
These  MOE -modified  nucleotides  confer  (1) increased  affinity  to the target  RNA ( Altmann  et al. 
1996 ; McKay et al. 1999 ), (2) increased resistance to exonucleases and endonucleases (thereby 
[CONTACT_526966]) ( Geary et al. 2003 ), and (3) amelioration of some of the high -dose 
toxicities thereby [CONTACT_526967] (DNA) ( Henry et al. 2000 ). 
The third region, the central portion of the oligonucleotide, is composed of  
10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and ISIS 766720 
employs  this chimeric  structure  to enable  use of the RNase  H1-mechanism  for antisense  activity. 
This is because while the 2ʹ -MOE modification confers increased stability and affinity, it does 
not support RNase H1 -catalyzed cleavage of RNA hybridized to 2ʹ -MOE -modified nucleotides 
(McKay et al. 1999 ). This is caused by [CONTACT_37802] 
2ʹ-alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H1 enzyme ( Inoue et al. 1987 ; Monia  
et al. 1993 ). By [CONTACT_37761] 2′ -O-(2-methoxyethyl) (2′ -MOE) modification to nucleotides  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
25 
25 of 84  
  
flanking  the phosphorothioate  oligodeoxynucleotide  core,  the beneficial  attributes  of the 2′-MOE 
chemistry are preserved while also retaining RNase H1 recogn ition.  
A fourth  region,  comprised  of a tri-antennary  cluster  of N-acetyl  galactosamine  (GalNAc)  sugars, 
is linked to the 5ʹ end of ISIS 766720 via a phosphodiester linkage.  The GalNAc cluster is a  
high affinity ligand for the asialoglycoprotein receptor (ASGPR), a receptor expressed primarily 
on the surface of liver hepatocytes ( Stockert 1995 ). The GalNAc 3 cluster enhances delivery of 
ISIS 766720 to liver hepatocytes over other cell types and enhances potency.  After 
internalization into cells, the GalNAc cluster is metabolized to release ‘free ASO’ inside the cell 
(Prakash et al. 2014 ). The internucleosidic linkages are a mixture of phos phorothioate and 
phosphodiester.  The phosphorothioate linkages are introduced into the DNA gap region and at 
both ends of the oligonucleotide to protect it from nuclease mediated metabolism.  The mixed 
backbone design reduces the total number of phosphoroth ioate linkages which reduces  
non-specific  interactions  with proteins  and further  enhances  potency  and therapeutic  index  of 
GalNAc conjugated ASOs.  
 
2′-MOE  wing  2′-Deoxy  gap 2′-MOE  wing  
(RNase  H active)  
5’- THA -AH o  
sCsCsAoCoCs  TsTsTsGsGsGsTsGsAsAs  ToAoGsCsA   
 
THA  = GalNAc  cluster  
AH=  Amino  hexyl  linker  
2′-MOE  = 2′-O-(2-methoxyethyl) 
2′-Deoxy = DNA  
s = phosphorothioate  diester  linkage 
o = phosphate diester linkage  
Figure 1  Design  of GalNAc  Conjugated  Chimeric  2ʹ-MOE  Phosphorothioate 
Oligonucleotides (MOE -Gapmer)  
The sequence  of ISIS 766720  is shown.  
 
 
2.3.3.  Preclinical  Experience  
Detailed  information  concerning  the preclinical  studies  conducted  with ISIS 766720  can be 
found in the Investigator’s Brochure.  A summary is included below.  
The pharmacologic effects of ASOs designed to reduce hepatic GHR messenger ribonucleic acid 
(mRNA) expression and reduce serum IGF -1 protein expression were examined in mice and in 
non-human primates.  ISIS 766720 exhibits full complementarity to the human and nonhuman 
primate  GHR  RNA  sequence.  ISIS 766720  is pharmacologically  active  in cynomolgus  monkeys, 
as shown by [CONTACT_526968] -1 plasma protein levels wi th 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
26 
26 of 84  
  
treatment.  The cynomolgus monkey is accepted as a relevant preclinical safety model for 
oligonucleotide -based  therapeutics  and the anticipated  pharmacologic  activity  of ISIS 766720  in 
this species.  Since the human GHR transcript is not expressed in rodents, a mouse -specific 
inhibitor of GHR RNA expression (ISIS 807403) was included in the mouse [ADDRESS_683747] noteworthy 
findings  observed  in mice  and monkeys  following  ISIS 766720  treatment  were,  in general,  non- 
specific class effects that are typi[INVESTIGATOR_21885] a 2′ -MOE ASO.  The intended pharmacologic effect of 
dose-dependent reduction in liver  GHR mRNA l evels was achieved in both mice and monkeys, 
with subsequent decreases in serum IGF -1 levels, but there were no toxicologically relevant 
findings considered to be related to the pharmacologic inhibition of GHR expression in either 
species.  
 
2.3.4.  Clinical  Experi ence 
Detailed  information  concerning  the clinical  studies  conducted  with ISIS 766720  can be found  in 
the Investigator’s Brochure.  A summary is included below.  
The safety and tolerability of ISIS 766720 was evaluated in a total of 36 healthy subjects in a 
double -blinded,  placebo -controlled,  dose-escalation  Phase  1 study  ISIS 766720 -CS1.  Of these 
36 subjects, 27 received ISIS 766720 (9 in the single -dose cohorts a nd 18 in the multiple -dose 
cohorts), and 9 received placebo.  ISIS 766720 was well -tolerated at doses up to 80 mg 
administered as a single -dose and 120 mg total dose (30 mg administered as 4 doses over  
2 weeks).  There  were  no SAEs  and all reported  AEs were  mild in severity.  There  were  no 
dose-dependent clinically meaningful trends in laboratory assessments.  
Since  GHBP  is a fragment  of GHR  released  into the circulation,  reducing  GHR  expression  with 
ISIS 766720  is expected  to lower  the circulating  GHBP,  thus making  GHBP  a useful  biomarker 
for the activity of ISIS 766720 in healthy volunteers.  Indeed, GHBP is decreased in a  
dose-dependent manner to a mean reduction of approximately 60% observed [ADDRESS_683748]  of ISIS 766720  on IGF-1 will be evaluated  in the 
current study in the relevant patient population.  
 
2.4. Rationale  for Dose  and Schedule  of Administration  
The dose levels of 60 mg/q28 days and 80 mg/q28 days were selected based on the safety, PK, 
and pharmacodynamic data from ISIS 766720 Phase 1 study  in healthy  volunteers.  The Phase 1 
study  evaluated  ISIS 766720  doses  of 40 mg, 60 mg, and 80 mg administered  as single  doses  and 
10 mg, 20 mg and 30 mg administered as 4 doses over a 2 -week period that were found to be 
generally well -tolerated and induced significant reductions in GHBP, a potential biomarker of 
GHR inhibition.  The sa fety data obtained in the Phase 1 study  (ISIS 766720 -CS1) as well as the 
clinical experience with several other 2ʹ -MOE modified ASOs ( Sewell et al. 2002 ; Chi et al.  
2005 ; Kastelein  et al. 2006 ) and GalNAc -conjugated  ASOs  (Viney  et al. 2016 ; Graham  et al. 
2017 ) supports the dosing regimen planned for this Phase 2 study.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
27 
27 of 84  
  
The every 28 -day dosing regimen (Days 1, 29, 57, 85 and 112) is supported by [CONTACT_526969]-life of this compound  (approximately  2-3 weeks)  and significant  GHBP  reductions  observed 
after single doses of [ADDRESS_683749] dose (Day 15), is included to achieve steady -state 
concentrations earlier in the Treatment Period to allow assessment of efficacy after steady -state 
concentrations are achieved.  
The range  of dosing  proposed  for the present  study  will provide  the equivalent  drug exposure  of 
[ADDRESS_683750] 4 weeks and 15 mg  and 20 mg  administered 
weekly for the remaining 12 weeks; respectively for Cohort A (60 mg) and Cohort B (80 mg). 
The highest dose selected for this study, 80 mg every 28 days (e.g., 20 mg per week), could 
decrease hepatic GHR expression resulting in at least a 50% reduction in serum IGF -1 levels in 
acromegaly patients.  
The dose level of 120 mg/q28 day, and potentially 160 mg/q28 day, have been added to assess 
the safety and eff icacy of higher doses of ISIS 766720.  Based on all available data from the 
nonclinical  toxicology  program,  the no-observed -adverse -effect -level  (NOAEL)  for ISIS 766720 
in the monkey was determined to be 30 mg/kg based on the weekly study for 16 weeks and t he 
monthly study for 9 months.  This provides a therapeutic margin of up to 35 -fold for an 
approximate  2.3 mg/kg/month  (160 mg/month)  clinical  dose based  on plasma  AUC  (extrapolated 
from the Phase 1, 80 mg data).  
Each  patient  will receive  6 SC injections  in the clinic  during  the 16-week  Treatment  Period  on 
Days 1, 15, 29, 57, 85 and 112.  
The 16-week  treatment  duration  of the trial is supported  by [CONTACT_526952] 766720  nonclinical  16-week 
toxicology studies (See Investigators Brochure) and by [CONTACT_526953] -term weekly clinical 
dosing studies with several other 2ʹ -MOE -modified ASOs.  
The SRL  dosing regimen will be every  [ADDRESS_683751] - 
Treatment Period.  If the SRL cannot be administered in the Clinic, the administration of SRL 
relative to Study Drug should be consistent (e.g., same number of days [1 -3 days ] post -Study 
Drug administration) throughout the trial.  The date and time of each SRL dose administered 
outside  of the clinic  will be documented  by [CONTACT_526954] a SRL dosing  diary  and provided  to the 
study center staff at subsequent visits.  See Section 6.1.[ADDRESS_683752] been safely 
administered intravenously and SC in multiple clinical studies at doses up to 1000 mg ( Kwoh  
2008 ; Crooke et al. 2016 ) and for treatment durations that exceed 24 months.  
 
2.5. Risk  Assessment  
2.5.1.  Risk  Assessment  
Given  the short  duration  of the study,  the risks  associated  with GHR  reduction  are not anticipated 
in this trial.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
28 
28 of 84  
  
3. EXPERIMENTAL  PLAN  
3.1. Study  Design  
This is a double blind, placebo -controlled, Phase 2 study to assess the safety, tolerability, and 
efficacy of ISIS 766720 administered once every 4 weeks for 16 weeks to patients with 
acromegaly uncontrolled (IGF -1 level between 1.3 × to 5 × ULN) on select  long-acting SRL. 
Patients  will be stratified  by [CONTACT_526970] -1 level  (IGF -1 > 2.5 ×  ULN  or ≤ 2.5 × ULN  age 
and sex adjusted by [CONTACT_35970]).  
 
3.2. Number  of Study  Centers  
This study  will be conducted  at multiple  centers  worldwide  at approximately  40 sites. 
 
3.3. Number  of Patients  
Approximately  60 patients  are planned  to be randomized  in this study.  The number  of evaluable 
patients per cohort and their corresponding randomization ratio (ISIS 766720 vs. Placebo) are 
listed as follows:  
 
Cohort  Number  of Patients  Randomization  Ratio  
A 15 2:1 
B 15 2:1 
C 12 5:1 
D 12 5:[ADDRESS_683753]  of the  following  periods:  
• A ≤ 9-week  Screening  Assessment  Period  
• A 16-week  Treatment  Period  during  which  Study  Drug  will be administered  as a once 
every 4 -week SC injection (except during Month 1 where a booster dose is 
administered on Day 15)  
• A 14-week  Post-Treatment  Evaluation  Period  
Once  in the Post-Treatment  Period,  patients  who meet  eligibility  requirements  for the open -label 
extension (OLE ) study may elect to enroll in the OLE study and will need to sign the IRB/IEC 
approved informed consent.  Patients not participating in the OLE study will enter the [ADDRESS_683754]-Treatment Evaluation Period.  
Patients may be required to attend additional vis its for monitoring of adverse events (AE) or 
abnormal  investigation  results.  The frequency  of additional  monitoring  will be determined  by 
[CONTACT_144369].  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
29 
29 of 84  
  
3.4.1.  Screening  
Patient  eligibility  for the study  will be determined within  63 days prior  to study  entry.  Sponsor 
Medical Monitor or designee approval is required for patients to enter the Treatment Period.  
 
3.4.2.  Treatment  
Eligible patients will report to the Study Center for Study Drug administratio n per schedule of 
procedures in Appendix A . Study Drug and SRL will be dosed in clinic every 28 days (in 
addition, a booster dose of Study Drug is administered on Day 15) while additional visits to 
collect  safety  assessments  (Day  43, Day 71 and  Day 99) could  be completed  either  in clinic  or by 
[CONTACT_278316].  If the SRL cannot be administered in the Clinic, the administration of 
SRL relative to Study Drug should be consistent (e.g., same number of days (1 to 3 days) p ost- 
Study  Drug administration) throughout the trial with date and time documented by [CONTACT_89410] 
a dosing  diary.  The treatment duration is [ADDRESS_683755] 1 dose of Study Drug 
(ISIS 766720 or placebo) will  be required to complete the Post -Treatment Period.  The final 
study visit will be [ADDRESS_683756] injection (PTWk15).  
 
3.5. End-of-Study  
The End-of-Study  is defined  as last patient,  last visit when  all patients complete  the last visit of 
the Post -Treatment Period.  
3.6. Data  and Safety  Monitoring  Board  
This trial will not have  a Data  and Safety  Monitoring Board.  
 
4. PATIENT  ENROLLMENT  
4.1. Screening  
Before  patients  may be enrolled  into the study,  the Sponsor  or designee requires  a copy  of the 
Study C enter’s written independent ethics committee/institutional review board (IEC/IRB) 
approval of the protocol, informed consent form, and all other patient information and/or 
recruitment material.  
Patients or their legally acceptable representatives must sign the consent form before any 
screening tests or assessments are performed.  At the time of consent, the patient will be 
considered enrolled into the study and will be assigned a unique screening number before any 
study  procedures,  including  screening  procedures,  are performed.  At the time of randomization, 
patients will be assigned a unique patient identification number.  This number will be used to 
identify the patient throughout the trial and must be used on all study documentation related to 
that patient.  The screening number and patient ide ntification number must remain constant 
throughout the entire trial.  In the event the patient is re -consented and re -screened the patient  
ISIS [ADDRESS_683757] been completed, after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2, and after 
approval  by [CONTACT_526971].  No patient  may begin  treatment  prior  to randomization 
and assignment of a unique patient identification number.  
Eligible  patients  will be stratified  based  on screening  IGF-1 levels  (≤ 2.5 × ULN  or > 2.5 ×  ULN 
age and sex adjusted by [CONTACT_35970]) and then patients will be randomized to 1 of 2 dose cohorts 
in a 1:1 ratio (Cohort A or Cohort B).  Within each dose cohort, patients will be further 
randomized to receive ISIS 766720 o r placebo in a 2:1 ratio.  
Eligible  patients for  Cohorts  C and D will be stratified  based  on screening  IGF-1 levels  
(≤ 2.5 × ULN  or > 2.5 × ULN,  age and sex adjusted  by [CONTACT_104073]). Patients  will be randomized 
to receive ISIS 766720 or placebo in a 5:1 ratio.  
After  enrollment  in Cohort  A and B is completed,  Cohort  C will begin  enrollment.  Cohort  D 
will be conducted based on the safety and efficacy results of the lower -dose cohorts  
 
4.3. Replacement  of Patients 
Patients  who withdraw  from  the study  will not be replaced.  
 
4.4. Unblinding  of Treatment  Assignment  
The Sponsor and representatives, and all patients, and Study Center personnel related to the 
study, will be blinded throughout the study.  However, if a patient has suffered a related Serious 
Adverse Event (SAE) (as defined in Section 9.3.3 ), and/or when knowledge of the treatment 
assignment will impact the clinical management of the patient, the Investigator will have the 
ability  to unblind the treatment assignment for that patient using the automated IRT (Interactive 
Response  Technology)  system.  The Sponsor  or designee  will be informed  of the unblinding  of a 
patient within 24 hours.  An unblinded randomization schema will be maintained securely  at the 
Sponsor’s designated vendor.  In addition, all suspected unexpected serious ad verse reactions 
(S[LOCATION_003]Rs) will be unblinded by [CONTACT_526972] 
(see Section 9.2). 
Every  reasonable  attempt  should  be made  to complete  the early  termination  study  procedures  and 
observations (see Appendix A  and Appendix B ) prior to unblinding if needed, as knowledge of 
the treatment arm could influence patient assessment.  
In addition, the Ionis Drug Safety Oversight committee, chaired by [CONTACT_526973], 
will also have  the ability  to request  for unblinding  the treatment  assignment  if needed  for safety 
and data interpretation.  
ISIS [ADDRESS_683758]  given  written  informed  consent  (signed  and dated)  and any authorizations 
required by [CONTACT_10523]  
2. Males  or females  with documented  diagnosis  of Acromegaly*.  Aged  18 to 75 years  old 
(inclusive) at the time of informed consent  
* Defined as a previous diagnosis of GH -secreting adenoma by  [CONTACT_38165]; or 
the presence of a pi[INVESTIGATOR_526908] (MRI) or 
computed  tomography  (CT)  scan (if MRI  is contraindicated)  and serum  IGF-1 levels 
above the upper limit of normal for age and sex at time of diagnosis (serum IGF -1 
level and MRI at diagnosis will be collected in the CRF)  
3. Patients must be on stable maximum or maximally tolerated dose of SRL (lanreotide 
Autogel or octreotide LAR, p er treating physician judgment) every 28 days* for a 
minimum  of 3 months  prior  to screening  and will be required  to continue  their stable  dose 
of SRL throughout the study.  In accordance with US approved prescribing information, 
the maximal dose recommended  per the package insert for lanreotide Autogel is 120 mg 
every 28 days and for octreotide LAR is 40 mg every 28 days (the reason for the 
maximally tolerated dose of SRL will be collected in the CRF).  SRL dose should not 
exceed  the maximum  dose as approved  in the local region  (as indicated  in the SRL label). 
Prior use of other medications for treating acromegaly (pasireotide, dopamine agonist or 
pegvisomant) is allowed but not within 6 weeks of screening  
* Patients  who are on a stable  monthly  dosing  regimen,  but not exactly  every  28 days 
will be  consider ed for inclusion to this study.  Patients who  are on a stable  regimen 
that is not monthly e.g., every 3 weeks or every 6 weeks are excluded.  
4. At screening,  serum  IGF-1 (performed  at central  lab) between  1.3 to 5 × ULN,  inclusive, 
adjusted for age and sex  
5. Females must  be non-pregnant and  non-lactating,  and either:  
a. surgically  sterile  (e.g.,  tubal  occlusion,  hysterectomy,  bilateral  salpi[INVESTIGATOR_1656], 
bilateral oophorectomy)  
b. post-menopausal  (defined  as 12 months  of spontaneous  amenorrhea  in females  
> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea 
without  an alternative  medical  cause  and FSH levels  in the postmenopausal  range  for 
the laboratory involved)  
c. abstinent  or 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
32 
32 of 84  
  
d. Women  of childbearing  potential  (WOCBP)  should  agree  to taking  all precaution  to 
avoid pregnancy during the trial period (including Post -Treatment), including 
agreeing to receive pregnancy testing before each monthly dose, using 1 highly 
effective method of birth control (Section 6.3.1 ) from the time of signing the 
informed consent form until [ADDRESS_683759] be using 1 highly effective 
contraceptive  method  (refer  to Section  6.3.1 ) from  the time of signing  the informed 
consent form until [ADDRESS_683760] dose of Study Drug.  
6. Willing  to refrain  from  strenuous  exercise/activity  (for example  heavy  lifting,  weight 
training, intense aerobics classes etc.) for at least 24 hours prior to study visits  
7. Willing  to refrain  from  alcohol or  tobacco use  for 8  hours  prior  to study  visits  
 
5.2. Exclusion  Criteria  
1. Clinically significant abnormalities in medical history (e.g., previous acute coronary 
syndrome  within  6 months  of screening,  major  non-pi[INVESTIGATOR_526909]  3 months  of 
screening) or from screening physical examination  
2. Patients  who received  surgery  for pi[INVESTIGATOR_526910] 6 months  before  the 
trial, and/or planning to receive surgery during the trial  
3. Patients  who received  radiotherapy  for pi[INVESTIGATOR_526910] 3 years  before 
the trial, and/or planning to receive radiotherapy during the trial  
4. Patients  with a pi[INVESTIGATOR_526912], per Investigator  judgment,  is worsening  (e.g.,  either 
growing,  or at risk of compressing  or abutting  the optic  chiasm  or other  vital structures) 
as assessed  by [CONTACT_21173][INVESTIGATOR_2117]/sellar  MRI  or CT scan protocol  at screening  or within  6 months 
of screening  
5. Evidence  of decompensated  cardiac  function  per medical  judgement  and/or  NYHA 
class 3 or 4  
6. Clinical  evidence  of symptomatic  hyperprolactinemia  that would  necessitate  treatment  
7. Symptomatic  cholelithiasis,  and/or  choledocholithiasis  
8. Have  a diagnosis  of Gilbert’s  disease  
9. Patients  with history  of hypoglycemia  unawareness  (who  have  had > [ADDRESS_683761] 6 months) or documented reactive hypoglycemia  
10. Screening  laboratory  results  as follows,  or any other  clinically -significant  abnormalities 
in screening laboratory values that would render a patient unsuitable for inclusion. 
(abnormalities may be retested for eligibility purposes)  
a. Urine  protein/creatinine  (P/C)  ratio ≥ 500 mg/g.  In the event  of P/C ratio above  this 
threshold eligibility may be confirmed by a quantitative total urine protein 
measurement of < 1000 mg/[ADDRESS_683762] (including  trace) for  blood  on urinalysis.  In the event  of a positive  test 
eligibility  may be confirmed  with urine  microscopy  showing  < [ADDRESS_683763]  > 1.2 × ULN,  bilirubin  > ULN;  alkaline  phosphatase  (ALP)  > 3 × ULN  
d. eGFR < 45 mL/min/1.73m2 as determined by [CONTACT_81105] - 
Epi[INVESTIGATOR_526919]  (CKD -EPI) equation  for creatinine  clearance  OR 
serum creatinine > 1.8 mg/dL in males and > 1.5 mg/dL in females  
e. Platelet  count  < LLN  
f. Abnormal  thyroid  function  tests must  be approved  by [CONTACT_526949]  
g. HbA1c  > 10% 
h.  Abnormal  morning  cortisol  test consistent  with symptomatic  adrenal  insufficiency 
based on Investigator judgement  
11. Active  infection  requiring  systemic  antiviral  or antimicrobial  therapy  that will not be 
completed prior to Study Day [ADDRESS_683764] for human  immunodeficiency  virus  (HIV),  hepatitis  C 
or chronic hepatitis B  
14. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin, 
carcinoma  in situ of the cervix,  follicular  Stage  1 or papi[INVESTIGATOR_526920]; patients with a history of other malignancies that have been treated 
with curative intent and which have no recurrence within 5 years may also be eligible if 
approved by [CONTACT_37755]  
15. Treatment  with another  investig ational  drug,  biological  agent,  or device  within  1 month 
of screening, or 5 half -lives of investigational agent, whichever is longer  
16. Treatment  with any non- ION- or ISIS -oligonucleotide  (including  siRNA)  at any time or 
prior treatment with an ION - or ISIS -oligonucleotide within [ADDRESS_683765] previously received only a single -dose of an ION - or 
ISIS-oligonucleotide as  part of a clinical  study  may be included as  long as a duration  
≥ [ADDRESS_683766] be on a stable dose and regimen (increases used to prevent adrenal 
crisis is permitted) for ≥ [ADDRESS_683767]  be on a stable  dose and regimen  for 
≥ [ADDRESS_683768]  be on a stable  dose and  regimen  for 
≥ [ADDRESS_683769] 
dose of Study Drug and regular clinical monitoring is performed during the trial  
23. Blood  donation  of 50 to 499  mL within  30 days of screening  or of > [ADDRESS_683770] 6 months  prior  to screening.  If MRI 
is contraindicated, then a computed tomography (CT) scan is acceptable.  
Individuals  may be disqualified  if the result  of any laboratory  test is outside  the range specified 
in the eligibility criteria (Sections 5.1 and 5.2) or, if no range is specified, is abnormal and 
clinically -significant (CS) as judged by [CONTACT_526974].  During the Screening Period, screening results may  be retested (Home Health Care 
Visit Option can be used)  for assessment by [CONTACT_526975].  
The IGF-1 screening  (and repeat IGF -1, if needed)  blood  sample  must  be drawn  up to 3 days 
prior to or on the day of SRL administration.  IGF-1 can be repeated once and aver aged to 
determine eligibility  if the initial result is between 1.1 -1.3 × ULN, or between 5 -5.3 × ULN.  
Sponsor  Medical  Monitor  or designee  approval  is required  for patients  to enter  the Treatment 
Period after eligibility is reviewed.  Qualified patients will  be stratified and randomized and 
proceed to the Treatment Period Week 1, Day 1 Assessments.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
35 
35 of 84  
  
Screening  failed  patients  may be re-screened  1 more  time after the Investigator  feels  the reason 
for screening failure has resolved.  
 
6.1.2.  Baseline  and Treatment  Period  
All randomized patients will return to the clinic for Study  Drug on Day  1, Day  15 (Study Drug 
administration only), Day 29, Day 57, Day [ADDRESS_683771] Study Drug 
administration  is conducted  at the END  of the Study  Week – Week  16, Day  112. The patient’s 
stable  SRL regimen  will continue  throughout  study  participation  and the  administration  of SRL 
relative to Study  Drug  must be  consistent  throughout the  trial. Therefore, plan to align all SRL 
injections  to be either  i) the same  day as the Study  Drug  administration,  or ii) up to [ADDRESS_683772] be taken prior to Study Drug 
administration.  
If the SRL cannot  be administered  in the Clinic,  the date and time of each SRL  dose will be 
documented by [CONTACT_89410] a SRL dosing diary and provided to the study center staff at 
subsequent visits.  
Safety,  efficacy,  PK and exploratory  assessments  will be performed  per Appendix  A, 
Appendix B , and Appendix C  throughout the Treatment Period on Study Drug administration 
days and on Day  43, Day  71 and Day  99. The study  procedures required on Day  43, Day  71 and 
Day 99 may be performed outside the clinic  by a Sponsor selected Home Health Care 
professional.  In consultation  with the Sponsor,  a Home  Health  Care  visit may be conducted for  a 
study visit that was intended to be a clinic visit.  A confirmation of Study Drug dosing by [CONTACT_526976] 48 hours.  It is 
preferable that the entire visit is conducted, however, the following assessments may be omitted 
from  the Home  Health  Care  visit: ECG,  body  weight,  physical  exam,  ring size, and OGTT.  Any 
assessments not performed at the Home Health Care visit should be attempted at the next clinic 
visit.  
If a visit cannot  be performed,  patient  contact  (e.g.,  phone,  text or video)  is required  by [CONTACT_526977].  
At each visit, patients should arrive fasting at least 8 hours for safety and clinical laboratory 
evaluations;  vital signs,  blood  pressure  (BP)  assessments,  AEs and concomitant  usage  will be 
assessed during each visit.  
A 2-hour Oral Glucose Tolerance Test (OGTT) will be conducted on Study Day 1 pre -dose and 
Day 57. The Day 1 OGTT can be conducted between Day -7 and Day -1. Acromegaly  symptom 
and treatment score (ASTS) questionnaire and quality of life via AcroQoL questionnaire will be 
assessed  along  with ring size assessment  periodically  throughout  the study.  See Section  6.2 for a 
description of the study procedures.  Study required procedu res at study visits are listed in the 
Schedule of Procedures in Appendix A , Appendix B  and Appendix C . 
Patient will be requested to complete AcroQoL, ASTS and ring size assessments prior to all  
other  procedures and  dosing  (see Section  6.2). All blood  samples  should  be drawn  prior  to Study 
Drug administration (exceptions are the post -dose samples for PK sampling).  
ISIS [ADDRESS_683773] the 
evaluation of efficacy.  
All safety  data including  AEs and concomitant  medications  will be reviewed  by [CONTACT_1034]’s 
Medical Monitor or designee on an ongoing basis throughout the trial.  
Early termination patients from the Treatment Period will be requested to enter the [ADDRESS_683774] visit to complete  is an “early  termination  from  treatment”  visit 
entitled ETTX.  The ETTX visit should be completed as soon as possible after the decision is 
made, preferably  [ADDRESS_683775] dose ( Appendix A ). 
All patients  receiving  at least [ADDRESS_683776] -treatment follow -up evaluations 
(Appendix A ). All patients will be followed for [ADDRESS_683777] -Treatment  
Week 15 (PTWk15) occurring [ADDRESS_683778] dose.  Note:  The visits are scheduled in 
intervals relative to the patient’s last dose, for example Post -Treatment Week 3 Visit (PTWK3) 
is [ADDRESS_683779]-Treatment  Week  5 (PTWk5)  is [ADDRESS_683780] dose.  
Safety and c linical laboratory evaluations as well as PD markers, including those for PK  
analysis, will be performed as indicated in the Appendix A , Appendix B  and Appendix  C. 
Patients will continue their SRL therapy, Safety and efficacy data, including any AEs and 
concomitant medications will be recorded and reviewed by [CONTACT_1034]’s Medical Monitor or 
designee.  The Investigator  after consultation  with the Sponsor  Medical  Monitor  or designee  may 
conduct an MRI (or CT when MRI is contraindicated) in the Post -Treatment Period if clinically 
indicated.  A 2-hour OGTT will be conducted at the PTWk5 visit.  The AcroQoL, ASTS, and 
ring size assessment will be conducted perio dically in the Post -Treatment Period.  
In consultation with the Sponsor, a Home Health Care visit may be conducted for a study visit 
that was intended to be a clinic visit.  It is preferable that the entire visit is conducted, however, 
the following  assessments  may be omitted  from  the Home  Healt h Care  visit:  ECG,  body  weight, 
physical exam, ring size, and OGTT.  Any assessments not performed at the Home Health Care 
visit should be attempted at the next clinic visit.  
If a visit cannot  be performed,  patient  contact  (e.g.,  phone,  text or video)  is required  by [CONTACT_526977].  
Once  in the Post-Treatment  Period,  patients  who meet  eligibility  requirements  for the open -label 
extension (OLE) study may elect to enroll in the OLE study and will need to sign the IRB/IEC 
approved informed consent.  Patients not participating in the OLE study will enter the [ADDRESS_683781]-Treatment  Period  will be required  to complete  the ETPT 
Study procedures ( Appendix A ). 
ISIS [ADDRESS_683782] 8 hours  (at 
least 10 hours for OGTT).  During this time the patient should ensure that they consume 
sufficient water in order to not become dehydrated.  
If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to 
clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient)  or missing, a repeat blood specimen should be 
re-drawn as soon as possible (ideally within 7 days) either in clinic or by [CONTACT_526978]. The next dose of Study  Drug  may not be administered  until a result  not meeting  a stoppi[INVESTIGATOR_526921] . 
At any time,  the Sponsor  Medical  Monitor  or designee  may request both  a central  and local  lab 
collection in parallel to assess patient safety.  
 
6.2.2.  Oral  Glucose  Tolerance Test  (OGTT)  
Patients  will undergo  3 OGTT  procedures  during  the Treatment  Period  (X2)  and Post-Treatment 
Period (X1) per Appendix A . For each OGTT procedure, patients should begin fasting for  
[ADDRESS_683783] (only  water is permitted).  It is preferable to collect blood 
samples  for OGT T through  indwelling  catheter,  but it is not mandatory.  (See Appendix A  and 
Table 1 ). After an indwelling catheter is inserted and a 5 -minute period is allowed to remove 
any effects linked to the stress induced by [CONTACT_48571].  Blood sampling will begin at  
Time 0 -before the glucose solution is consumed.  The glucose solution (75 grams in a 3 00-mL 
solution) will be consumed within a [ADDRESS_683784] refrain from smoking until the fasting period is completed (after the  
120-minute  blood  draw).  During  the Treatment  Period,  the OGTT  should  be completed  before 
Study Drug is administered.  
Table  1 Sampling  Schedule:  Day of Oral  Glucose  Tolerance  Test (OGTT)  
 
Intervention  Time  (Minutes)  OGTT  Sampling  
Study  Day D1*,  57, 141 
 -5 Catheter  Insertion  (if used)  
T0 = 75 grams  Glucose 
Ingestion  0 
Prior  to Glucose 
ingestion  Glucose,  Insulin,  C-peptide  
30 Glucose,  Insulin,  C-peptide  
60 Glucose,  Insulin,  C-peptide  
90 Glucose,  Insulin,  C-peptide  
120# Glucose,  Insulin,  C-peptide  
* Day 1 OGTT:  The Day 1 OGTT can  be conducted  between  Day-7 and Day-1. The procedure  can be conducted  in 
the clinic or as arranged by a Home Health Care professional  
# After  the 120-min blood  draw,  the fasting  period  is completed  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
38 
38 of 84  
  
6.2.3.  Assessments  for Acromegaly  
There  are up to 3 procedures  that will be conducted  that assess  signs,  symptoms  and quality  of 
life (QoL)  for an acromegaly  patient.  For purposes  of this clinical  trial and consistency  across 
visits, it is requested that these assessments for acromegaly be:  
1. Conducted  at the beginning  of the study  visit (prior  to other  study  procedures  and drug 
administration)  
2. Conducted sequentially in this order:  1) AcroQoL; 2) Acromegaly Symptoms and 
Treatment  Score  Questionnaire  (ASTS);  3) Ring  Size Assessment.  AcroQoL and ASTS 
will be a paper  assessment  filled  out by [CONTACT_526979]  
3. It may take approximately  20 minutes to  complete  all 3 assessments  
Prior to filling out the AcroQoL and ASTS questionnaires, the patient should sit quietly in a 
room  without  distraction,  and be reminded  of the following,  i) the purpose  of the questionnaires,  
ii) to complete  the questionnaire  honestly,  iii) they should  be aware  that there  are no wrong 
answers, and iv) it is important to answer all questions.  
Note:  Deviations  from  the order  of completion  or relati on of completion  to Study  Drug 
administration will not be considered a significant deviation that will impact efficacy.  
[IP_ADDRESS].  Acromegaly  Quality  of Life Questionnaire  (AcroQoL)  
To assess the health -related quality of life affected by [CONTACT_526980], patients will complete the 
AcroQoL questionnaire during the Treatment and Post -Treatment Periods (per Appendix A ). 
AcroQoL is a [ADDRESS_683785] of acromegaly in 
patients’  life. It contains  2 scales  that evaluate  physical  (8 questions)  and psychological  aspects 
related to the appearance and personal relations (7 items each) ( Webb et al. 2002 ). This 
questionnaire will take about 10 minutes to be completed.  
[IP_ADDRESS].  Acromegaly  Symptoms  and Treatment  Score  Questionnaire  (ASTS)  
Patients will be asked to complete the assessment to monitor symptoms relating to the 
acromegaly  and its treatments.  Each question is answered on a scale of 0 to 4 from no symptom 
to very severe.  The questions address acromegaly -specific symptoms (e.g., he adache, 
perspi[INVESTIGATOR_1516], paresthesia) and treatments (burden of Study  Drug and effectiveness of SRL).  This 
questionnaire  will take about  [ADDRESS_683786]  Question  #[ADDRESS_683787] -Treatment days 127, 141, 155, 183, 211, and ETPT.  
[IP_ADDRESS].  Ring  Size Assessment  
Finger size is an objective measure of soft tissue swelling and over growth and can be used to 
monitor the response to treatment.  Measurement should be taken prior to  any intravenous 
cannulation.  Ring size is assessed using the study provided ring sizer widget and the fourth 
finger of the non -dominant hand.  The ring size to record is the one with the tightest fit.  If the 
finger is too large to be measured by  [CONTACT_526981] s izer then use the fifth finger (and make a note of 
this).  The same  finger  will be used throughout  the trial ( Barts  Endocrine  2009 ). If possible,  the 
same study personnel should conduct the ring size assessment at each clinic  visit.  
ISIS [ADDRESS_683788] refrain from sperm/egg donation and practice highly 
effective  contraception  from  the time of signing  the informed  consent  form  until [ADDRESS_683789] dose of study treatment.  
If the male patient’s non -pregnant fema le partner is using a highly effective contraception 
method,  from  the time of signing  the informed  consent  form  until [ADDRESS_683790] dose 
of study treatment, the male patient’s contraception requirement is considered fulfilled.  
For the purposes  of this study,  WOCBP  are defined  as any female  who has experienced 
menarche, and who does not meet 1 of the following conditions:  
• Postmenopausal:  12 months  of spontaneous  amenorrhea  in females  > 55 years  of age 
or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an 
alternative medical cause and FSH levels in the postmenopausal range for the 
laboratory involved  
• 6 weeks  after surgical  bilateral  oophorectomy  with or without  hysterectomy  
• Post-hysterectomy  
For the purposes  of the study,  highly  effective  contraception  is defined  as follows: 
For male patients:  
• Highly effective male contraception includes:  a vasectomy with negative semen 
analysis  at Follow -up, sexual  abstinence†, non-pregnant  female  partner  uses 1 highly 
effective contraceptive methods (defined below)  
• Male  patients  with partners  that are pregnant  must  use condoms  as contraception  to 
ensure t hat the fetus is not exposed to the Study Drug  
• For female  partners  of male  patients,  contraception  should  be encouraged 
Female patients of childbearing potential:  
• Using  1 highly  effective  method  of contraception:  surgical  sterilization  (e.g.,  bilateral 
tubal occlusion), hormonal contraception associated with inhibition of ovulation 
(combined [estrogen and progestogen containing] or progestogen -only), intrauterine 
device (IUD), intrauterine hormone -release system (IUS), a vasectomized partner or  
sexual abstinence † 
† Note : Abstinence is only acceptable as true abstinence, refraining from heterosexual 
intercourse throughout the duration of study participation.  Periodic abstinence (e.g., 
calendar,  ovulation,  symptothermal,  post-ovulation  methods),  declaration  of abstinence 
for the duration of a trial and withdrawal are not acceptable methods of contraception.  
ISIS [ADDRESS_683791]  refrain  from  strenuous  exercise/activity  (for example  heavy  lifting,  weight  training, 
intense aerobics classes, etc.) for at least 24 hours prior to each study  visit and also be willing to 
refrain from alcohol or tobacco use for 8 hours prior to study visits and/or laboratory sampling.  
All patients  will be required  to fast for at least [ADDRESS_683792] 
10 hours before OGTT.  
 
7. STUDY  DRUG  
7.1. ISIS  766720  or Placebo  
The characteristics  of the Study  Drug  (ISIS 766720  or placebo)  are listed  in Table  2. 
The Study  Drug  is contained  in [ADDRESS_683793] be 
stored securely at 2 -8 °Celsius and be protected from light.  
Table  2 Study  Drug  Char acteristics  
 
Study  Drug  ISIS  766720  Placebo  
Strength  100 mg/ mL Not Applicable  
Volume/Formulation  0.8 mL solution  per vial 0.8 mL solution  per vial 
Route  of Administration  subcutaneous  subcutaneous  
 
 
7.2. Packaging  and Labeling  
The Sponsor  will provide  the Investigator  with packaged  ISIS 766720  and placebo  labeled  in 
accordance with specific country regulatory requirements.  
 
7.3. Study  Drug  Accountability  
The study  staff is required  to document  the receipt,  dispensing,  and return/destruction  of Study 
Drug (ISIS 766720 or placebo) supplies provided by [CONTACT_84210].  
 
8. TREATMENT  OF PATIENTS  
8.1. Study  Drug  Administration  
During  Treatment  Period,  Study  Drug  will be administered  subcutaneously  during  clinic  visits  by 
[CONTACT_526982] A . Study  Drug  (ISIS 766720 or  placebo) injection volumes  will be  0.6 and 0.8 mL  for 
Cohort A (60 mg) and Cohort B (80 mg) respectively.  For Cohort C the total injection volume 
will be 1.2 mL (120 mg) and for Cohort D the total injection volume will be 1.6 mL (160 mg).  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
41 
41 of 84  
  
The administration of  Study  Drug  for Cohort C and D  may be delivered as  a single injection or 
2 non-contiguous  injections  (If 2 non-contiguous  injections,  volumes  such as, 0.6 mL × 2 for 120 
mg and 0.8 mL × 2 for 160 mg may be used).  
Please  refer  to the Study  Drug  Manual  provided  by [CONTACT_526983] (ISIS 766720 or placebo) preparation and administration.  
Table  [ADDRESS_683794]  be on stable  maximum  or maximally  tolerated  dose of SRL (lanreotide  Autogel  or 
octreotide LAR every *28 days), for a minimum of 3 months prior to screening and will be 
required to continue their SRL throughout the study.  During study participation, SRL can be 
administe red during  clinic  visits  by [CONTACT_526984].  
*  Patients who are  on a stable monthly  dosing regimen, but not exactly  every  28 days will 
be allowed.  Patients  who are on a stable  regimen that  is not monthly  e.g., every  3 weeks 
or every 6 weeks are excluded.  
 
8.3. Other  Protocol -Required  Treatment  Procedures  
There  is no other  protocol  required  treatment procedures.  
 
8.4. Treatment  Precautions  
There  are no specific  treatment  precautions  required for  this study.  
 
8.5. Safety  Monitoring  Rules  
Please  refer  also to the ‘Guidance  for Investigator’  section  of the Investigator’s  Brochure. 
For the purposes of safety monitoring baseline is defined as:  
• Monitoring  Rules  for Liver  Chemistry  Tests,  Renal  parameters,  and Platelets – Unless 
otherwise specified, baseline is defined as the average of pre -dosed values  
In addition  to the standard  monitoring  of clinical  safety  parameters,  the following  guidelines are 
provided for the monitoring of selected parameters chosen base d on preclinical and clinical 
observations for ISIS 766720 as well as other ASOs.  
Confirmation Guidance : At any time during the study (Treatment or Post -Treatment Periods), 
the initial  clinical  laboratory  results  meeting  the safety  monitoring  criteria  presented  below must 
be confirmed by [CONTACT_10533] (ideally in the same laboratory that performed the  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
42 
42 of 84  
  
initial  measurement)  on new specimens.  All new specimen  collections  should  take place  as soon 
as possible (ideally within 3 days of the initial collection).  For stoppi[INVESTIGATOR_004], if the initial 
laboratory result is observed during the Treatment Period, the results from the re -test must be 
available prior to administering the next dose of Study D rug (ISIS 766720 or placebo).  
Re-dosing Guidance : Patients with initial laboratory test values that reach a stoppi[INVESTIGATOR_10447] -dosed until the re -test results are available.  In general, patients who do not meet the 
stoppi[INVESTIGATOR_526922] -test may continue dosing.  However, the Investigator and the 
Sponsor Medical Monitor (or appropriately qualified designee) should confer as to whether 
additional  close  monitoring  of the patient  is appropriate.  If any of the stoppi[INVESTIGATOR_526923] 8.6 are met, th e patient will be permanently discontinued from further treatment with 
Study  Drug  (ISIS  766720  or placebo),  evaluated fully  as outlined  below  and in consultation  with 
the Sponsor Medical Monitor (or appropriately qualified designee), and will be followed up in 
accordance with Section 8.8 of the Protocol.  
8.5.1.  Safety  Monitoring  Rules  for Liver  Chemistry  Tests  
The following rules are adapted  from the draft guidance for industry, “Drug -Induced Liver 
Injury:  Premarketing  Clinical  Evaluation,”  issued  by [CONTACT_941] U.S. Department  of Health  and Human 
Services,  Food and  Drug  Administration,  July 2009.  For a definition  of Baseline  please  refer  to 
guidance  in Section 8.[ADDRESS_683795]  measurement  that is > 3 × ULN  or the greater  of [ADDRESS_683796] if the baseline value was > ULN at any  time during the study  (Treatment or 
Post-Treatment Period), the  initial measurement(s) should be  confirmed as described above.  
Additional,  confirmatory  measurements  should  also be performed  if ALT  or AST  levels  increase 
to 5 × ULN.  
Frequency  of Repeat  Measurements : Patients  with confirmed  ALT  or AST  levels  > 3 × ULN  or 
the greater of 2 × baseline value or 3 × ULN if the baseline value was > ULN should have their 
liver chemistry  tests (ALT,  AST,  ALP,  international  normalized  ratio [INR],  and total bilirubin) 
retested at least once -weekly until ALT and AST levels become  ≤ 1.2 × ULN or 1.2 × baseline 
value if the baseline value was > ULN.  
Further  Investigation  into Liver  Chemistry  Elevations : For patients  with confirmed  ALT  or AST 
levels > 3 × ULN or the greater of 2 × baseline value or 3 × ULN if the baseline value was  
> ULN, the following  evaluations should be performed:  
1. Obtain  a more  detailed  history  of symptoms  and prior  and concurrent diseases  
2. Obtain  further  history  for concomitant  drug use (including  nonprescription  medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain  a history  for exposure  to environmental  chemical agents  and travel  
4. Serology  for viral hepatitis  (hepatitis  A virus  [HAV]  immunoglobulin  M [IgM],  hepatitis 
B surface antigen [HBsAg], hepatitis C virus [HCV] antibody, CMV IgM, and  
Epstein -Barr Virus [EBV] antibody  panel)  
5. Serology  for autoimmune  hepatitis  (e.g.,  antinuclear antibody)  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
43 
43 of 84  
  
Additional  liver evaluations,  including  gastroenterology/hepatology  consultations,  hepatic  CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor.  Repetition of the above evaluations should be considered if  a 
patient’s ALT and/or AST levels reach 5 × ULN.  
[IP_ADDRESS].  Dose  Adjustments  Guidelines  for Liver  Monitoring  
Patients with a confirmed ALT or AST ≥ 3 × ULN but ≤ 5 × ULN without an alternative 
explanation,  with normal  bilirubin  levels,  and who have  not met other  stoppi[INVESTIGATOR_241491],  may have 
their Study Drug adjusted downward in consultation with the Sponsor Medical Monitor or 
designee.  
Dose  adjustment  will not be allowed  for patients  with confirmed  elevations  > 5 × ULN.  These 
patients will follow steps outlined in Section 8.6 Stoppi[INVESTIGATOR_1869].  
8.5.2.  Safety  Monitoring  Rules  for Platelet  Count  Results  
If a patient’s  platelet  count  falls by 30% or greater  from  Baseline  or the absolute  platelet  count  is 
100,000/mm3 or less, then the patient’s platelet counts should be monitored weekly.  In case of 
platelet reduction to below 75,000/mm3, the platelet monitoring rule defined in Stoppi[INVESTIGATOR_004] 
(Section 8.6.3 ) should be followed.  
Treatment  should  be held if there  is no evaluable  platelet  count  within  the 2 weeks (+7  days) 
prior to the scheduled dose.  Any unreportable platelet count result must be rechecked and 
determined not to have met a stoppi[INVESTIGATOR_526924] c ontinue.  
In the event  of a platelet  count  < 75,000/mm3, additional  laboratory  investigations  may be 
conducted in consultation with Medical Monitor ( Table 4 ). 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
44 
44 of 84  
  
Table  4 Additional  Labs  to be Performed  in the Event  of a Platelet Count  
< 75,000/mm3 
 
To Be Performed  at Local  Lab 
Peripheral  smear  (should  be performed  locally,  fixed  and sent to central  lab for review)  
Fibrinogen  split products  or D-dimer  on fresh  blood  
To Be Performed  at Central  Lab 
Citrated  sample  for platelets  
Coagulation  panel  (PT/INR,  activated  partial  thromboplastin  time [aPTT])  
CBC  (complete  blood count)  with reticulocytes  and mean  platelet  volume  (MPV)  
Fibrinogen  
von Willebrand  factor  
Total  globulins,  total IgA, IgG and IgM 
Complement:  total C3, total C4, Bb, C5a 
CRP measured  by [CONTACT_526985]  (hsCRP)  
Serology  for: 
hepatitis  B virus  (HBV),  HCV,  HIV (if not done  for screening)  
Rubella  
cytomegalovirus  (CMV)  
EBV  
Parvo B19 
Helicobacter  pylori  (IgG  serum  test) 
Auto -antibody  screen:  
Antiphospholipid  
Rheumatoid  factor  
Anti-dsDNA  
Anti-thyroid  
Vitamin  B12 
Folic Acid 
To Be Performed  at Specialty Lab(s)  
Antiplatelet  antibodies  and Anti-PF4 assay  
Anti-ASO  antibody  
Note:  The above  labs may change  as additional  data is assessed,  and sites will be updated  regarding  any changes  
 
8.5.3.  Safety  Monitoring  for Minor  Bleeding Events  
Minor  bleeding  events  are those  that do not fulfill  the criteria  for major  bleeding  or clinically - 
relevant, non -major bleeding events (which are defined in Section 8.6.3 ), for example excess 
bruising, petechiae, gingival bleeding on brushing teeth.  If a minor bleeding event occurs, 
additional testing of coagul ation parameters (aPTT, PT, INR) and platelet count should be 
performed.  
ISIS [ADDRESS_683797] Results  
If a patient’s  results  meet Criteria  1 or 2 below,  please  confirm  the results  and initiate  weekly 
monitoring  if confirmed.  If the event  of a persistent  elevation  is observed  over 2 consecutive 
weeks, then go to Section 8.6.2 : 
1. Serum creatinine increase that fulfills all of the following: ≥ 0.3 mg/dL (26.5 μmol/L) 
and ≥ 40% above  baseline  creatinine  values  and > ULN  (refer  to definition  of baseline  in 
Section 8.6) 
2. Proteinuria, Urine protein/creatinine ratio > 750 mg/g for baseline > 200 mg/g, or 4 × 
baseline  for baseline  < 200 mg/g  that is confirmed  by [CONTACT_526986] a quantitative 
total urine protein measurement of > 1.0 g/24 hr  
 
8.6. Stoppi[INVESTIGATOR_526925] s of the stoppi[INVESTIGATOR_526926]: the average  of pre-dose values 
(unless otherwise specified).  
 
8.6.1.  Stoppi[INVESTIGATOR_526927], and the event is without an 
alternative  explanation  as discussed  with  the Sponsor  Medical  Monitor,  dosing  of a patient 
with Study Drug (ISIS 766720 or placebo) will be stopped permanently; values that are not 
confirmed due to failure to retest or missing lab values will be presumed confirmed:  
1. ALT  or AST  > 8 × ULN,  which  is confirmed  
2. ALT  or AST  > 5 × ULN, which  is confirmed  and persists  for ≥ [ADDRESS_683798]  > 3 × ULN or  the greater  of 2 × baseline  value  or 3 × ULN  if the baseline 
value was > ULN, which is confirmed and total bilirubin > 2 × ULN or INR > 1.[ADDRESS_683799]  > 3 × ULN  or the greater  of 2 × baseline  value  or 3 × ULN  if the baseline 
value was > ULN with the new appearance (i.e., onset coincides with the changes in 
hepatic  enzymes)  of fatigue,  nausea,  vomiting,  right  upper  quadrant  pain or tenderness, 
fever, rash, and/or concomitant eosinophilia (> ULN)  
 
8.6.2.  Temporary  Stoppi[INVESTIGATOR_526928] a persistent elevation that is observed over 2 consecutive weeks, for either  of the  
2 criteria  below,  dosing  of a patient  with Study  Drug  (ISIS 766720  or placebo)  will be suspended 
temporarily:  
1. Serum creatinine increase that fulfills all of the following:  ≥ 0.3 mg/dL (26.5 μmol/L) 
and ≥ 40% above  baseline  creatinine  values  and > ULN  (refer  to definition  of baseline  in 
Section 8.6 of protocol)  
2. Proteinuria, Urine protein/creatinine ratio > 750 mg/g  for baseline > 200 mg/g, or 4 × 
baseline  for baseline  < 200 mg/g  that is confirmed  by [CONTACT_526986] a quantitative 
total urine protein measurement of > 1.0 g/24 hour  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
46 
46 of 84  
  
The possible  dosing  re-initiation  or follow -up schedule  for any events  meeting  either  of these 
criteria will be determined by [CONTACT_84255].  
8.6.3.  Stoppi[INVESTIGATOR_526929] 50,000/mm3, dosing  of the patient  with Study  Drug 
will be stopped permanently.  Platelet count will be monitored at least twice weekly until  
3 successive  values >  75,000/mm3 then weekly  until 3 values  > 100,000/mm3 (Table  5). 
Administration of steroids  is recommended for patients whose platelet count is less than 
25,000/mm3. Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010 ) 
recommend Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1 -4 cycles; 
Prednis(ol)one  0.5-2 mg/kg/d  for 2-4 weeks  then taper;  or methylprednisolone  30 mg/kg/day  for 
7 days.  
Note:  Patient  may require  continuation  with oral steroids  after methylprednisolone  treatment  is 
stopped.  
In the event of a platelet count ˂ 75,000/mm3 and > 50,000/mm3, and in the absence of major 
bleeding  or clinically -relevant  non-major  bleeding  (defined  below; ( Schulman  and Kearon  2005 ; 
Buller  et al. 2007 ), dosing with Study Drug should be suspended temporarily until the platelet 
count has recovered to > 100,000/mm3. The suitability of the patient for continued dosing will 
be determined by [CONTACT_526987]’s platelet count, whether any 
bleedin g events were experienced, and the speed of recovery of platelet count after interruption 
of dosing.  If dosing  is reinitiated,  platelet  count  must  be measured  weekly  until the end of study.  
If, after reintroduction  of Study  Drug,  the platelet  count  falls below  75,000/mm3, further  dosing 
of the patient with Study Drug will be stopped permanently.  
Definition  of Major  Bleeding  Events  (Schulman  and Kearon  2005 ): 
1. Fatal  bleeding, and/or  
2. Symptomatic  bleeding  in a critical  area or organ,  such as intracranial,  intraspi[INVESTIGATOR_1304], 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome  
3. Clinically overt bleeding leading to transfusion of ≥ 2 units of packed red blood cells or 
whole  blood  or a fall in hemoglobin  of 2.0 mg/dL  (1.24  mmol/L)  or more  within  24 hours  
Definition  of Clinically  Relevant  Non-Major  Bleeding  Events  (Buller  et al. 2007 ): 
Clinically  relevant non -major bleeding  (CRNMB) is defined as overt bleeding not meeting  the 
criteria  for major  bleeding  but that resulted,  for example,  in medical  examination,  intervention, 
or had clinical consequences for a patient.  
Definition  of Minor  Bleeding  Events  
Minor bleeding events are  those that do not fulfill the criteria for major bleeding or 
clinically -relevant,  non-major  bleeding  events  (defined  above),  for example  excess  bruising, 
petechiae, gingival bleeding on brushing teeth.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
47 
47 of 84  
  
Table  5 Actions  in Patients  with  Low  Platelet  Count  
 
Platelet  Count  on Rx Drug  Dose  Monitoring  
> 100,000/mm3 No action  Monitor  every  2 weeks  
≥ 75,000  - 
≤ 100,000/mm3 No action  Monitor  every  week  until 3 successive  values  
> 100,000/mm3 
≥ 50,000  - < 75,000/mm3 Pause  dosing  
When  platelet  count  returns  to 
> 100,000/mm3 restart dosing only if 
approved  by [CONTACT_526988] 3 successive 
values  > 75,000/mm3 then weekly  until 3 values  
> 100,000/mm3 
If redosing  then continue  to monitor  weekly  for the 
remainder  of the Treatment  Period.  If not redosing 
then subsequent monitoring should be per the 
schedule of procedures.  
Consider  discontinuation  of antiplatelet  agents/non - 
steroidal anti -inflammatory drug 
(NSAIDS)/anticoagulant medication while platelet 
count < 75,000/mm3 
≥ 25,000  - < 50,000/mm3 Permanently  discontinue  Study  Drug  Monitor  twice weekly  until 3 successive  values  
> 75,000/mm3 then weekly  until 3 values  
> 100,000/mm3. Subsequent  monitoring  should  be 
per the schedule of procedures.  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant  medication  while 
platelet count ˂ 75,000/mm3 if possible  
˂ 25,000/mm3 Permanently  discontinue  Study  Drug  Monitor daily until 3 successive values show 
improvement  then monitor  twice  weekly  until 
3 successive values  
> 75,000/mm3 then weekly  until 3 values  
> 100,000/mm3. Subsequent  monitoring  should  be 
per the schedule of procedures.  
Steroids recommended*  
Consider  need  for hospi[INVESTIGATOR_526930]/NSAIDS/ 
anticoagulant  medication  while  platelet  count  
˂ 75,000/mm3 if possible  
* Recovery  in platelet  count  may be accelerated  by [CONTACT_526989].  Treatment  guidelines  for 
immune thrombocytopenia ( Provan et al. 2010 ) recommend Dexamethasone 40 mg daily for 4 days every  
2-4 weeks  for 1-4 cycles;  Prednis(ol)one  0.5-2 mg/kg/d  for 2-4 weeks  then taper;  or Methylprednisolone 
30 mg/kg/day for 7 days (Note:  May require continuation with oral steroids after methylprednisolone).  
 
 
8.7. Adjustment  of Dose  and/or  Treatment  Schedule  
Dose  adjustments,  including  dose interruptions,  and/or  decreasing  the dose will be allowed  for 
safety or tolerability after consultation with the Sponsor Medical Monitor.  
Patients  may have  their dose interrupted  in response  to AEs after consultation  with Study 
Medical Monitor.  
ISIS [ADDRESS_683800] permanently  discontinue  study  treatment for  any of the  following:  
• The patient  becomes  pregnant.  Report  the pregnancy  according  to instructions  in 
Section 9.5.4  
• The patient  withdraws  consent  
• The patient  experiences  an AE that necessitates  permanent  discontinuation  of Study 
Drug  
• The patient  develops  laboratory  test abnormalities  that meet  any of the stoppi[INVESTIGATOR_10457] 8.6.1  to Section 8.6.3  
• The patient  experiences  an AE that necessitates  unblinding  of the Investigator  or 
Sponsor to the patient’s treatment assignment  
• The patient  meets  any of the following  Exclusion  Criteria  (see Section  5.2) after 
discussion with the Sponsor Medical Monitor  
− Patient needing  pi[INVESTIGATOR_526931]  
− Patient  with a pi[INVESTIGATOR_526932]  (e.g.,  either  growing,  or at risk of 
compressing  or abutting  the optic  chiasm  or other  vital structures)  as assessed  by 
[CONTACT_21173][INVESTIGATOR_2117]/sellar MRI/CT protocol  
The reason  for discontinuation  of Study  Drug  must  be recorded  in the electronic  Case  Report 
Form (eCRF) and source documentation.  
Patients  who discontinue  Study  Drug  should  complete  ETTX  visit and then enter  the 
Post-Treatment  Period)  unless  consent  is withdrawn.  Minimally,  every  effort  should  be made  to 
complete the early termination study procedures (see Appendix A , Section 6.1.2 ). 
If the patient  declines  or is unable  to participate  in the above,  the Investigator  should  clarify  what 
type of follow -up the patient is agreeable to:  in person, by [CONTACT_648]/mail, through family/friends, 
via correspondence/communication with other physicians, and/or from review of the medical 
records.  Wherever possible these patients should continue to be followed up via the agreed 
means to collect information on AEs, concomitant medications and survival status.  At the very 
least, the patient’s status at the end of the protocol defined study period should be ascertained  
and documented wherever possible.  The agreed means of follow -up will be documented in the 
patient records and notified to the Sponsor.  
 
8.9. Withdrawal  of Patients  from  the Study  Procedures  
Patients  must be  withdrawn  from  the study  for any of the following:  
• Withdrawal  of consent  
• The patient is  unwilling  or unable to  comply  with the protocol  
Other  reasons  for withdrawal  of patients  from  the study  Procedures  might  include:  
• At the discretion  of the Investigator for  medical  reasons  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
49 
49 of 84  
  
• At the discretion  of the Investigator  or Sponsor  for noncompliance  
• Significant  protocol  deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All information,  including  the reason  for withdrawal  from  study,  must  be 
recorded in the eCRF.  
Any patient who withdraws consent, in writing or via verbal communication (documented by 
[CONTACT_147568])  to participate  in the study  will be removed  from  further  treatment  and study 
observation  immediately  upon  date of reques t. These  patients  should  be encouraged  to complete 
the ETTX visit procedures at the time of withdrawal if patient is in the Treatment Period, or the 
ETPT visit if patient is in the Post -Treatment Period ( Appendix A ). If the patient declines or is 
unable to participate in the above, the Investigator should clarify what type of follow -up the 
patient is agreeable to:  in person, by [CONTACT_648]/mail, through family/friends, via 
correspondence/communication with other physicians, and/or from review of the medical 
records.  Wherever possible these patients should continue to be followed up via the agreed 
means to collect information on AEs, concomitant medications and survival status.  At the very 
least, the patient’s status at the end of the protocol defined study period shou ld be ascertained 
and documented wherever possible.  The agreed means of follow -up will be documented in the 
patient records and notified to the Sponsor.  
For patients  withdrawn  for reasons  other  than withdrawal  of consent  every  effort should  be made 
to comp lete the Post -Treatment Period and early termination study procedures.  
 
8.10. Concomitant  Therapy  and Procedures  
The use of concomitant  therapi[INVESTIGATOR_526933]’s 
eCRF.  Adverse events related to administration of thes e therapi[INVESTIGATOR_10459].  
 
8.10.1.  Concomitant  Therapy  
A concomitant therapy is any non -protocol specified drug or substance (including over -the- 
counter  medications,  herbal  medications  and vitamin  supplements)  administered  between  signing 
of informed consent and last visit (PTWk15/ETPT).  
Allowed  Concomitant  Therapy  
Any other  medications  deemed  necessary  by [CONTACT_526990].  
Disallowed  Concomitant  Therapy  
The following medications or interventions cannot be started during the trial:  other approved or 
investigational  medications  for acromegaly  (e.g.,  pasireotide,  dopamine  agonist  or pegvis omant), 
anti-obesity agents or weight loss programs, and chronic systemic use of glucocorticoids.  
Changes to a stable regimen of estrogen containing medication or antidiabetic medications 
allowed  at screening  may be considered  after consultation  with the Sponsor  Medical  Monitor  or 
designee.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
50 
50 of 84  
  
Any investigational  therapeutic  drug or device  including  other  marketed  agents  at experimental 
dosages/utilities  that are being  tested for  treatment  of glucose  lowering  effects – patient will be 
withdrawn.  
8.10.2.  Concomitant  Procedures  
A concomitant  procedure  is any therapeutic  intervention  (e.g.,  surgery/biopsy,  physical  therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
signing of informed consent and the last visit (PTWk15)  
Surgery  and radiotherapy  for pi[INVESTIGATOR_526934]  (see Section  5.2) 
and patients who undergo these procedures during the study will be early terminated from the 
Treatment Period and enter the Post -Treatment Period.  
8.11. Treatment  Compliance  
Compliance  with treatment  dosing  and SRL dosing  is to be monitored  and recorded  in the eCRF 
by [CONTACT_37714].  
There  is not a patient  diary  for this trial for  all patients,  but there  is a SRL dosing  diary  for 
patients who receive SRL administration outside of the clinic.  
 
9. SERIOUS  AND  NON -SERIOUS  ADVERSE  EVENT  REPORTING  
9.1. Sponsor  Review  of Safety  Information  
Safety  information  will be collected,  reviewed,  and evaluated  by [CONTACT_526991].  
9.2. Regulatory  Requirements  
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators  of SAEs  including  suspected  unexpected  serious  adverse  reactions  (S[LOCATION_003]Rs)  per 
the International Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country - 
specific regulatory  requirements will be followed in accordance with local country  regulations 
and guidelines.  
Institutional  Review  Board s (IRB)/Independent  Ethics  Committees  (IEC)  will be notified  of any 
SAE according to applicable regulations.  
In addition  to the Investigator’s  assessment  of relatedness,  the Sponsor  or designee  will evaluate 
the available information and perform an indepen dent assessment of all reported SAEs and 
determine if there is a reasonable possibility that the Study Drug (ISIS 766720 or placebo) is 
causally  related to a  reported SAE  While  the Sponsor may  upgrade  an Investigator’s decision it 
is not permissible to dow ngrade the Investigator’s opi[INVESTIGATOR_84152] a S[LOCATION_003]R.  
Appropriate personnel at the Sponsor or designee will unblind S[LOCATION_003]Rs for the purpose of 
regulatory  reporting.  The Sponsor  or designee  will submit  S[LOCATION_003]Rs  to Regulatory  Agencies  in 
blinded or unblinded fashion according to local law.  The Sponsor or designee will submit 
S[LOCATION_003]Rs to Investigators in a blinded fashion.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
51 
51 of 84  
  
9.3. Definitions  
9.3.1.  Adverse  Event  
An adverse event  (AE) can be any unfavorable and unintended sign (including a n abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of 
medicinal  (investigational)  product,  whether  or not the AE is considered  related  to the medicinal 
(investigational) product/Study Drug.  
An AE can therefo re be any of the  following:  
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom,  or disease  temporally  associated  with the use of a medicinal  product,  whether  or 
not considered related to the medicinal product  
• Any new disease  or exacerbation  of an existing  disease  (a worsening  in the character, 
frequency, or severity of a known condition)  
• Recurrence  of an intermittent  medical  condition  (e.g.,  headache)  not prese nt at Baseline  
• Any deterioration in a laboratory value or other clinical test (e.g., electrocardiogram 
[ECG],  X-ray) that is associated  with symptoms  or leads  to a change  in study  treatment  or 
concomitant treatment or discontinuation from Study Drug  
• Adverse  events  that are related  to a protocol -mandated  intervention,  including  those  that 
occur  prior  to assignment  of study  treatment  (e.g., screening  invasive  procedures  such as 
biopsies)  
9.3.2.  Adverse  Drug  Reaction  and Unexpected  Suspected  Adverse  Drug  Reaction 
Adverse Drug Reaction (ADR)  
In the pre-approval clinical experience with a new medicinal product or its new usages, 
particularly  as the therapeutic  dose(s)  may not have  been  established,  ADR  is defined  as follows:  
All noxious  and unintended  responses  to a medicinal  product  related  to any dose should  be 
considered adverse drug reactions.  
The phrase  "responses  to a medicinal  product"  means  that a causal  relationship  between  the 
medicinal product and the AE has been determined by [CONTACT_10548] a reasonable 
possibility, i.e., the relationship cannot be ruled out.  
Suspected  Unexpected  Adverse  Drug  Reaction  
A suspected  unexpected  ADR  is any ADR,  the nature  or severity  of which  is not consistent  with 
the applicable product information, e.g., Investigator's Brochure for an unapproved medicinal 
(investigational) product.  
A suspected  adverse  reaction  implies  a lesser  degree  of certainty  about  causality  than an adverse 
reaction.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
52 
52 of 84  
  
9.3.3.  Serious  Adverse  Event  (SAE)  
A SAE  is any AE that in the view  of either  the Investigator  or Sponsor,  meets  any of the 
following criteria:  
• Results  in death  
• Is life threatening:  that is,  poses  an immediate  risk of death  at the time  of the event  
• An AE or suspected  adverse  reaction  is considered  “life-threatening”  if, in the view  of 
either the Investigator or Sponsor, its occurrence places the patient at immediate risk 
of death.  It does not include  an AE or suspected  adverse  reaction  that, had it  occurred 
in a more severe form, might have caused death  
• Requires  inpatient  hospi[INVESTIGATOR_526935]  
• Hospi[INVESTIGATOR_476091] 24 hours  to a medical 
facility and does not always qualify as an AE  
• Results  in a persistent  or significant  incapacity  or substantial  disruption  of the ability 
to conduct normal life functions  
• Results  in a congenital  anomaly  or birth  defect  in the offspring  of the patient  (whether 
the patient is male or female)  
• Important medical events  that may not result in death, are not life -threateni ng, or do 
not require hospi[INVESTIGATOR_10462], based upon 
appropriate medical judgment, they may jeopardize the patient and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  Examples  of such medical  events  include  allergic  bronchospasm  requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse  
The terms "severe" and "serious" are not synonymous.  Severit y refers to the intensity of an AE 
(e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common 
Terminology  Criteria  for Adverse  Events  [NCI  CTCAE];  OR Toxicity  Grading  Scale  for Healthy 
Adult and Adolescent Volunteers Enroll ed in Preventive Vaccine Clinical Trials; the event itself 
may be of relatively minor medical significance (such as severe headache without any further 
findings).  
Severity  and seriousness  need  to be independently  assessed  for each AE recorded  on the eCRF.  
 
[IP_ADDRESS].  Adverse  Events  of Special  Interest  (AESI)  
For the purpose of this study, severe reductions in platelet count < 50,000/mm3 accompanied by 
a major bleeding (MB) event or clinically -relevant non -major bleeding (CRNMB) event, or 
platelet  count  of < 25,000/mm3 independent  of a MB or CRNMB  event  are considered  as AEs of 
special interest and should be subject to 15 -day expediting r eporting by [CONTACT_526992].  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
53 
53 of 84  
  
9.4. Monitoring  and Recording  Adverse  Events  
Any pre-existing  conditions or signs and/or symptoms  present in a patient prior  to the  start of the 
study (i.e., before informed consent) should be r ecorded as Medical History and not recorded as 
AEs unless  the pre-existing  condition  worsened.  The Investigator  should  always  group  signs  and 
symptoms into a single term that constitutes a single unifying diagnosis if possible.  Before a 
diagnosis is confirmed, all symptoms should be reported as AEs.  
9.4.1.  Serious  Adverse  Events  
In the interest  of patient safety, and in order to fulfill regulatory requirements, all SAEs,  and any 
case of platelet count < 50,000/mm3 (regardless of their r elationship to Study Drug) should be 
reported to the Sponsor or designee within 24 hours of the Study  Center’s first knowledge of the 
event.  The collection of SAEs will begin after the patient signs the informed consent form and 
stop at the end of the patient’s  Follow -up Period  which  is defined  as ET15/PT15  visit.  When  the 
Investigator is reporting by [CONTACT_756], it is important to speak to someone in person versus 
leaving a message.  SAEs should be reported using an Initial Serious Adverse Event Form.  The 
Form should be completed, and a copy faxed or emailed to the Sponsor or designee.  
Detailed information should be actively sought and included on follow -up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be follo wed 
until resolution.  SAEs that remain ongoing past the patient’s last protocol -specified follow -up 
visit will be evaluated  by [CONTACT_476145].  If the Investigator  and Sponsor  agree  the 
patient’s condition is unlikely to resolve, the Investigator and Sponsor will determine the  
follow -up requirement.  
 
9.4.2.  Non-Serious  Adverse  Events  
The recording of non -serious AEs will begin after the patient signs the informed consent form 
and will stop at the end of the patient’s Follow -up Period, which is defined as PTWk15/ETPT 
visit,  or the last visit when  patient  withdraws  consent.  The Investiga tor will monitor  each patient 
closely and record all observed or volunteered AEs on the Adverse Event Case Report Form.  
 
9.4.3.  Evaluation  of Adverse  Events  (Serious  and Non-Serious)  
The Investigator’s  opi[INVESTIGATOR_526936]:  
[IP_ADDRESS].  Relationship  to the Study  Drug  
The event’s  relationship  to the Study  Drug  (ISIS  766720 or  placebo)  is characterized  by [CONTACT_144393]:  
• Related:  There  is clear  evidence  that the event  is related  to the  use of Study  Drug, 
e.g., confirmation by [CONTACT_38000] -challenge test  
• Possible:  The event cannot be explained by [CONTACT_102]’s medical condition, 
concomitant  therapy,  or other  causes,  and there  is a plausible  temporal  relationship 
between the event and Study Drug adminis tration  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
54 
54 of 84  
  
• Unlikely:  An event for which an alternative explanation is more likely (e.g., 
concomitant  medications  or ongoing  medical  conditions)  or the temporal  relationship 
to Study  Drug  (ISIS  766720  or placebo)  administration  and/or  exposure  suggests  that 
a causal relationship is unlikely (For reporting purposes, Unlikely/Remote will be 
grouped together with Not Related)  
• Not Related:  The event can  be readily  explained by  [CONTACT_102]’s  underlying  medical 
condition, concomitant therapy,  or other causes, and therefore, the Investigator 
believes no relationship exists between the event and Study Drug  
[IP_ADDRESS].  Severity  
The severity  of AEs and SAEs  relating  to laboratory  tests and adverse  events  at the injection  site 
will be graded based on criteria from the Common Terminology Criteria for Adverse Events 
(CTCAE) Version 5.0, November 2017 (refer to Appendix D ). Any AE not listed in  
Appendix  D will be graded  as follows:  
• Mild:  The event  is easily  tolerated  by [CONTACT_526993]’s 
usual daily activities  
• Moderate:  The event  causes  the patient  more  discomfort  and interrupts  the patient’s 
usual daily activities  
• Severe:  The event  is incapacitating  and causes  considerable  interference  with the 
patient’s usual daily activities  
If the event  is an SAE,  then all applicable  seriousness  criteria  must  be indicated  (criteria  listed  in 
Section 9.3.3 ). 
[IP_ADDRESS].  Action  Taken  with  Study  Drug  
Action  taken  with Study  Drug  (ISIS  766720  or placebo)  due to the event  is characterized  by [CONTACT_144394].  
• None:  No changes  were  made  to Study  Drug  (ISIS  766720  or placebo) 
administration and dose  
• Permanently  Discontinued:  Study  Drug  was discontinued  and not restarted  
• Temporarily  Interrupted,  Re-started  – Same  Dose:  Dosing  and/or  dosing 
frequency  was temporarily  interrupted/changed  or delayed  due to the AE and 
restarted at the same dose  
• Reduced Dose and/or dosing frequency:  Dosing was redu ced, temporarily 
interrupted  or delayed  due to the AE and restarted  at the next lower  dose or reduced 
dosing frequency  
[IP_ADDRESS].  Treatment  Given  for Adverse  Event  
Any treatment  (e.g.,  medications  or procedures)  given  for the AE should  be recorded on  the 
Adverse Event Case Report Form.  Treatment should also be recorded on the concomitant 
treatment or ancillary procedures eCRF, as appropriate.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
55 
55 of 84  
  
[IP_ADDRESS].  Outcome  of the  Adverse  Event  
If the event  is a non-serious  AE, then the event’s  outcome  is characterized  by [CONTACT_38012]:  
• AE Persists:  Patient  terminates  from  the trial and the AE continues  
• Recovered:  Patient  recovered  completely  from  the AE 
• Became  Serious:  The event  became  serious  (the date that the event  became  serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE)  
• Change  in Severity  (if applicable):  AE severity  changed  
If the event  is an SAE, then  the event’s outcome  is characterized  by [CONTACT_526994]:  
• Ongoing:  SAE continuing  
• Persists  (as non-serious  AE):  Patient  has not fully  recovered  but the event  no longer 
meets serious criteria and should be captured as an AE on the non -serious eCRF (the 
SAE resolution date should be entered as the date of onset of that AE)  
• Recovered:  Patient  recovered  completely  from  the SAE  (the date of recovery  should 
be entered as the SAE resolution date)  
• Fatal:  Patient  died (the date of death  should  be entered  as the SAE  resolution  date)  
[IP_ADDRESS].  Follow -up of Adverse  Event 
Investigator Follow -Up 
During  the study  period,  the Investigator  should  follow  each AE until the event  has resolved  to 
baseline grade or better, the event is assessed as stable, the patient is lost to follow -up, or the 
patient withdraws consent.  Every effort should be made to follow all SAEs considered to be 
related to Study Drug or related to stu dy procedures until a final outcome can be reported.  
Resolution  of AE (with  dates)  should  be documented  on the Adverse  Event  eCRF  and in the 
patient’s medical record to facilitate source data verification.  
Investigator should follow -up, or support the Spon sor’s effort to follow -up with all pregnancies 
reported  during  the study  from  either  the study  patient  or the female  partner  of male  study  patient 
until pregnancy outcome is available.  
Sponsor  Follow -Up 
For SAEs,  AESI  and pregnancy  cases,  the Sponsor  or a designee  should  follow -up by [CONTACT_756], 
fax, electronic mail, and/or a monitoring visit to obtain additional case details and outcome 
information (e.g., from hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in 
order to perfor m an independent medical assessment of the reported case.  
ISIS [ADDRESS_683801] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE.  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bl eeding due to thrombocytopenia, 
tetany  due to hypocalcemia,  or cardiac  arrhythmias  due to hyperkalemia.  Whenever  possible,  the 
underlying diagnosis should be listed in preference to abnormal laboratory values as AEs.  
Clinically -significant abnormalities will be monitored by [CONTACT_526995].  Laboratory abnormalities deemed not clinically -significant (NCS) by [CONTACT_526996].  Similarly,  laboratory  abnormalities  reported  as AEs 
by [CONTACT_37724].  
The Investigator is responsible for reviewing and signing all laboratory reports.  The signed 
clinical  laboratory  reports  will serve  as source  documents  and must  include  the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values.  
9.5.2.  Prescheduled  or Elective  Procedures  or Routinely  Scheduled  Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE,  even  if the patient  is hospi[INVESTIGATOR_057];  the Study  Center  must  document  all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled  (or was on a waiting  list to be scheduled)  prior  to obtaining  the patient’s 
consent to participate in t he study  
• The condition that required the prescheduled or elective procedure or routinely 
scheduled  treatment  was present  before  and did not worsen  or progress  in the opi[INVESTIGATOR_10464]’s consent to participate in the study and the 
timing of the procedure or treatment  
• The prescheduled  or elective  procedure  or routinely  scheduled  treatment  is the sole 
reason for the intervention or hospi[INVESTIGATOR_063]  
9.5.3.  Dosing  Errors  
Study  Drug  (ISIS  766720  or placebo)  errors  (including  overdose,  underdose,  and administration 
error) should be documented as Protocol Deviations.  A brief description should be provided in 
the deviation,  including  whether  the patient was  symptomatic  (list symptoms)  or asymptomatic, 
and the event accidental or intentional.  
Dosing  details  should  be captured  on the Dosing  Case  Report  Form.  If the patient  takes  a dose 
of Study  Drug (ISIS 766720 or placebo) that exceeds protocol specifications and the patient is 
symptomatic, then the symptom(s) should be documented as an AE and be reported per 
Section 9.4. 
An overdose is the accidental or intentiona l use of a drug in an amount higher than the dose 
being  studied.  An overdose  or incorrect  administration  of study  treatment  is not itself  an AE, but 
it may result in an AE.  All AEs associated with an overdose or incorrect administration of  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
57 
57 of 84  
  
Study Drug  should  be recorded  on the Adverse  Event  eCRF.  If the associated  adverse  event 
fulfills  seriousness  criteria,  the event  should  be reported  to the Sponsor  immediately  (i.e., no 
more than 24 hours after learning of the event).  
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigator’s  section  of the Investigator’s  Brochure  and contact  [CONTACT_476148] 
[ADDRESS_683802] learnin g of the occurrence of pregnancy.  Follow -up 
information  including  delivery  or termination  is reported  by [CONTACT_84261] ‘Follow -up’ on the 
Pregnancy Forms and reported within 24 hours.  
Payment  for all aspects  of obstetrical  care,  child  or related  care will be the patient’s 
responsibility.  
Female patients : If a suspected pregnancy occurs while on the study (including follow -up), a 
pregnancy test will be performed.  The patient with a confirmed pregnancy will be immediately 
withdrawn from treatment with St udy Drug.  However, the patient will be encouraged to 
complete  the post-treatment  follow -up portion  of the study  to the extent  that study  procedures  do 
not interfere with the pregnancy.  Regardless of continued study participation, the study 
physician will a ssist the patient in getting  obstetrical care and the progress of the pregnancy  will 
be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or 
spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and 
Sponsor may require access to the mother and infant’s medical records to obtain additional 
information relevant to the pregnancy progress and outcome . A longer follow -up may be 
required if the newborn child experiences a medical condit ion. 
Male patients : The progress of the pregnancy of a male patient’s partner should be followed 
until the outcome  of the pregnancy  is known  (i.e., delivery,  elective  termination,  or spontaneous 
abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
follow -up with the mother and may request access to the mother and infant’s medical 
records to obtain additional information relevant to the pregnancy progress and outcome . A 
longer follow -up may be required if a newborn -child experiences a medical condition.  
Follow -up will be performed  to the extent  permitted  by [CONTACT_84262]; e.g. partner ICF may be required.  
ISIS [ADDRESS_683803] 
dose (PTWk5 Visit).  
10.1.2.  Secondary  Efficacy  Endpoints  
The secondary  efficacy  endpoints  include:  
• Proportion  of patients  achieve  normalized  IGF-[ADDRESS_683804] dose (PTWk5 Visit)  
• Proportion  of patients  achieve  normalized  IGF-[ADDRESS_683805] dose (PTWk5 Visit)  
• Change  from Baseline  in serum  IGF-1 over time 
• Percent  change  from  Baseline  in serum IGF -1 over time 
10.1.3.  Tertiary  and Pharmacodynamic  Endpoints  
The tertiary  and pharmacodynamic endpoints  include:  
• Change  from Baseline  in growth  hormone  (GH)  over time 
• Percent  change  from  Baseline  in GH over time 
• Change  from  Baseline  over time in pharmacodynamic  endpoints,  including  fasting 
plasma GHBP, acid -labile subunit (ALS), and insulin -like growth factor binding 
protein 3 (IGFBP3)  
• Percent  change  from  Baseline  over time in pharmacodynamic  endpoints,  including 
fasting plasma GHBP, ALS, and IGFBP3  
10.1.4.  Exploratory  Endpoints  
The exploratory  endpoints  include:  
• Glycemic  parameters  over time,  including  HbA1c,  fasting  plasma  glucose  and 
glycated albumin  
• Glycemic  parameters  during  2-hour oral glucose  tolerance  test, including  plasma 
glucose, insulin and C -peptide  
• Acromegaly  Quality  of Life Questionnaire (AcroQoL)  
• Acromegaly  Symptom  and Treatment  Score  Questionnaire  (ASTS)  
• Ring  Size Assessment  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
59 
59 of 84  
  
10.1.5.  Safety  Endpoints  
The safety  endpoints  include:  
• Adverse  events  
• Vital  signs  and weight and  calculated  BMI 
• Physical  examination  
• Clinical  laboratory  tests 
• ECG  
• Use of concomitant  medication  
10.2. Sample  Size Considerations  
Based on prior clinical trial experience, it is estimated that the standard deviation of the mean 
percent change from Baseline IGF -1 is approximately  20%.  In the Per Protocol Set,  with at least 
planned [ADDRESS_683806] 90% power to detect a 45% difference in mean percent change from 
Baseline  IGF-1 between  each of the ISIS 766720  dose groups  and the pooled  placebo  group  at an 
alpha level of 0.05.  
10.3. Populations  
Safety  Set: All patients  who are randomized and  receive  at least 1 dose of Study  Drug.  
Full Analysis  Set (FAS) : All randomized  patients  who receive  at least [ADDRESS_683807] -baseline efficacy or pharmacodynamic assessment.  
Per Protocol  Set (PPS) : All FAS patients  who complete  at least [ADDRESS_683808] efficacy.  
PK Set: All patients  who are randomized  and receive  at least [ADDRESS_683809] 
administration of Study Drug (ISIS 766720 or placebo).  
10.5. Interim  Analysis  
To ensure  patient  safety,  blinded  data including  the AEs and safety  laboratory  data will be 
reviewed by [CONTACT_51872].  
An interim  analysis  may be conducted  when  at least 6 patients  in the higher  strata  (> 2.[ADDRESS_683810] 
IGF-1) or at least 6 patients in the lower strata (≤ 2.5 × ULN IGF -1) complete the Week 11 
(Study Day 71) assessments (2 weeks after Day 57 (e.g., 3 month) dose).  Additional interim 
analysis for each cohort may  also be conducted once each cohort completes the Post -Treatment 
Week 5 assessments.  Unblinded data may be evaluated at this analysis for comparative safety  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
60 
60 of 84  
  
and efficacy.  The Investigator, study  staff, patients, monitors, Sponsor’s Medical Monitor and 
members of the Sponsor’s clinical operations team and data management team will remain 
blinded throughout the study.  The analysis will be executed with controlled dissemination to 
ensure  the integri ty of ongoing  data collection.  Details  of these  controls  will be described  in the 
Statistical Analysis Plan (SAP).  
10.6. Planned  Methods  of Analysis  
The primary endpoint analysis will take place after all randomized patients complete Post - 
Treatment  Week  [ADDRESS_683811]  deviation,  interquartile  range 
(25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and 
counts and percentages for ca tegorical variables will be used to summarize most data.  Where 
appropriate, p -values will be reported.  All statistical tests will be conducted using 2 -sided tests 
with 5% type I error rates unless otherwise stated.  
For data summaries and statistical analys es, the placebo patients from both cohorts will be 
pooled.  The efficacy  endpoints  will be assessed  on the FAS and Per Protocol  Set with the latter 
being the basis for the primary efficacy analysis.  The safety analyses will be performed on the 
Safety Set.  Pharmacokinetic analysis will be conducted in the PK Set.  
 
10.6.1.  Demographic  and Baseline  Characteristics  
Demographic and Baseline characteristics will be summarized using descriptive statistics by 
[CONTACT_2948].  Patient  randomization  and disposition  will be summarized  by [CONTACT_2948]. 
All patients enrolled will be included in the summary of patient dispo sition.  
10.6.2.  Safety Analysis  
Treatment duration and amount of Study Drug (ISIS 766720 or placebo) received will be 
summarized  by [CONTACT_2948].  The treatment -emergent  adverse  events  (TEAEs)  and SAEs 
will be summarized for each treatment group using the Medica l Dictionary for Regulatory 
Activities  (MedDRATM) coding  system,  by [CONTACT_2943],  preferred  term,  relationship  to 
Study  Drug,  and severity.  Tables  and/or  narratives  of treatment -emergent  deaths,  serious  and 
significant AEs, including early withdrawals due to AEs, will also be provided.  
Laboratory tests including chemistry panel, CBC with differential, coagulation panel, 
complement etc., will be summarized by [CONTACT_213341].  These sa fety 
variables will also be presented as change and percent change from Baseline over time after 
Study  Drug  (ISIS  766720  or placebo)  administration,  as appropriate.  Vital  sign,  calculated  BMI, 
and ECG measures will be summarized by [CONTACT_1570].  
10.6.3.  Efficac y Analysis  
The primary  analysis  will be the comparison  of percent change  from  Baseline  to PTWk5  
([ADDRESS_683812] dose)  in serum  IGF-1 between  an ISIS 766720  dose group  and pooled  placebo 
group in the Per Protocol Set.  The data will be analyzed using analysis of variance (ANOVA)  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
61 
61 of 84  
  
with treatment  and randomization  stratification  factor  (screening  IGF-1 level)  as independent 
variables.  In the case data departs substantial ly from normality, the nonparametric test,  
van Elteren  Test,  will be employed  instead.  
The primary  efficacy  endpoint  will also be assessed,  as a secondary  analysis,  in the FAS. 
Additional secondary efficacy analyses are:  
• Comparison of change and percent change from Baseline to each schedule post - 
baseline  visit in serum  IGF-[ADDRESS_683813] to the primary analysis  
• Difference  between  each of the ISIS 766720  dose groups  and the pooled  placebo 
group in the proportion of patients achieve normalized IGF -1 levels to within  
1.2 times  of gender  and aged  limits  at PTWk5  ([ADDRESS_683814] dose)  will be 
assessed by a Fisher’s exact test in the PPS and FAS  
• Difference  between  each of the ISIS 766720  dose groups  and the pooled  placebo 
group in the proportion of patients achieve normalized IGF -1 levels to within  
1.0 times  of gender  and aged  limits  at PTWk5  ([ADDRESS_683815] dose)  will be assessed 
by a Fisher’s exact test in the PPS and FAS  
Tertiary  and pharmacodynamic  analyses  include:  
• Comparison of change and percent change from Baseline to each scheduled post - 
baseline visit in GH between each of the ISIS [ADDRESS_683816] to the primary  analysis  in 
both the PPS and FAS  
• Comparison of change and percent change from Baseline to each scheduled post - 
baseline visit in pharmacodynamic endpoints, including fasting plasma GHBP, acid - 
labile  subunit  (ALS),  and IGFBP3,  between  each of the ISIS [ADDRESS_683817] to the primary 
analysis in both the PPS and FAS  
 
10.6.4.  Pharmacokinetic  Analysis  
Non-compartmental  PK analysis  of ISIS 766720  (as total full -length  ASO)  will be carried  out on 
each individual patient data set.  Calculated PK parameters may include:  Maximum observed 
drug concentration (C max), time to reach C max (Tmax), area under the concentration -time curve 
from time zero (pre -dose) to select times after dose administration (A UC t), and the plasma  
half-life (t1/2λz) associated  with the terminal  disposition  phase.  Additional  PK parameters  may be 
calculated at the discretion of the PK analyst.  Population PK analysis and PK/PD analysis with 
relevant PD biomarker levels using data from this study or in combination with data from other 
ISIS 766720 studies may be performed if deemed appropriate.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
62 
62 of 84  
  
10.6.5.  Additional Analyses  
The exploratory  analyses  include:  
• Comparison of change and percent change from Baseline to each scheduled post - 
baseline  visit in Glycemic  parameters,  including  HbA1c,  and fasting  plasma  glucose 
and glycate albumin between each of the ISIS [ADDRESS_683818] to the primary  analysis  in 
both the Per Protocol Set and FAS.  
• Comparison of change and percent change from Baseline to each scheduled post - 
baseline visit in Glycemic parameters during [ADDRESS_683819] to the primary analysis in both the Per Protocol Set and FAS.  
• Comparison  of change and  percent change from Baseline  to each scheduled  post- 
baseline  visit in AcroQoL,  ASTS  and Ring  Size between  each of the ISIS [ADDRESS_683820] to the primary analysis in both the Per Protocol Set and FAS.  
 
11. INVESTIGATOR’S  REGULATORY  OBLIGATIONS  
11.1. Informed  Consent  
The written  informed  consent  document  should  be prepared  in the language(s)  of the potential 
patient population, based on an English version provided by [CONTACT_16015].  
Before  a patient’s participation in the trial, the Investigator is responsible for obtaini ng written 
informed  consent  from  the patient  after adequate  explanation  of the aims,  methods,  anticipated 
benefits, and potential hazards of the study and before any protocol -specific screening 
procedures  or any Study  Drug  (ISIS  766720  or placebo)  are administered.  The patient  must  be 
given sufficient time to consider whether to participate in the study.  
The acquisition of informed consent and the patient’s agreement or refusal to notify his/her 
primary care physician should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by [CONTACT_526997]  (not necessarily  an Investigator).  The original  signed 
informed consent form should be retained in the Study Master File and in any other locations 
required by  [CONTACT_10569], and a copy  of the signed consent form should be provided to the 
patient.  
 
11.2. Ethical  Conduct  of the Study  
All applicable  regulations  and guidelines  of current  Good  Clinical  Practice  (GCP)  as well as the 
demands  of national  drug and data protection  laws and other  applicable  regulatory  requirements 
must be followed.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
63 
63 of 84  
  
11.3. Independent  Ethics  Committee  (IEC)/Institutional  Review  Board 
(IRB)  
A copy of the protocol proposed informed consent form, other written patient information, and 
any proposed advertising material must be submitted to the IEC/IRB for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received by [CONTACT_526998].  A copy  of the 
written approval of any other items/materials that must be approved by [CONTACT_526999]/IRB must also be received by [CONTACT_3433]  
e Sponsor  before  recruitment  of patients  into the study  and shipment  of Study  Drug.  The 
Investigator’s Brochure must be submi tted to the IEC/IRB for acknowledgement.  
The Investigator  must  submit  to and, where  necessary,  obtain  approval  from  the IEC/IRB  for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should notify the IEC/IRB of deviations from the protocol in accordance with ICH 
GCP Section 4.5.2.  The Investigator should also notify the IEC/IRB of SAEs occurring at the 
Study Center and other AE reports received from the Sponsor or designee, in accordance with 
local procedures.  
The Investigator  will be responsible  for obtaining  annual  IEC/IRB  approval/renewal  throughout 
the duration  of the study.  Copi[INVESTIGATOR_476094]’s  reports,  all IEC/IRB submissions  and the 
IEC/IRB continuance of approval must be sent to the Sponsor.  
11.4. Patient  Confidentiality  
The Investigator must ensure that the patient’s confidentiality is maintained.  On the CRFs or 
other documents submitted to the Sponsor, patients should be identified b y initials (if permitted 
by [CONTACT_169291]) and a patient  identification  number  only.  Documents  that are not for submission  to 
the Sponsor (e.g., signed informed consent forms) should be kept in strict confidence by [CONTACT_3786].  
In compliance with Federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator  and institution  permit  authorized  representatives  of the company,  of the regulatory 
agency(s), and the IEC/IRB direct access to review the patient’s original medical records for 
verification  of study -related  procedures  and data.  Direct  access  includes  examining,  analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the pa tient.  
 
12. ADMINISTRATIVE  AND  LEGAL  OBLIGATIONS  
12.1. Protocol  Amendments  
Protocol  amendments  must  be made  only with the prior  approval  of the Sponsor.  Agreement 
from the Investigator must be obtained for all protocol amendments and amendments to the 
informed conse nt document.  The regulatory  authority  and IEC/IRB must be informed of all  
ISIS [ADDRESS_683821] send a copy of the approval letter from the 
IEC/IRB to the Sponsor.  
 
12.2. Study Termination  
The Sponsor  reserves  the right  to terminate  the study.  The Investigator  reserves  the right  to 
terminate their participation in the study, according to the terms of the s ite contract.  The 
Investigator/Sponsor  should  notify  the IEC/IRB  in writing  of the trial’s  completion  or early 
termination . 
12.3. Study  Documentation  and Storage  
An eCRF  utilizing  an Electronic  Data Capture  application will  be used for  this study.  
The Investigator should ensure that all appropriately qualified persons to whom he/she has 
delegated  trial duties  are recorded  on a Sponsor -approved  Delegation  of Site Responsibilities 
Form.  
Source documents are original documents, data, and records from w hich the patient’s CRF data 
are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory  and pharmacy  records,  imaging,  and correspondence.  In this study,  eCRF  may not be 
used as source documents.  
The Investig ator and Study Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation in accordance with 
Section  8 of the ICH Guidelines  (E6),  suitable  for inspection  at any time by [CONTACT_476161]/or applicable regulatory authorities.  Elements should include:  
• Patient  files containing  completed  CRFs,  informed  consents,  and supporting  copi[INVESTIGATOR_526937]  
• Study files containing the protocol with all amendments, Investigator’s Brochure, 
copi[INVESTIGATOR_526938]-study  documentation  and all correspondence  to and from  the IEC/IRB 
and the Sponsor  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug 
Product  Accountability  Record,  Return  of Study  Drug  Product  for Destruction,  final 
Study Drug product reconciliation, and all drug -related correspondence  
In addition,  all original  source  documents  supporting  entries  in the CRFs  must  be maintained  and 
be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor 
and the Investigator.  Should  the Investigator  wish  to assign  the study  records  to another  party  or 
move them to another location,  he/she must notify the Sponsor.  
 
12.4. Study  Monitoring  
The Sponsor  representative  and regulatory  authority  inspectors  are responsible  for contact[CONTACT_84269], upon request, inspecting  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
65 
65 of 84  
  
the various  records  of the trial (e.g.,  CRFs  and other  pertinent  data)  provided  that patient 
confidentiality is respected.  
The Sponsor m onitor or designee is responsible for inspecting the CRFs at regular intervals 
throughout the study to verify adherence to the protocol; completeness, accuracy, and 
consistency  of the data;  and adherence  to local  regulations  on the conduct  of clinical  research. 
The monitor should have access to patient medical records and other study -related records 
needed to verify the entries on the CRFs.  
The Investigator  agrees  to cooperate  with the monitor  to ensure  that any problems  detected  in the 
course of these monitoring visits, including delays in completing CRFs, are resolved.  
In accordance  with ICH GCP  and the Sponsor’s  audit  plans,  this study  may be selected  for audit 
by [CONTACT_10576]’s Clinical Quality Assurance Department (or designees).  
Inspection  of Study  Center  facilities  (e.g.,  pharmacy,  drug storage  areas,  laboratories)  and review 
of study -related records will occur to evaluate the trial conduct and compliance with the  
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on 
patient data received by [CONTACT_16015].  During this review, patient data will be 
checked  for consistency,  omissions,  and any apparent  discrepancies.  In addition,  the data will be 
reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the 
clinical data management review process, data queries and/or Study Center notifications will be 
sent to the Study Center for completion and  return to Sponsor or designee.  
The Principal  Investigator  [INVESTIGATOR_526939].  These  signatures 
will indicate that the  Principal Investigator [INVESTIGATOR_526940], the data 
queries, and the Study Center notifications, and agrees with the content.  
 
12.5. Language  
Case  report  forms  must  be completed  in English.  Generic  names  and trade  names  are acceptable 
for concomitant medications.  Combination medications should be recorded using their trade 
name.  
All written  information  and other  material  to be used by [CONTACT_527000].  
12.6. Compensation  for Injury  
The Sponsor m aintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws.  Patients will be treated and/or compensated for any study - 
related  illness/injury  in accordance  with the information  provided  in the Compensatio n for Injury 
section of the Informed Consent document.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
66 
66 of 84  
  
13. REFERENCES  
Altmann,  K-H, Dean  NM, Fabbro  D, et al. Second  generation  of antisense  oligonucleotides:  From  nuclease 
resistance to biological efficacy in animals.CHIMIA Int J Chem 1996.  50: 168‑176.  
Barts Endocrine 2009. 'E -Protocols Acromegaly and Growth Hormone'. 
http://www.bartsendocrinology.co.uk/resources/ACROMEGALY+AND+GH+PROTOCOLS+$5Bfinal$5D.pdf.  
Buller,  HR, Cohen  AT, Davidson  B, et al. Idraparinux  versus  standard  therapy  for venous  thromboembolic 
disease.N Engl J Med 2007.  357: 1094 -1104. 
Chi, KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX -011, a 
2'‑methoxyethyl  antisense  oligonucleotide  to clusterin,  in patients  with localized  prostate  cancer.J  Natl Cancer  Inst 
2005.  97: 1287‑1296.  
Crooke,  ST, Baker  BF, Kwoh  TJ, et al. Integrated  safety  assessment  of 2'-o-methoxyethyl  chimeric  antisense 
oligonucleotides in nonhuman primates and healthy human volunteers.Mol Ther 2016.  24: 1771‑1782.  
Fisker,  S. Physiology  and pathophysio logy of growth  hormone -binding  protein:  methodological  and clinical 
aspects.Growth Horm IGF Res 2006.  16: 1 -28. 
Geary,  RS, Yu RZ, Watanabe T,  et al. Pharmacokinetics  of a tumor  necrosis  factor -alpha  phosphorothioate  2'-O-(2- 
methoxyethyl) modified antisense  oligonucleotide:  comparison  across  species.Drug  Metab Dispos  2003.  31: 1419 - 
1428.  
Graham,  MJ, Lee RG, Brandt  TA, et al. Cardiovascular  and metabolic  effects  of ANGPTL3  antisense 
oligonucleotides.N Engl J Med 2017.  
Henry,  S, Stecker  K, Brooks  D, et al. Chemically  modified  oligonucleotides  exhibit  decreased immune  stimulation 
in mice.J Pharmacol Exp Ther 2000.  292: 468 -479. 
Inoue,  H, Hayase  Y, Iwai S, et al. Sequence -dependent  hydrolysis  of RNA  using  modified  oligonucleotide  splints 
and RNase H.FEBS Lett 1987.  215: 327 -330. 
Kastelein, JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low -density lipoprotein 
cholesterol  by [CONTACT_69506] -term administration  of an antisense  inhibitor  of apolipoprotei n B.Circulation  2006.  114: 
1729‑1735.  
Katznelson,  L, Atkinson  JL, Cook  DM, et al. American  Association  of Clinical  Endocrinologists  medical  guidelines 
for clinical practice for the diagnosis and treatment of acromegaly --[ADDRESS_683822] 4: 
1‑44.  
Katznelson,  L, Laws  ER, Jr., Melmed  S, et al. Acromegaly:  an endocrine  society  clinical  practice  guideline.J  Clin 
Endocrinol Me tab 2014.  99: 3933 -3951.  
Kwoh,  J. 2008.  Chapter  13: An Overview  of the Clinical  Safety  Experience  of First- and Second -Generation 
Antisense Oligonucleotides.' in S. T.  Crooke (ed.), Antisense Drug Technology: Principles, Strategies, and 
Applications (Boca Raton).  
Liu, JL, Yakar  S, and LeRoith  D. Conditional  knockout  of mouse  insulin -like growth  factor -1 gene  using  the 
Cre/loxP system.Proc Soc Exp Biol Med 2000.  223: 344 -351. 
McKay,  RA, Miraglia  LJ, Cummins  LL, et al. Characterization  of a potent  and specific  class  of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression.J Biol Chem 1999.  274: 1715 -1722. 
Melmed, S. Medical progress: Acromegaly.N Engl J  Med 2006.  355: 2558 -2573.  
Monia,  BP, Lesnik  EA, Gonzalez  C, et al. Evaluation  of 2'-modified  oligonucleotides  containing  2'-deoxy  gaps as 
antisense inhibitors of gene expression.J Biol Chem 1993.  268: [ZIP_CODE] -[ZIP_CODE].  
Prakash, TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using 
triantennary  N-acetyl  galactosamine  improves  potency  10-fold in mice.Nucleic Acids  Res 2014.  42: 8796 -8807.  
Provan,  D, Stasi  R, Newland  AC, et al. International  consensus  report  on the investigation  and management  of 
primary immune thrombocytopenia.Blood 2010.  115: 168 -186. 
Rowland,  JE, Lichanska  AM, Kerr LM, et al. In vivo analysis  of growth  hormone  receptor  signaling  domains  and 
their associated transcripts.Mol Cell Biol 2005.  25: [ADDRESS_683823] 2005.  3: 692 -694. 
Sewell,  KL, Geary  RS, Baker  BF, et al. Phase  I trial of ISIS 104838,  a 2'-methoxyethyl  modified  antisense 
oligonucleotide targeting tumor necrosis factor -alpha.J Pharmacol Exp Ther 2002.  303: 1334 -1343.  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
67 
67 of 84  
  
Stockert,  RJ. The asialoglycoprotein  receptor:  relationships  between  structure,  function,  and expression.Physiol  Rev 
1995.  75: 591 -609. 
Trainer, P, Newell -Price J, Ayuk J, et al. A phase 2 study of antisense oligonucleotide therapy directed at the GH 
receptor  demonstrates  lowering  of serum  IGF1  in patien ts with acromegaly.Endocrine Abstracts  2015.  37 GP19.10. 
van der Lely, AJ, Biller BM, Brue T, et al. Long -term safety of pegvisomant in patients with acromegaly:  
comprehensive  review  of 1288  subjects  in ACROSTUDY.J  Clin Endocrinol  Metab  2012.  97: 1589 -1597.  
Viney, NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people 
with raised  lipoprotein(a):  two randomised,  double -blind,  placebo -controlled,  dose-ranging  trials.Lancet  2016.  388: 
2239 -2253.  
Webb, SM, Prieto  L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health -related 
quality  of life questionnaire  for patients  with acromegaly:  development  and psychometric  properties.Clin  Endocrinol 
(Oxf) 2002.  57: 251 -258. 
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
68 
68 of 84  
  
14. APPENDICES  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
69 
69 of 84  
  
 
APPENDIX  A. SCHEDULE  OF PROCEDURES  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
71 7o0f 84  
  
Appendix  A Schedule  of Procedures  
Study  Period  Screen  Treatment  Period  
Study  Week  -9 to -1 1 3 5 7 9 11 13 15 16 
Study  Day -63 to -1 1 15 29 43 57 71 85 99 112A 
Visit Window  ± Day 0 0 3 5 5 5 5 5 5 3 
Home  Health  Care  Visit  OptionB     X  X  X  
Informed  Consent  X          
Inclusion/Exclusion  X          
Medical  History  X          
Disease  History  X          
MRI  of sellar  (if no prior  MRI  results  within  the 
last 6 months)  or CT  when MRI contraindicated  X          
AcroQoL   Xa    Xa    Xa 
ASTS17  Xa  Xa  Xa  Xa  Xa 
Ring  Size Measurement18 X Xa  Xa  Xa  Xa  Xa 
Body  Weight and  Height1 X X  X  X  X   
Vital  Signs2 X Xa Xa Xa X Xa X Xa X Xa 
Physical  Exam3 X X  X  X  X  X 
ECG  (12-Lead) in  Triplicate4 X Xa  X  X  X  X 
Adverse  Events  X X X X X X X X X X 
Concomitant  Medications  X X X X X X X X X X 
HIV,  Hepatitis  B & C X          
FSH6 X          
Pregnancy  Test7 X Xa  Xa  Xa  Xa  Xa 
Chemistry  Panel  (Fasting)8, 9 X Xa Xa Xa X Xa X Xa X Xa 
Hematology9 X Xa Xa Xa X Xa X Xa X Xa 
Partial  PD Panel:  GH, IGF-1, GHBP8   Xa  X  X  X  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
Appendix  A Schedule  of Procedures  Continued  
72 7o1f 84  
  
 
 
Study  Period  Screen  Treatment  Period  
Study  Week  -9 to -1 1 3 5 7 9 11 13 15 16 
Study  Day -63 to -1 1 15 29 43 57 71 85 99 112A 
Visit Window  ± Day 0 0 3 5 5 5 5 5 5 3 
Home  Health  Care  Visit  OptionB     X  X  X  
Full PD Panel8, X Xa  Xa  Xa  Xa  Xa 
hs CRP  Xa Xa* Xa*       
PT, INR, aPTT  X Xa  Xa  Xa  Xa   
Pi[INVESTIGATOR_526941]19, Thyroid panel  X     Xa     
Bone  Biomarker   Xa    Xa     
Lipid  panel8 X Xa    Xa     
Screening  HbA1c  X          
Glycemic  Panel  (Including  HbA1c)  and 2-hr. 
OGTT8, a  
X16, a,b    
Xa,b     
Archived  Serum  Sample11 X Xa    Xa     
Immunogenicity  Testing   Xa  Xa  Xa  Xa  Xa 
PK Blood  Sampling12  Xd Xa Xa  Xa  Xa  Xd 
Urinalysis13 X Xa Xa Xa X Xa X Xa X Xa 
Study  Drug  (ISIS  766720  or placebo) 
Administration   
X X X  
X  
X  
X 
Somatostatin  Receptor  Ligand  (SRL)[ADDRESS_683824]-Treatment  Period  (14 Weeks)  
Study  Week  (Wk) from  Last  Dose  PTWk3  PTWk5  PTWk7  PTWk11  PTWk15  ETTX14,[ADDRESS_683825]  Dose  PTD1515 PTD2915 PTD4315 PTD7115 PTD9915 NA NA 
Study  Day from  Day 1 127 141 155 183 211 NA NA 
Visit  Window  ± [ADDRESS_683826] when  MRI 
contraindicated  MRI/CT  after treatment  if clinically  indicated as  assessed by  [CONTACT_527001]   X  X X X X 
ASTS17 X X X X X X X 
Ring  Size Measurement18 X X X X X X X 
Body  Weight   X   X X X 
Vital  Signs2 X X X X X X X 
Physical  Exam3  X  X X X X 
ECG  (12-Lead) in  Triplicate4  X  X X X X 
Adverse  Events  X X X X X X X 
Concomitant  Medications  X X X X X X X 
Pregnancy  Test7  X  X X X X 
Chemistry  Panel  (Fasting)8, 9 X X X X X X X 
Hematology9 X X X X X X X 
Partial  PD Panel:  GH, IGF-1, GHBP8   X     
Full PD Panel8 X X  X X X X 
hs CRP  X*    X*  
PT, INR, aPTT   X   X X X 
Pi[INVESTIGATOR_526941]19, Thyroid panel   X   X X X 
Bone  Biomarker   X   X X X 
ISIS [ADDRESS_683827]-Treatment  Period  (14 Weeks)    
Study  Week  (Wk) from  Last  Dose  PTWk3  PTWk5  PTWk7  PTWk11  PTWk15  ETTX14,[ADDRESS_683828]  Dose  PTD1515 PTD2915 PTD4315 PTD7115 PTD9915 NA NA 
Study  Day from  Day 1 127 141 155 183 211 NA NA 
Visit  Window  ± 5 3 5 5 5 NA NA 
Home  Health  Care  Visit  OptionB X  X     
Lipid  panel8  X   X X X 
Glycemic  Panel and  2 hr OGTT8,a  Xb    Xb  
Archived  Serum  Sample11  X   X X X 
Immunogenicity  Testing  X X X X X X X 
PK Blood  Sampling12 X X X X X X X 
Urinalysis13 X X X X X X X 
Somatostatin  Receptor  Ligand  (SRL)[ADDRESS_683829]  is required  by [CONTACT_527002]  
A Please  note this visit is at the end of the 16th week  at Day 112 
B In consultation with the Sponsor, a Home Health Care visit may  be conducted for a study day visit that was intended to be a clinic visit; it is preferable that 
the entire visit is conducted, however the following assessments may be omitted ECG:  body weight , physical exam, ring size, and OGTT.  These 
assessments  should  be attempted  at the next clinic  visit if not performed  at the Home  Health  Care  visit.  A confirmation  of ISIS [ADDRESS_683830]  of 3 ECGs  with 2 minutes  between  each ECG  (± 2 mins  window  between  each assessment)  
5 (Left  intentionally  blank)  
6 FSH:  Required  to confirm  menopause for women  ≤ [ADDRESS_683831] is required at Screening, however, o nce menopausal status is 
confirmed, a pregnancy tes t is not required in subsequent visits  
8 Fasting  is not required at  Screening  Visit.  Fasted  samples  should  be taken  after fasting  for 8 hours  (or 10 hours  prior  to OGTT).  During  this time the patient 
can drink water and they should ensure that they consume sufficient water in order to not become dehydrated  
9 If the platelet value, serum  creatinine or liver enzyme tests  are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis  or quantity  not sufficient) or missing over a 
period  greater  than 21 days (per  Section  8.5.2 ), the test must be  repeated  or drawn  and a result not meeting  stoppi[INVESTIGATOR_526942]. 
In consultation with the Medical Monitor a local lab and central lab may be drawn and evaluated prior to dosing (per Section 6.2.1 ). 
10 Plan to align all SRL injections to be either i) the s ame day  as the  Study  Drug administration, or ii) up to 3 days after the Study Drug administration. If 
dosing  is not done  in the clinic, the  date and time of each SRL dose will  be documented  by [CONTACT_526954] a SRL dosing  diary  and provided  to the study  center 
staff at subsequent visits.  The window  for SRL  dosing  is 1-3 days  after Study  Drug  administration.  The visit window  in the Schedule of  Procedures  table is 
not applicable to SRL dosing  
11 Stored  at -70 (± 10) °C for follow -up exploration  of laboratory  findings  and/or  AEs (e.g.,  measurement  of cytokine  and/or  chemokine  levels, measurement  of 
additional markers of kidney function, measurement of antibodies, etc.)  
12 If time is not specified  PK draw  can be done  at anytime  
13 If hematuria  or 2+ proteinuria  is observed,  see confirmation  guidance  in Section  8.5 
14 If patient  terminates  early  from  the Treatment  Period,  an early  termination  visit from  treatment  (ETTX)  is required as  soon  as possible.  After ETTX  visit, 
patient should continue in Post -Treatment Period, following the schedule in intervals relative to patient’s last dose.  Patient terminating from the Post - 
Treatment Period should complete the early termination visit from post -treatment (ETPT)  
15 PT = Post-Treatment  visit;  ETTX  = Early  Termination  visit from  treatment;  ETPT  = Early  Termination  visit from  Post-Treatment  Period  
[ADDRESS_683832]  ASTS  Question  #[ADDRESS_683833]  the ring size assessment  at each clinic  visit 
19 A morning  cortisol  sample  is required,  and the sample  should  be drawn  prior  to 09:00  
 
Time  (time  is in hours  relative  to Study  Drug  administration):  
a Pre-dose 
b -5, 0, 30, 60, 90, 120 mins  (Note:  The 2-hr. OGTT is  conducted  prior  to Study  Drug  administration  during  the Treatment  Period,  these  times  are relative  to 
oral glucose ingestion)  
c Any time after ISIS 766720  or placebo  injection  
d Pre-dose,  1, 2, 4, 6 hours  
* May be analyzed  
ISIS [ADDRESS_683834]  OF LABORATORY  ANALYTES  
ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
76 
77 of 84  
 Clinical  Chemistry  Panel  
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• Sodium 
Potassium 
Chloride 
Bicarbonate 
Total  protein 
Albumin 
Calcium 
Magnesium 
Phosphorus 
Glucose 
BUN  
Creatinine 
Cholesterol 
Uric Acid 
Total  bilirubin  
Direct  (conjugated) 
bilirubin  
Indirect  (unconjugated) 
bilirubin  
ALT 
AST 
ALP 
Creatine  kinase 
GGT  
Lipase  Screening  Tests  
• Hepatitis  B surface 
antigen  
• Hepatitis  C antibody  
• HIV antibody  
• FSH (women  only)  
• Serum  βhCG  
Coagulation  
• aPTT  (sec) 
• PT (sec)  
• INR 
PD Panel  (*Partial  Panel)  
• IGF-1* 
• GH* 
• GHBP*  
• ALS 
• IGFBP3  Hematology  Inflammatory  
• Red blood cells • hs-CRP 
• Hemoglobin  
• Hematocrit  
• MCV,  MCH,  MCHC  
• Platelets  
• White  blood  cells 
• WBC  Differential  (% and 
absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
Thyroid  Panel  
• TSH 
• Free T4 
• Total  T3 Urinalysis  
• Color  
• Appearance  
• Specific  gravity  
• pH 
• P/C Ratio  
• A/C Ratio  
• Protein  
• Blood  
• Ketones  
• Urobilinogen  
• Glucose  
• Bilirubin  
• Leukocyte  esterase  
• Nitrate  
• Microscopic  examination2 
• 
• 
• 
• 
• 
• Glycemic  Panel  
• HbA1c  
• Glucose  
• glycated  albumin  
• During  OGTT:  Glucose, 
insulin and C -peptide  Bone  Biomarkers  
• Urinary  N-telopeptide 
crosslink (NTX)  
• Bone  specific  alk phos 
• Amino terminal 
propeptide  of Type  1 
procollagen (PI[INVESTIGATOR_680])  
Pi[INVESTIGATOR_526941] 
• Morning  Cortisol  (before 
09:00)  
• ACTH  
• Prolactin  Lipid  Panel  
• Total  Cholesterol  
• LDL  cholesterol  
• HDL  cholesterol  
• Triglycerides  
• VLDL  
• Lp(a)  
Pharmacokinetics1 
• ISIS 766720  levels  in 
plasma  
Immunogenicity1 
• Anti-ISIS [ADDRESS_683835]- Week  1 Week  3 Week  5 Week  9 Week  13 Week  16 PTWk3  PTWk5  PTWk7  PTWk11  PTWk15  
           Treatment  Treatment  
D1 D15 D29 D57 D85 D112  D127  D141  D155  D183  D211  ETTX  ETPT  
Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  Blood:  
Pre-dose, 
1, 2, 4,  
[ADDRESS_683836]-SC 
Injection  Anytime  Anytime  Anytime  Anytime  Anytime  Anytime  Anytime  
Note:  If 6-hour PK sampling  is not possible  a protocol  deviation can  be entered  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[ADDRESS_683837] abnormalities  are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 
November 2017.  
 

ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
81 
81 of 84  
  
 

ISIS 766720 -CS2 
Protocol  CONFIDENTIAL  Amendment  4 
18 May  2020  
82 
81 of 84  
  
 

84 of 84  
 2 
20 May 2020  
ISIS 766720 -CS2 Amend  4 - A DB, Placebo -Controlled,  Phase  2 Study  to Assess 
Safety, Tolerability, & Efficacy of 766720 Administered Once Every 28D for 16 
Wks in Pts w/Acromegaly Being Treated w/Long -acting SRL  Version: 
Version  Date:  
Title:   
 
Protocol  
 
 
 
 
 
 
 
 
 
 
 
APPROVALS:  
 
 
  
 20-May-2020 16:47:05 GMT[PHONE_006]  
 

 
  
A Double -Blind, Placebo -Controlled, Phase 2 Study to Assess the Safety, 
Tolerability, and Efficacy of ISIS 766720 (IONIS -GHR -LRx, an Antisense 
Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 
Days for 16 Weeks in Patients With Acromegal y Being Treated With Long - 
acting Somatostatin Receptor Ligands (SRL)  
 
 
[STUDY_ID_REMOVED]  
 
 
Statistical  Analysis  Plan  Version  2.0: 05-March -2021  Official  Title:  
 
 
 
NCT Number:  
 
Document  Dates:  
 
1 of 30  
 Clinical Study Report  CONFIDENTIAL  Ionis  Pharmaceuticals,  Inc. 
Study  Number:  ISIS 766720 -CS2   1 March  2022  
16. Appendices   
 
1.9 Documentation  of Statistical  Methods  
Statistical  Analysis  Plan,  Version 2.0  (5 March  2021),  is provided.  
2 of 30  
 766720 -CS02 Statistical  Analysis  Plan 05 Mar 2021 | 2.0 
 
 
 
 
 
 
 
 
Name:  
 
[CONTACT_15261]:  766720 -CS02 Statistical  Analysis  Plan 05 Mar 2021  
2 
 
 
 
 
 
 
 
 
APPROVALS:  
 
 
 Approved  
 05-Mar-2021 20:22:56 GMT[PHONE_006]  
 Approved  
 05-Mar-2021 20:32:06 GMT[PHONE_006]  
Approved  
 05-Mar-2021 22:17:34 GMT[PHONE_006]  
Approved  
 08-Mar-2021 16:28:54 GMT[PHONE_006]  
 

Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS [ZIP_CODE] 0-CS2 CONFIDENTIAL  
3 of 30  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical  Analysis  Plan  
 
 
 
ISIS  766720  –CS2 
A Double -Blind,  Placebo -Controlled,  Phase  2 Study  to Assess  the 
Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR - 
LRX, an Antisense Inhibitor of the Growth Hormone Receptor) 
Administered Once  Every  28 Days  for 16 Weeks  in Patients  with 
Acromegaly Being Treated with Long -acting Somatostatin 
Receptor Ligands (SRL)  
 
 
 
 
 
Date:  March  5, 2021  
Version:  2.0 
CONFIDENTIAL  
Confidential/Trade  Secret  information  subject  to 18-USC -[ADDRESS_683838]  Carlsbad,  CA [ZIP_CODE]  
 
 
Compound  Name:  766720  
 
 
Protocol:  CS2 
 
 
Study Title:  A Double -Blind, Placebo -Controlled, Phase 2 Study to Assess the Safety, 
Tolerability, and Efficacy  of ISIS 766720 (IONIS GHR -LRX, an Antisense  Inhibitor 
of the Growth  Hormone  Receptor)  Administered  Once  Every  28 Days  for 16 Weeks 
in Patients with  
Acromegaly  Being  Treated  with Long -acting  Somatostatin  Receptor  Ligands  (SRL)  
 
 
Issue  Date:  18 MAY  2020  (Protocol  Amendment  4) 
 
 
 
 
See electronic  signature  [CONTACT_527021] 
, 
Ionis  Pharmaceuticals,  Inc. 
[ADDRESS_683839]  ................................ ................................ ................................ ..............................  10 
2.4 Data  Monitoring  ................................ ................................ ................................ .................  10 
2.4.1 Safety  Data  Monitoring  ................................ ................................ ................................ .................  10 
2.5 Data  Management  ................................ ................................ ................................ .............  11 
2.5.1 Case  Report  Form  (CRF)  Data ................................ ................................ ................................ ...... 11 
2.5.2 Laboratory  Data ................................ ................................ ................................ ............................  11 
2.5.3 Pharmacokinetics  (PK)  Data ................................ ................................ ................................ .........  11 
3 Analysis  Plan  ................................ ................................ ................................ ...............................  12 
3.1 General  Overview  of Analyses  ................................ ................................ ..........................  12 
3.2 Sample  Size Considerations  ................................ ................................ ..............................  12 
3.3 Scoring  of Questionnaires  and Ring  Size Assessment  ................................ ....................  13 
3.3.1 Acromegaly  Quality  of Life Questionnaire  (AcroQoL) ................................ ................................ . 13 
3.3.2 Acromegaly  Symptom  and Treatment  Score  Questionnaire  (ASTS)  ................................ ............  16 
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
v 
5 of 30  
 3.3.3 Ring  Size Assessment  ................................ ................................ ................................ ....................  17 
3.4 Statistical  Methods  ................................ ................................ ................................ ............  17 
3.4.1 Patient  Population  Analyzed  ................................ ................................ ................................ .........  17 
3.4.2 Handling  of Missing  Data ................................ ................................ ................................ .............  18 
3.4.3 Planned  Interim  Analysis  ................................ ................................ ................................ ..............  18 
3.5 Demographic  and Baseline  Characteristics  ................................ ................................ ..... 18 
3.6 Efficacy  (Pharmacodynamic)  Analysis  ................................ ................................ ............  18 
3.6.1 Primary  Efficacy  Analysis ................................ ................................ ................................ .............  18 
3.6.2 Secondary  Efficacy  Analysis  ................................ ................................ ................................ .........  19 
3.6.3 Tertiary  and Pharmacodynamic  Analyses  ................................ ................................ .....................  19 
3.6.4 Exploratory  Analyses  ................................ ................................ ................................ ....................  19 
3.6.5 Subgroup  analysis  on the glycemic  parameters  ................................ ................................ .............  20 
3.7 Pharmacokinetic  Analysis  ................................ ................................ ................................ . 21 
3.7.1 Plasma  Concentration  Data  of Total  Full-Length  Oligonucleotides  ................................ ..............  21 
3.7.2 Plasma  Pharmacokinetic  Parameters  ................................ ................................ .............................  21 
3.7.3 Pharmacokinetic/Pharmacodynamic  Exposure -Response  Analysis  ................................ ...............  22 
3.7.4 Immunogenicity  (IM)  Analysis  ................................ ................................ ................................ ...... 22 
3.8 Safety  Analyses  ................................ ................................ ................................ ..................  24 
3.8.1 Exposure  ................................ ................................ ................................ ................................ ....... 24 
3.8.2 Adverse  Events  ................................ ................................ ................................ .............................  24 
3.8.3 Laboratory  Measurements  ................................ ................................ ................................ ..............  26 
3.8.4 Vital  Signs  ................................ ................................ ................................ ................................ ..... 26 
3.8.5 12-Lead  Electrocardiograms  (ECG)  ................................ ................................ ..............................  [ADDRESS_683840] Medications  and Concomitant  Medications  ................................ .......................  27 
4 References  ................................ ................................ ................................ ................................ ... 28 
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
6 
8 of 30  
  
1 INTRODUCTION  
This document  provides  a description  of the study  organization,  study  procedures,  and the plan for the 
statistical analysis of the study data. Section 1  discusses study design, objectives, and endpoints; 
Section 2  provides the study procedures; Section 3  provides the detailed plan for the statistical 
analyses.  
The purpose  of this plan is to provide  specific  guidelines  from  which  the analysis  will proceed.  Any 
deviations from these guidelines will be documented in the clinical study report (CSR).  
 
Within  this document,  the terms  ‘patient’  and ‘subject’  are both used to describe  the individual  who 
enrolls in this study.  
 
1.1 Study  Overview  
This is a randomized,  double  blind,  placebo -controlled,  Phase  2 study  to assess  the safety,  tolerability, 
and efficacy of ISIS 766720 administered once every 4 weeks for 16 weeks to patients with 
acromegaly uncontrolled (IGF -[ADDRESS_683841]) on sele ct long -acting SRL. Patients 
will be stratified by [CONTACT_526970] -1 level (IGF -1 > 2.[ADDRESS_683842] or ≤ 2.[ADDRESS_683843] age and sex 
adjusted by [CONTACT_35970]).  
 
This study  will be conducted  at multiple  centers  worldwide  at approximately 40  sites.  Approximately 
60 patients  are planned  to be randomized  in their corresponding  randomization  ratio (ISIS  766720  vs. 
Placebo) are as following:  
 
Cohort A:    ISIS 766720  60 mg + SRL or placebo  + SRL (2 active  :1 placebo)  every  28 days. 
In addition,  a booster dose of Study  Drug  is administered on Day  15. Total of 15 
patients are enrolled.  
 
Cohort B:    ISIS 766720  80 mg + SRL or placebo  + SRL (2 active  :1 placebo)  every  28 days. 
In addition,  a booster  dose of Study  Drug  is administered  on Day 15. Total  of 15 
patients are enrolled.  
Cohort C:  ISIS 766720  120 mg + SRL or placebo  + SRL (5 active  :1 placebo)  every  28 days. 
In addition, a booster dose of Study Drug is administered on Day 15. Total of 12 
patients are enrolled.  
Cohort D:  ISIS 766720  160 mg + SRL or placebo  + SRL (5 active  :1 placebo)  every  [ADDRESS_683844]  of the following  periods:  
 
• A ≤ 6-week  Screening  Assessment  Period  
• A 16-week  Treatment  Period  during  which  Study  Drug  will be administered  as a once  every 
28 days SC injection (except during Month 1 where a booster dose is administered on Day 
15) 
• A 14-week  Post-Treatment  Evaluation  Period  
The study  design  and treatment  schema  are depi[INVESTIGATOR_144352]:  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
7 
7 of 30  
  
 
 
 

Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
8 
8 of 30  
  
1.2 Objective  
1.2.1 Primary  Objectives  
To evaluate the efficacy of ISIS 766720 subcutaneous (SC) injection on serum insulin -like growth 
factor  1 (serum  IGF-1) vs. placebo  as an add-on therapy  to long acting  somatostatin  receptor  ligands 
(SRL) octreotide and lanreotide.  
 
To evaluate  the safety  and tolerability  of ISIS [ADDRESS_683845]  of ISIS 766720  to normalize  serum  IGF-1 levels.  
 
1.2.3 Tertiary  Objectives  
To evaluate  the effects  of ISIS 766720  SC injection  on GH over time.  
 
To evaluate  the effects  of ISIS 766720  SC injection  on the following  pharmacodynamic  endpoints: 
fasting plasma GHBP, ALS, IGFBP3.  
 
1.2.4 Exploratory  Objectives  
To evaluate  the effects  of ISIS 766720  SC injection  on the following  glycemic  parameters:  HbA1c, 
fasting plasma glucose, glycated albumin as well as glucose, insulin and C -peptide  
during  2-hour oral glucose  tolerance  test. 
 
To evaluate the effects of ISIS 766720 SC injection on the clinical endpoints using AcroQoL, 
acromegaly  sign and symptom  treatment  score  questionnaire  (ASTS)  and ring size measurement.  
 
To evaluate  pharmacokinetic  (PK)  exposure  over time and potential  PK/P D correlation  on relevant 
biomarkers.  
 
1.[ADDRESS_683846] dose 
(PTWk5 Visit).  
 
1.3.2 Secondary  Efficacy  Endpoints  
The secondary  efficacy  endpoints  include:  
 
• Proportion  of patients  achieve  normalized  IGF-[ADDRESS_683847] dose (PTWk5 Visit)  
• Proportion  of patients  achieve  normalized  IGF-[ADDRESS_683848] dose (PTWk5 Visit)  
• Change  from  Baseline  in serum  IGF-1 over time 
• Percent  change  from  Baseline  in serum  IGF-1 over time 
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
9 
9 of 30  
  
1.3.3 Tertiary  and Pharmacodynamic  Endpoints  
The tertiary  and pharmacodynamic endpoints  include:  
• Change  from  Baseline  in growth  hormone  (GH)  over time 
• Percent  change  from  Baseline  in GH over time 
• Change from Baseline over time in pharmacodynamic endpoints, including fasting plasma 
GHBP,  acid-labile  subunit  (ALS),  and insulin -like growth  factor  binding  protein  3 (IGFBP3)  
• Percent  change  from  Baseline  over time in pharmacodynamic endpoints,  including  fasting 
plasma GHBP, ALS, and IGFBP3  
 
1.3.4 Exploratory  Endpoints  
The exploratory  endpoints  include:  
• Glycemic  parameters  over time,  including  HbA1c,  fasting  plasma  glucose  and glycated 
albumin  
• Glycemic  parameters  during  2-hour oral glucose  tolerance  test (OGTT),  including  plasma 
glucose, insulin and C -peptide  
• Acromegaly  Quality  of Life Questionnaire  (AcroQoL ) 
• Acromegaly  Symptom  and Treatment  Score  Questionnaire  (ASTS)  
• Ring  Size Assessment  
 
1.3.5 Safety  Endpoints  
The safety  endpoints  include:  
• Adverse  events  
• Vital  signs  and weight  and calculated  Body  mass  index  (BMI)  
• Physical  examination  
• Clinical  laboratory  tests 
• Electrocardiogram  (ECG)  
• Use of concomitant  medication  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
10 
10 of 30  
  
2 PROCEDURES  
2.1 General  Overview  of Procedures  
Ionis Pharmaceuticals, Inc. (or designee) will review all study data including source documents, 
CRFs,  and laboratory  reports.  The study  site will enter  patient  source  data into the case report  form. 
Some laboratory data will be transferred electronically from Endocrine Lab LMU Munich via 
Medpace Reference Laboratories, and from  [COMPANY_003] Development (plasma concentration data) to Ionis 
Pharmaceuticals, Inc.  
 
2.[ADDRESS_683849] been completed, after the 
Investigator has verified that they are eligible per criteria in protocol Sections 5.1  and 5.2. No patient 
may begin  treatment  prior  to randomization  and assignment  of a unique  patient  identific ation  number.  
Eligible patients will be stratified based on screening  IGF-1 levels (≤ 2.[ADDRESS_683850]  or > 2.[ADDRESS_683851]  age 
and sex adjusted by [CONTACT_35970]) and then patients will be randomized to 1 of 2 dose cohorts in a 1:1 
ratio (Cohort  A or Cohort  B). Within  each dose cohort,  patients  will be further  randomized  to receive 
ISIS 766720 or placebo in a 2:1 ratio.  
Eligible  patients  for Cohorts  C and D will be stratified  based  on screening  IGF-1 levels  (≤ 2.[ADDRESS_683852] 
or > 2.[ADDRESS_683853], age and sex adjusted by [CONTACT_35970]). Patients will be randomized to receive ISIS 
766720 or placebo in a 5:[ADDRESS_683854]  
The study will be conducted in accordance with current Good Clinical Practice (GCP) and 
International Conference  on Harmonization  (ICH) guidelines,  the World  Medical  Association 
Declaration  of Helsinki  guidelines,  the Food  and Drug  Administration  (FDA)  Code  of Federal 
Regulations, and all other local regulatory requirements.  
 
2.4 Data  Monitoring  
2.4.1 Safety  Data  Monitoring  
Ionis Pharmaceuticals, Inc. (or designee) is responsible for processing all reported adverse events 
(AEs). All serious adverse events (SAEs), reported to  Ionis Pharmaceuticals, Inc. (or designee), are 
reviewed  according  to standard  operating  procedures.  The medical  monitor  will review  all AEs and 
SAEs on an ongoing basis throughout the study.  Ionis Pharmaceuticals, Inc. (or designee) will 
prepare and submit safety reports to the health authorities worldwide in accordance with local 
requirements.  If it becomes necessary to communicate new safety information, Ionis 
Pharmaceuticals, Inc. (or desig nee) will also prepare a safety notification letter and transmit it to 
study site.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
11 
11 of 30  
  
2.5 Data  Management  
An electronic  case report  form  (eCRF)  utilizing  an Electronic  Data  Capture  (EDC)  application  will be 
used for this Study.  
 
2.5.1 Case  Report  Form  (CRF) Data  
BioClinica (or designee) is responsible for creating the Electronic Data Capture (EDC) data entry 
screens,  database  and edit checks  using  definitions  developed  by [CONTACT_81797],  Inc. Ionis 
Pharmaceuticals, Inc. is responsible for the review, data management querying and locking of the 
database.  
Data are single -entered into the EDC system by [CONTACT_10590]. Programmed edit checks 
(computer  logic  that checks  the validity  of the data entered  and also prompts  for missing  data that is 
expected to be entered) are run and automatic queries are generated. Ionis Pharmaceuticals, Inc. 
reviews all  data for accuracy  and validity  and generates additional queries  in the EDC system  when 
necessary. The data are corrected or an explanation concerning the query is provided in the EDC 
system. After all data are entered, reviewed (by [CONTACT_84276]) and 
queried, and all queries resolved, the database is locked.  
 
2.5.2 Labora tory Data  
Ionis Pharmaceuticals, Inc. is responsible for the format of the laboratory electronic data transfers, 
transfer  schedule  and review  of the clinical  laboratory  data.  This lab data will be stored  as SAS data 
sets or Excel files.  
 
2.5.3 Pharmacokinetics  (PK)  Data  
Ionis Pharmaceuticals, Inc. is responsible for the management and review of the plasma drug 
concentration data.  This process involves reviewing the patient and visit identifiers (i.e., patient 
demographics)  with the clinical  data collected  in the EDC  syste m. The PK data are not stored  in the 
EDC system.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, [ADDRESS_683855]  data. 
All statistical tests will be conducted using 2 -sided tests with 5% Type I error rate unless otherwise 
stated.  
PK parameters  will be summarized  to include  number  of patients,  mean,  standard  deviation, 
coefficient of variat ion (CV), geometric mean, median, minimum, and maximum.  
Pooled  groups:  
Patients  who are placebo -treated  will be pooled  and analyzed  as a single  placebo  group.  Patients  who 
are ISIS 766720 -treated may be pooled and summarized as the ISIS 766720 low dose, and ISIS 
766720 high dose, or total ISIS 766720 treated group.  
Baseline  definition:  
Unless  otherwise  specified,  baseline  is defined  as the last non-missing  value  prior  to the first 
administration of Study Drug (ISIS 766720 or placebo).  
The baseline  for Platelets  is defined  as the average  of all  values  prior  to the first administration  of 
Study Drug (ISIS 766720 or placebo).  
Analytical  visits:  
All post-baseline  data will be summarized  using  the visit labels  provided  in the data.  Multiple  results 
with the same visit label will be averaged for the continuous variables, and the worst result will be 
used for the categorical variables. Results with visit labels as “Unsched uled” will not be included in 
the by -visit summary  tables  and figures  except  for determining  baseline, but  will be presented  in data 
listings.  
 
 
3.[ADDRESS_683856]  deviation  of the mean  percent 
change from Baseline IGF -1 is approximately 20%. In the per protocol set, with [ADDRESS_683857] 90% 
power to detect a 45% difference  in mean percent change from Baseline IGF -1 between each of the 
ISIS 766720 dose groups and the pooled placebo group at an alpha level of 0.05.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
13 
13 of 30  
  
3.3 Scoring  of Questionnaires  and Ring  Size Assessment  
3.3.1 Acromegaly  Quality  of Life Questionnaire  (AcroQoL ) 
AcroQoL  is a specific  questionnaire  designed  to evaluate Health  Related  Quality  of Life (HRQoL)  in 
patients with acromegaly. It comprises 22 items ( Table 1 ), which are spread across 2 dimensions: 
physical (8 items) and psychological (14 items). There is a further breakdown of the psychological 
dimension into 2 sub -dimensions (each comprising 7 items): one evaluates appearance and the other 
evaluates the impa ct of the disease on the patient’s personal relationships.  
Table  1: The AcroQoL  Questionnaire  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
14 
14 of 30  
  
 
 
 
 
 
AcroQoL  dimension  Questions  included  in each  dimension  
Physical  1, 3, 9, 13,  14, 15,  19, 22 
Psychological  2, 4, 5, 6, 7, 8, 10, 11, 12, 16, 17,  18, 20, 21 

Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
15 
15 of 30  
  
 
Sub-dimensions (of the 
psychological  dimension)  Questions  included  in each  sub-dimension  
Appearance  2, 4, 7, 11,  12, 16,  17 
Personal  relations  5, 6, 8, 10,  18, 20,  21 
 
Each of the 22 items of the AcroQoL is answered in a 1 to 5 Likert scale measuring either the 
frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of 
agreement  with the items  (completely  agree,  moderately  agree,  neither agree  nor disagree,  moderately 
disagree, completely disagree). Answers to each of the items are rated on a scale of 1 to 5: 1 
corresponds to the response category “Always” or “Completely agree”, depending on the item type, 
and 5 is equivalent to the r esponse category “Never” or “Completely disagree”. This means that the 
lower the score the greater the impact on HRQoL.  
The scores for each dimension or sub -dimension are the sum of the item responses given for each 
dimension / sub -dimension. Consequently,  the score for the physical dimension can range from 8 to 
40 points, the psychological dimension from 14 to 70 points, and each of the sub -dimensions 
(appearance  and personal  relationships)  from  [ADDRESS_683858] imaginable HRQoL, as expressed through the specific scales of this 
questionnaire. In addition, a global score can be calculated by [CONTACT_527003] 22 
items, which can range from 22 points (worst HRQoL) to 110 points (best HRQoL).  
To simplify  interpreting  questionnaire  scores,  the raw scores  can be standardized  on a scale  running 
from 0 (worst HRQoL) to 100 (best HRQoL), by [CONTACT_21734]:  
(X) − min 𝑌 = [ ] × 100 
(max  − min)  
Here  Y is the re-calculated  score,  and X is the sum of all the item responses  within  the dimension  or 
study score (min. is the minimum possible score in the study dimension, and max. is the maximum 
possible score in the study dimension).  
For example, to standardize the global score (Y), substitute X for the sum of the scores of the 22 
items,  min for 22 and max for 110 (being  the two extreme values);  thus,  scores  range  from  0 (worst 
HRQoL) to 100 points (best HRQoL).  
 
 
Global  score  𝑌 = [ (𝑋)−22 ] × 100 
(110−[ADDRESS_683859] 
HRQoL questionnaires a score is considered calculable if the percentage of un -answered questions 
does not exceed  25% of the items  used to obtain  the score . In such cases,  one assumes  that the scoring 
of the missing item or items is equivalent to the average score obtained in the rest of the items that 
make  up the calculation  of the score.  In the case of AcroQoL,  scores  can be interpreted  for each of the 
dimensions if the number of unanswered items does not exceed 2 in the physical dimension, 1 in the  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
16 
18 of 30  
  
appearance  and personal  relationships  sub-dimensions,  or 3 in the psychological  dimension.  To get a 
global score, the maximum number of un answered questions permissible is 5.  
 
3.3.2 Acromegaly  Symptom  and Treatment  Score  Questionnaire  (ASTS)  
ASTS  is an Ionis  internally  developed  questionnaire  to assess  acromegaly  symptom  and treatment, 
which contains 6 items ( Table 2 ). 
Table  2: The ASTS  Questionnaire  
 
Item  Question    Response   
[ADDRESS_683860]  FEW       
 DAYS  BEFORE  THIS       
 UPCOMING       
 LANREOTIDE  /      
 OCTREOTIDE       
 INJECTION       
 
Each  of the 6 items  of the ASTS  is answered  in a 1 to 5 Likert  scale  measuring  either  the frequency  of 
occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement with  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
17 
19 of 30  
  
the items (completely agree, moderately agree, neither agree nor disagree, moderately disagree, 
completely  disagree).  Answers  to each of the items  are rated  on a scale  of 1 to 5: 1 corresponds  to the 
response category “Always” or “Completely agree”, depending on the item type, and 5 is equivalent 
to the response category “Never” or “Completely disagree”. This means that the lower the score the 
greater the impact on the acromegaly symptom and treatm ent. 
The item [ADDRESS_683861]-treatment  period.  No change  and percent  change  from  baseline  analyses 
will be performed for item 5, since no baseline (Day 1) is available for item 5.  
Each  of the 6 items  will be analyzed  individually.  If the response to  an item is missing  at a visit,  it 
will not be included in  the analysis for that item at that visit.  The range of the individual score for 
each item is 1 to 5.  
In addition, a composite score (Acromegaly Symptom Composite Score) will be calculated by 
[CONTACT_527004] 1, item 2, item 3, and item [ADDRESS_683862] fit. If the 
finger  is too large  to be measured  by [CONTACT_527005] (and  make  a note of 
this). The same finger will be used throughout the trial.  
Only  subjects  with post-treatment  values  using  the identical  finger  as the one used for baseline  value 
will be included in the change and percent change from baseline analysis.  
 
3.4 Statistical  Methods  
3.4.1 Patient  Population  Analyzed  
The following  analysis  populations  are defined  for this study:  
• Safety  Set: All patients  who are randomized  and receive  at least 1 dose of Study  Drug.  
 
• Full Analysis  Set (FAS):  All randomized  patients  who receive  at least [ADDRESS_683863] -baseline efficacy or pharmacodynamic assessment.  
 
• Per Protocol  Set (PPS):  All FAS patients  who complete  at least [ADDRESS_683864] efficacy.  
 
• PK Set: All patients  who are randomized  and receive  at least [ADDRESS_683865] 6  patients in the higher strata (> 2.[ADDRESS_683866] IGF - 
1) or at least 6 patients  in the lower  strata  (≤ 2.[ADDRESS_683867]  IGF-1) complete  the Week  11 (Study  Day 71) 
assessments (2 weeks after Day 57 (e.g., 3 month) dose). Unblinded data may be evaluated at this 
analysis for comparative safety and efficacy. The Investigator, study staff, patients, monitors, 
Sponsor’s Medical Monitor and members of the Sponsor’s cli nical operations team and data 
management team will remain blinded throughout the study. The analysis will be executed with 
controlled dissemination to ensure the integrity of ongoing data collection. The individuals involved 
in the unblinded interim analy sis will be identified and documented at the time of unblinded interim 
analysis according to Ionis standard operation procedure (SOP).  
 
3.5 Demographic  and Baseline  Characteristics  
Demographic  and Baseline  characteristics  (e.g.,  age, gender,  ethnicity,  race,  weight,  height,  BMI)  will 
be summarized using descriptive statistics by [CONTACT_1570].  
BMI  will be computed  using  the formula:  BMI  = (weight  in kilograms)  / [height  in cm / 100]2 
Patient  randomization  and disposition  will be summarized  by [CONTACT_527006].  All patients 
enrolled will be included in the summary of disposition.  
Protocol  deviations  will be listed.  
 
3.6 Efficacy  (Pharmacodynamic)  Analysis  
3.6.1 Primary  Efficacy  Analysis  
The primary analysis will be the comparison of percent change from Baseline to PTWk5 ([ADDRESS_683868] dose)  in serum  IGF-1 between  an ISIS 766720 dose  group  and pooled placebo group  in the 
Per Protocol Set.  The data will be analyzed  using  analysis  of variance  (ANOVA)  with treatment and 
randomization stratification factor (screening IGF -1 level) as independent variables.  The normality 
assumption  for the ANOVA  model  will be assessed  by [CONTACT_144407][INVESTIGATOR_2152] -Wilks  test on the residuals. In  the 
case data  departs substantially from normality, the nonparametric test, van Elteren Test, will be 
employed instead.  Additional analysis with baseline IGF -[ADDRESS_683869]  after all patients  complete  Treatment  Period  and the database  has 
been locked.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
19 
19 of 30  
  
3.6.2 Secondary  Efficacy  Analysis  
[IP_ADDRESS]  Secondary  analysis  on the primary  efficacy  endpoint  
Comparison of percent change from Baseline to PTWk5 ([ADDRESS_683870] dose) in serum IGF -[ADDRESS_683871] to the primary analysis.  
[IP_ADDRESS]  Additional  secondary  efficacy  analyses  
• Comparison  of change  and percent  change  from  Baseline  to each schedule  post-baseline  visit 
in serum IGF -[ADDRESS_683872] to the primary analysis  
• Difference between each of  the ISIS 766720 dose grou ps and  the pooled placebo group  in the 
proportion  of patients  achieve  normalized  IGF-1 levels  to within  1.2 times  of gender  and aged 
limits at PTWk5 ([ADDRESS_683873] dose) will be assessed by [CONTACT_3493]’s exact test in the PPS 
and FAS  
• Difference between each of  the ISIS 766720 dose groups and  the pooled placebo group  in the 
proportion  of patients  achieve  normalized  IGF-1 levels  to within 1.0 times  of gender  and aged 
limits at PTWk5 ([ADDRESS_683874] dose) will be assessed by [CONTACT_3493]’s exact test in the PPS 
and FAS  
For the proportion  difference,  additional  analyses  may be conducted  by [CONTACT_527007].  
 
3.6.3 Tertiary  and Pharmacodynamic  Analyses  
The following  analyses  will be performed:  
• Comparison of change and percent change from Baseline to each scheduled post -baseline 
visit in GH between  each of the ISIS [ADDRESS_683875] to the primary analysis in both the PPS and FAS  
• Comparison of change and percent change from Baseline to each scheduled post -baseline 
visit in pharmacodynamic endpoints, including fast ing plasma GHBP, acid -labile subunit 
(ALS), and IGFBP3, between each of the ISIS [ADDRESS_683876] to the primary  analysis  in both the PPS and 
FAS 
Additional  analyses  may be conducted  to explore  the relationship  among  PDs. 
 
3.6.4 Exploratory  Analyses  
The exploratory  analyses  include:  
• Comparison of change and percent change from Baseline to each scheduled post -baseline 
visit in Glycemic parameters, including HbA1c, and fasting plasma glucose and glycate 
albumin between each of the ISIS [ADDRESS_683877] to the primary  analysis  in both the Per Protocol  Set and 
FAS.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
20 
19 of 30  
  
• Comparison of change and percent change from Baseline to each scheduled post -baseline  
visit in Glycemic parameters during 2 hours OGTT, including the area under curve (AUC) 
and the incremental AUC of plasma glucose,  insulin  and C -peptide, between  each of the ISIS 
[ADDRESS_683878] 
to the primary analysis in both the Per Protocol Set and FAS.  
• Comparison of change and percent change from Baseline to each scheduled post -baseline  
visit in  AcroQoL (Global AcroQoL, Physical Dimension, Psychological Dimension, 
Appearance Sub -dimension, Personal Relationships Sub -dimension), ASTS and Ring Size 
between  each of the ISIS [ADDRESS_683879] -baseline visit in glycemic 
parameters during 2 hours OGTT, including the area under curve (AUC) and th e incremental AUC 
(iAUC) of plasma glucose, insulin and C -peptide, will be summarized. The AUC will be calculated 
for plasma glucose, insulin and C -peptide taken between 0 to 120 minutes responses to the OGTT. 
The plasma measurement taken prior to start ti me of glucose ingestion (defined as T0 time) will be 
used as the T0 plasma glucose and all subsequent time point will be relative to this T0 in the AUC 
calculation.  The actual sample  time (defined  by [CONTACT_527008]  T0 time) will 
be used in  the AUC calculation.  If a scheduled  120 minutes  result  is missing, then  the AUC will not 
be calculated.  If the actual sample time of the scheduled 120 mins result is more than 135 mins or 
less than 105 mins,  then the AUC  will also not be calculated.  If a scheduled  result  at other  timepoints 
is missing, the data will be linearly interpolated using the results prior to and immediate after the 
missing result.  
The iAUC  is defined  as total AUC  minus  the rectangle  area under  basal  (i.e., T0  plasma glucose 
measurement multiplied by [CONTACT_527009]).  
Additional  analyses  for the AcroQoL  and ASTS  may be described  in the other  analysis  plan for 
exploratory purpose.  
 
3.6.5 Subgroup  analysis  on the glycemic  parameters  
The comparison  of change  and percent  change  from  Baseline  to PTWk5  ([ADDRESS_683880] dose)  in 
HbA1c and Glycemic parameters during 2 hours OGTT, including AUC and incremental AUC of 
plasma glucose and C -peptide, between each of the ISIS 766720 dose groups and pooled placebo 
group wi ll be performed on the following baseline HbA1c subgroups in the PPS:  
• <5.7%  vs. >=5.7%  
• <6.5%  vs. >=6.5%  
• <7.5%  vs. >=7.5%  
• <8.0%  vs. >=8.0%  
• <8.5%  vs. >=8.5%  
• <9.0%  vs. >=9.0%  
• <6.5%  vs. 6.5-8% vs. >8% 
The data will be analyzed  in a similar  way to the primary  analysis.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
21 
19 of 30  
  
3.7 Pharmacokinetic  Analysis  
Pharmacokinetic (PK) analysis will be conducted in the PK Population.  The plasma PK of ISIS 
766720  (as total full-length  oligonucleotide  or ISIS 766720 -equivalent  [ISIS  766720 -eq.]) will be 
assessed  following first and last SC dose administration(s).  
Metabolite  identification  and profiling  may be determined  in some  of the collected  plasma  samples 
and will be reported separately.  
 
3.7.1 Plasma  Concentration  Data  of Total  Full-Length  Oligonucleotides  
Plasma concentrations of ISIS 766720 (total full -length ASO, reported as ISIS 766720 -eq.), along 
with the scheduled (nominal) and actual samples times (i.e., time from SC dosing) will be listed 
(when applicable) for each patient, by [CONTACT_3227], dose cohort, nominal dose, and day.  In 
addition, percent differences between scheduled and actual sampling times will be listed for all 
patients.  Percent  differences  between  actual  administered  dose and nominal dose  will also be listed.  
Plasma  concentrations  below  the lower  limit  of quantification  (LLOQ)  will be indicated  by “BLQ”. 
For the purpose of calculating typi[INVESTIGATOR_10476] (n, mean, SD, %CV, geometric mean, 
geometric  %CV,  median,  minimum,  and maximum)  for plasma  concentrations,  all BLQ  values  will 
be set to zero.  Mean plasma concentrations that are BLQ will  be presented as “BLQ”, and the SD 
and %CV, as well as geometric mean and geometric% CV, will be reported as not applicable.  
Summary  statistics  of the ISIS [ADDRESS_683881] 
and/or  biostatistician,  samples  may be excluded  from  descriptive  statistics  if there  are large  deviations 
between scheduled and actual sampling times, or large deviations between actual dose and nominal 
dose.  
ISIS 766720 -eq. plasma trough (pre -dose) and post -treatment concentration versus time (actual) 
profiles  for each individual  patient that  recei ved ISIS 766720  active  treatment,  as well as the mean  (± 
SD or SE) plasma concentrations versus time (scheduled) profiles following first and last dose, will 
be presented graphically on linear and semilogarithmic scales without and with stratification by 
[CONTACT_527010] (see Section 3.7.4 ). At the discretion of the pharmacokineticist  and/or 
biostatistician, samples may be excluded from the mean plots if there are large deviations between 
scheduled and actual sampling times.  
 
3.7.2 Plasma  Pharmacokinetic  Parameters  
The plasma PK of ISIS 766720 (as total full -length ASO) will be assessed follo wing first - and last - 
dose SC administration(s).  Non-compartmental pharmacokinetic analysis of ISIS 766720 (as total 
full-length ASO) will be carried out on each individual patient data set where full PK sampling 
profiles and/or post -treatment profiles are  collected using Phoenix WinNonlin version 8.0 or higher 
(Pharsight Corporation, Mountain View, CA).  Plasma pharmacokinetic parameters in each patient 
(when  applicable)  will be determined.  For calculation  of PK parameters,  all BLQ  values  will be set to 
zero. The following plasma PK parameters will be calculated (when applicable and not necessarily 
limited to) based on actual sampling times:  
1. Cmax: the maximum  observed  ISIS 766720  concentration  in plasma  will be determined  on Day 1 
and Day 112.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
22 
19 of 30  
  
2. Tmax: the time at which  Cmax occurs  will be determined  on Day 1 and Day 112. 
3. AUC 0-6hr: partial area under the plasma concentration -time curve (AUC) from  time zero to 6 
hours  will be calculated  using  the linear -up log-down  trapezoidal  rule on Day 1 and Day 112. 
4. CL 0-6hr /F (L/hr):  partial  clearance  (e.g. 6 hr) divided  by F (fraction  of the dose absorbed) 
determined by [CONTACT_50726]/AUC 0-6hrwill be determined on Day 1 and Day 112.  
5. t1/2λz: apparent terminal elimination half -life will be calculated from the equation,  t1/2λz = 
0.693/λ z, where  λz is the rate constant associated with  the apparent  terminal elimination phase. 
A minimum of three data points in the elimination phase will be used to define z and the 
coefficient  of determination  values  (r2 adjusted)  has to be at or greater  than 0.8 for the estimate 
to be accepted.  This parameter will on ly be calculated following the dose on Day 112 for all 
evaluable patients receiving active study drug.  
Plasma  pharmacokinetic  parameters  will be summarized  using  descriptive  statistics  (n, mean,  
SD, %CV,  geometric  mean,  geometric  %CV,  median,  minimum,  and maximum) by  [CONTACT_2948], 
dose cohort, nominal dose, and day.  
 
3.7.3 Pharmacokinetic/Pharmacodynamic  Exposure -Response  Analysis  
Exposure -response  correlations  may be explored  graphically  between  plasma  exposure  (AUC,  Cmax, 
Cmin, as appropriate) a nd selected PD measures (e.g. serum IGF -1, GH, and GHBP levels).  
Population  PK and PKPD  analysis  may be performed  using  the PK and PD data from  this study 
and/or combined with other ISIS 766720 clinical PK data later in the development timeline.  
 
3.7.4 Immunogenicity  (IM)  Analysis  
Samples  collected  at pre-dose on Days  1, 29, 57, 85, and 112, and anytime  on Day 127, 141, 155, 
183, and 211, including early termination samples for IM assessment may be analyzed for  
anti-ISIS 766720 antibodies (ADA).  However, plasma samples collected at other time points (for 
PK purposes) may also potentially be evaluated if deemed of further interest and warranted by [CONTACT_527011].  An evaluable sample will be designated ‘IM positive’ based on both 
positive screening and confirmation assay results (i.e., confirmed positive result), and otherwise will 
be deemed ‘IM negative’.  Sample IM results (screen positive/negative, confirmed positive/negative 
or unevaluable, and when applicable, titer of anti -ISIS 76 6720 antibodies) before, during, and after 
treatment  with study  drug (ISIS  766720  or placebo)  (sample  IM status)  will be listed  by [CONTACT_527012].  
Study patients will be given ‘IM positive’ status if they have at least one confirmed positive sample 
result at any time during the treatment or post -treatment evaluation periods.  Study patients will be 
given ‘IM negative’ status if all evaluated IM sample results during the treatment and post -treatment 
evaluation  periods  are IM negative  and they have  at least one evaluable  IM result  collected  post study 
drug treatment.  Otherwise, a study patient will be given ‘unknown’ IM status.  Patient IM results 
will be listed by [CONTACT_527013], which will include but may not be 
limited to: p atient IM status (positive, negative or unknown), the study day associated with the first 
positive IM status emerged (T first, i.e., onset of ADA development), the last positive IM status 
observed (T last), the time of last evaluable IM sample collected (T last sampling ), peak titer, and time to 
reach peak titer. The onset of ADA and time to reach peak titer will be calculated by:  
[CONTACT_81797],  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
23 
19 of 30  
  
• Onset  in days = The date of first sample  has “positive”  sample  IM status  - first dose date +1; 
• Time  to reach  peak  titer in days = The date of first peak  titer observed - first dose date +1; 
Other  immunogenicity  data analysis  (e.g. classification  as transient  or persistent  status  for IM positive 
patients) may be conducted if there are sufficient number of patients with transient IM status.  
Transient  and Persistent  ADA  definitions  are defined  below  and based  on Shankar  et al. (2014) . 
Transient ADA response w ill be defined as:  
• Treatment -induced  ADA  detected  only at one sampling  time point  during  the treatment  or 
follow -up observation period (excluding the last sampling time point, which will be 
considered persistent unless shown to be undetectable at a later time) or  
• Treatment -induced  ADA  detected  at two or more  sampling  time points  during  the treatment 
(includ ing follow -up period if any), where the ﬁrst and last ADA -positive samples 
(irrespective of any negative samples in between) are separated by a period less than 16 
weeks, and the patient’s last sampling time point is ADA -negative.  
Persistent  ADA  response  will be defined  as: 
• Treatment -induced  ADA  detected  at two or more  sampling  time points  during  the treatment 
(including follow -up period if any), where the ﬁrst and last ADA -positive samples 
(irrespective of any negative samples in between) are separated by a period of 16 weeks or 
longer or  
• Treatment -induced  ADA  detected  only at the last sampling  time point  of the study  treatment 
period or at a sampling time point with less than [ADDRESS_683882] 
sample.  
The sample  IM incidence  (number)  and incidence  rate (percent)  at each evaluated  study  time point, 
and for the overall treatment and post -treatment eval uation period, as well as patient IM incidence 
and incidence rate, will be determined and appropriately summarized by [CONTACT_3148], as the total 
number of and percentage of evaluated patients with IM negative, positive, and unknown status.  
Patients  with posit ive IM status  may further  be classified  as transient  or persistent  status  if applicable, 
and incidence and incidence rate for being transient or persistent will be appropriately summarized.  
Furthermore, onset, titer over time, and peak titer of the ADA response, if applicable, will be also 
appropriately summarized (using descriptive statistics) as median, quartiles (25% and 75%), and  
range and presented graphically, if deemed appropriate, by [CONTACT_527014]/or  statistician  (e.g.,  summarized  at each evaluated  study  time 
point and overall; summarized by [CONTACT_527015]; 
etc.).  
In additi on to PK assessments  (Section  3.7.2 ), selected  safety  (Section  3.8) and efficacy  (Sections 3.6 ) 
assessments may be further stratified by [CONTACT_476245] (i.e. , patient IM status being positive, 
negative or unknown) and presented in tables and/or graphically, as deemed appropriate or warranted 
by [CONTACT_84309], medical monitor, and/or biostatistician.  Other 
stratifications (e.g., based on antibody titer, onset of ADA, etc.) of selected PK, efficacy and safety 
assessments may also be performed if deemed warranted at the discretion of the pharmacokineticist, 
medical monitor, and/or biostatistician.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
24 
19 of 30  
  
3.8 Safety  Analyses  
The safety  analysis  will be conducted  on the Safety  Set. 
 
3.8.1 Exposure  
Treatment  duration  and amount  of Study  Drug  (ISIS  766720  or placebo)  received  will be summarized 
by [CONTACT_1570].  The treatment duration for each subject is defined as last dose date - first dose 
date +1.  
 
3.8.2 Adverse  Events  
The incidence  of AEs will be summarized  by [CONTACT_527016] 
(MedDRA) version 21.1 (or higher) preferred term and system organ class (SOC) for:  
• Any treatment  emergent  adverse  events  (TEAEs)  
• Related  treatment  emergent  adverse  events.  Related  is defined  as “Related”,  “Possible”, 
or missing relationship to s tudy drug  
• Any treatment emergent adverse events by [CONTACT_926]. At each level of subject 
summarization, a subject is classified according to the highest severity if the subject 
reported  one or more  events.  Adverse  events  with missing  severity  will categorized  as 
“Missing” for this summary  
• Serious  treatment  emergent  adverse  events  
• Treatment  emergent  adverse  events  leading  to study  drug permanently  discontinued  
SAEs  and non-serious  AEs that lead to study  discontinuation  or investigational  drug discontinuation 
will be listed separately. Non -treatment emergent adverse event will be flagged in the data listing.  
To determine  the AE as treatment -emergent  or not, if there  is no “Formlink”  link, and the AE (start 
date/time) occurs after the subject’s first dosing date/time, then the AE is treatment - 
emergent.  Otherwise,  if the AE (start  date/time)  occurs  prior  to the subject’s  first dosing  date/time, 
then the AE is not treatment -emergent.  
In addition, if the re is a “Formlink” link between two AE records, then we compare them pairwise, 
and consider  two cases,  where  we compare  the AE severity  (mild/moderate/severe)  and seriousness 
(Yes/No) between the two records in the pair.  We chronologically order the 2 records (by [CONTACT_527017]) and refer to the “first” and “second” AE.  
 
Case  1: The first AE record  in the pair occurs  before  first dosing,  and the second  AE record  occu rs 
after dosing.  
If the AE severity  or seriousness of  the second  record  is worse  than  that of the first record, 
then only the second AE is deemed as a TEAE.  Otherwise, neither record is considered as 
TEAE.  
 
Case  2: Both  AE records  in the pair occur  after first dosing.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, [ADDRESS_683883] study treatment date.  
[IP_ADDRESS]  Local  Cuta neous  Reactions  at the Injection  Site 
Local cutaneous reaction at injection site (LCRIS) is defined as (A) moderate or severe adverse 
events with  the PTs Injection site erythema, Injection  site swelling, Injection site  pruitus, or Injection 
site pain that started  on the day of injection,  persisted  for at least two days or  ongoing;  or (B) any AE 
at the study drug injection site, regardless of severity, that leads to discontinuation of study drug, 
where AE at the injection site is the principal reason for discontinuation.  
Percentage  of injections  leading  to local  cutaneous  reaction  at the inject ion site will be calculated  as 
follows for each subject: (A/B)*100, where A=number of injections with a LCRIS, and B=total 
number  of injections.  Doses  that are split across multiple  injections  are counted  as a single  injection  
LCRIS  will be summarized  using  the MedDRA  coding  system,  by [CONTACT_2946]/PT.  Percentage  of the 
injections leading to LCRIS at injection site will also be summarized.  
LCRIS  will be listed  by [CONTACT_2940].  
[IP_ADDRESS]  Flu-like Reactions  
Flu-like reactions  will also be summarized  by [CONTACT_2940].  
Flu-like reactions are defined as either (A) flu -like illness or (B) Pyrexia or feeling hot or body 
temperature  increased,  plus at least two of the following symptoms  with the PTs: Chills,  Myalgia,  and 
Arthralgia, starting on day of injection or the next day.  
Percentage  of injections  leading  to flu-like reactions  will be summarized  using  the descriptive 
statistics.  
Percentage  of the injections  leading  to flu-like reactions  will be calculated  as follows  for each subject: 
(A/B)*100, where A=number of injections leading to flu -like reactions , and B=total number of 
injections.  
FLRs  will be summarized  using  the MedDRA  coding  system,  by [CONTACT_2946]/PT. Percentage  of the 
injections leading to FLRs at injection site will also be summarized.  
FLRs  will be listed  by [CONTACT_2940].  
[IP_ADDRESS]  AE of special  interest  (AESI)  
Per protocol,  severe  reductions in  platelet count  < 50,000/mm3 accompanied by  a clinically -relevant 
bleeding  even t or platelet  count  of < 25,000/mm3  independent  of a clinically -relevant  bleeding  event 
are considered as AESI. The AEs meeting the AESI criteria will be captured in the AE CRF page  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
26 
19 of 30  
  
with a check  box to indicate.  AESI  will be summarized  by [CONTACT_2940].  A listing  of AESI  will also 
be generated.  
 
3.8.3 Laboratory  Measurements  
Bone biomarkers,  pi[INVESTIGATOR_417483], thyroid  panel,  inflammatory,  lipid panel,  chemistry,  hematology, 
coagulation,  complement  and urinalysis  (result,  change  and percent  change  from  baseline)  will be 
summarized by [CONTACT_527018] -baseline visit.  
 
 
For ALT and  AST,  the number  and percent  of subjects  falling  in each of the following  categories  will 
be tabulated by [CONTACT_1570]:  
• ALT/AST  > [ADDRESS_683884],  confirmed  
• ALT/AST  > [ADDRESS_683885] within 7 days then the initial value is presumed 
confirmed.  
If there  are multiple  results  on the same  day (no matter  from  the same  lab vendor  or different  lab 
vendors), then the worst value will be utilized in the analysis.  
The number  and percentage  of patients  falling  in each of the following  categories  (using  available 
central and local laboratory assessments) based on post -baseline ass essments will be provided:  
• Confirmed  Platelet  count  100,000 mm3 to lower  limit  of normal  
• Confirmed  Platelet  count  75,000  to < 100,000 mm3 
• Confirmed  Platelet  count  50,000  to < 75,000 mm3 
• Confirmed  Platelet  count  25,000  to < 50,000 mm3 
• Confirmed  Platelet  count  < 25,000 mm3 
• Confirmed  ≥ 30% Platelet  count  decrease  from  baseline  
 
Subjects  with more  than one confirmed  value  will be counted  exactly  once  under  the worst  confirmed 
category.  
 
3.8.[ADDRESS_683886] -baseline visit.  
 
3.8.5 12-Lead  Electrocardiograms  (ECG)  
Safety  [ADDRESS_683887] dose of study  drug.  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
27 
19 of 30  
  
The ECG data will include ventricular rate (VR), PR interval, QRS duration, QT, QTcF (QT 
corrected  using  the Fridericia’s  formula),  and QTcB  (QT corrected  using  the Bazett’s  formula).  QTcF 
and QTcB will be calculate d based on the subject’s reportable ECG data at each time point using the 
formula described below:  
QTcF  = QT / (RR) 1/3, where  RR=  60/VR 
QTcB  = QT / (RR) 1/2, where  RR=  60/VR  
Only  calculated  QTcB  and QTcF  will be  summarized  and included  in the data listing. The  QTcB  and 
QTcF  values  recorded  on the CRF  will not be summarized  and will be excluded  from  the data listing.  
For the continuous  variables above, descriptive statistics (n,  mean, standard error,  standard  deviation, 
median,  25th percentile,  75th percentile,  minimum  and maximum)  of the average  of triplicate  results  at 
each study visit, as well as the change and percent change from Baseline to each study visit, will be 
presented in summary tables; for the categorical responses to ov erall interpretation, the worst of 
triplicate results at each visit will be summarized by [CONTACT_33335]. All the ECG data 
collected in triplicate, except the CRF QTcB and QTcF values, will be listed.  
 
3.8.[ADDRESS_683888] Medications and concomitant medications will be coded using WHO Drug 
dictionary  (version  March  2018)  and summarized  by [CONTACT_527019],  generic  name  [CONTACT_527022].  
Ionis  Pharmaceuticals,  Inc. 
Statistical Analysis Plan  MAR  05, 2021 
ISIS 766720 -CS2 CONFIDENTIAL  
28 
19 of 30  
  
4 REFERENCES  
1) “Acromegaly  Quality  of Life Questionna ire (AcroQoL)  User’s  Manual. ” Version:  August 
2017.  
2) “Acromegaly  Quality  of Life  Questionnaire  (AcroQoL). ” Xavier  Badia,  Susan  M Webb,  Luis 
Prieto and Nuria Lara. Health and Quality of Life Outcomes 2004, 2:13 
3) G Shankar  et al. Assessment  and reporting  of the clinical  immunogenicity  of therapeutic  proteins 
and peptides -harmonized terminology and tactical recommendations AAPS J. 2014 
Jul;16(4):658 -73. 